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ABSTRACT
The present thesis consists of a series of studies 
that explored the dimensions of the phenomena of depression; 
clinical, psychological, biological and therapeutic.
Study I examined differences in clinical and psychological 
characteristics of patients with bipolar, endogenous uni­
polar and nonendogenous depressions. The frequency dis­
tribution of Newcastle diagnostic (endogenicity) scores 
of a large number of patients was plotted in relation to 
their ICD-9 diagnosis. The relationship of these scores 
to severity of depression, both subjectively and objectively 
rated, and to trait anxiety was studied. The results were 
that these clinical types showed differences in clinical 
(age of onset, previous number of episodes and family 
history of affective illness) and psychological character­
istics; with bipolar and endogenous unipolar patients 
showing less personality disturbance than those with non­
endogenous depression. The frequency distribution of 
Newcastle diagnostic scores was unequivocally unimodal, 
suggesting that mixed forms of depression predominate. 
Greater endogenicity on the Newcastle Scale was associated 
with greater severity of depression on objectively but not 
on subjectively rated scales and with lower trait anxiety.
Study II explored the functional activity of 5-HT 
receptors on platelets using platelet aggregation tech­
niques in drug-free ill depressive patients, in control 
subjects, and in patients on prophylactic lithium. It was 
found that endogenous depressive patients, and patients on 
prophylactic lithium showed 5-HT receptor supersensitivity 
in comparison with control subjects.
Study III investigated the role of folate in depression 
by determining plasma and red blood cell concentrations 
in drug-free ill depressive patients, patients on prophy-
lactic lithium, alcoholic patients and control subjects.
The therapeutic value of physiological doses of folic acid 
was studied in patients on prophylactic lithium who had 
lower plasma folate concentrations in the context of a 
double-blind placebo-controlled trial over six months.
It was shown that plasma and red blood cell folate concen­
trations were reduced in drug-free depressive patients in 
comparison with control subjects. Plasma folate concen­
trations were reduced in patients on prophylactic lithium, 
particularly unipolars, compared with control subjects.
Lower plasma folate concentrations were associated with 
greater concurrent affective morbidity in alcoholic and 
lithium-treated patients. On the trial, folate supplements 
restored lower plasma folate concentrations but were not 
associated with improvement in residual morbidity.
Study IV examined clinical, psychological and biological 
correlates of antidepressive therapies. Endogenicity scores 
on the Newcastle Scale showed a curvilinear relationship to 
response to EOT and antidepressants and a linear relation­
ship to response to prophylactic lithium. Bipolar patients 
with a family history of depression had more favourable 
responses to lithium than those with a family history of 
mania and those without a family history of affective dis­
order. Unipolar patients with pure familial depressive 
disease had more favourable responses to lithium than those 
with sporadic and depressive spectrum diseases. Good res­
ponders to prophylactic lithium showed generally less 
personality disturbance on a variety of measures than fair 
to poor responders. Patients on prophylactic lithium in­
vestigated with DST on two occasions showed non-suppression 
in one-third of cases, with few changing status from 
normal to abnormal and vice versa. DST status was not 
associated with concurrent affective morbidity or with 
morbidity over the preceding two years. Greater subjective 
side-effects were associated with greater affective morbid-
ity in drug-free ill depressives and in patients on pro­
phylactic lithium. In the latter group greater subjective 
side-effects were associated with greater affective mor­
bidity over time and with greater personality disturbance.
The comparative efficacy of 25-50% reduction in lithium 
dosage as determined by 1 2h plasma lithium levels was 
examined in the context of a double-blind study over one 
year. Lower plasma lithium levels were associated with a 
reduction in morbidity, particularly in nonendogenous uni­
polar patients and with reduction in tremor and subjective 
side-effects in general.
Last, but not least, response to lithium over six 
months in unipolar illness and over the first year in bi­
polar illness was strongly associated with long-term 
response.
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CHAPTER 1
GENERAL INTRODUCTION, AIMS AND HYPOTHESES, 
DIAGNOSTIC CRITERIA AND RATING SCALES
14
Affective disorders are by far the commonest single 
group of psychiatric disorders. Surveys of their incid­
ence and prevalence in the general population have indic­
ated a wide range of estimates. Variations in these 
estimates have been related to differences in survey 
methodology including definition, threshold for 'case- 
ness* and population studied (Bebbington, 1978). Extensive 
community surveys by Scandinavian psychiatrists have 
estimated the life-time morbid risk for affective dis­
orders at 85 per 1,000 for males and 177 per 1,000 for 
females (Essen-Moller and Hagnell, 1961). A community 
survey of women in Camberwell, England used the Present 
State Examination (PSE) (Wing et al, 1974) to define 
'caseness' found 15% prevalence of depression (Brown and 
Harris, 1978). The prevalence of depression in the 
developing world may be even greater than in the developed 
world: a community survey of women in Ugandan villages 
found a prevalence of 23% by PSE criteria for ’caseness' 
(Orley and Wing, 1979). The nine-centre International 
Pilot Study of Schizophrenia found severe manic and depress­
ive disorders to occur in all the areas investigated (WHO, 
1973).
Affective disorders are by nature recurrent (Angst et 
al, 1973), are often precipitated by psychosocial strain 
and life events (Paykel, 1978), and commonly occur against 
a background of psychosocial and economic disadvantage 
(Brown and Harris, 1978). Moreover, they are associated 
with the highest mortality rate by suicide: 15% of depress­
ive patients, whether classified as endogenous or neurotic, 
will ultimately die by suicide (Miles, 1977) and up to 
64% of suicides had suffered from primary depression 
(Barraclough et al, 1974).
Affective disorders are thus a public health problem 
that consumes a large percentage of expenditure on mental
15
health. They are a priority in psychiatric research, 
and research into their nosology, aetiopathogenesis and 
cost-effective approaches to their long-term management 
is of paramount importance.
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1. AFFECTIVE DISORDERS
1.1 Definition
A group of illnesses of variable severity in which the 
central symptom is an alteration of mood into either mania, 
depression, or both. These illnesses are by nature re­
current with a variable capacity for recovery into normal­
ity between, episodes of illness.
1.2 Symptoms and signs
1.2.1 Depression (based on Ashcroft et al (1973)
Mood; Excessive sadness or unhappiness expressed by 
the patient, or tearfulness. Facial expression and posture 
are consistent with the professed mood. An important 
feature of the mood state is the degree of reactivity shown. 
In severs depression this reactivity is lost. Another 
feature is diurnal variation of mood state. In severe 
depression there is a tendency for worsening of mood state 
in the mornings. Mood may show excessive anxiety, fearful­
ness and/or irritability.
Thought content; Thought content is consistent with 
mood and is occupied by morbid thoughts. The future is void 
and holds nothing for the patient. The patient displays a 
negative self-concept associated with self-reproaches and 
inappropriate guilt. Suicidal wishes and ideas are a common 
symptom of depression and in severe depression these may 
lead to overt, suicidal behaviour. In psychotic depression 
delusions and/or hallucinations prevail. The patient may 
express delusional ideas of guilt or sin, poverty and 
nihilism (organ or body loss or change) and/or hypochond­
riasis. Paranoid ideation appears as an alternative to 
ideas of self-depreciation and guilt. In severe cases this 
may reach delusional degrees.
Motor activity ; Observed motor activity is either 
increased, as in agitation, or decreased, as in retardation.
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Agitation is different from anxiety and is largely in­
dependent of environmental précipitants. The main 
component is one of excitement or restlessness which has 
both motor and psychic components, Subjectively the 
patient is in a state of turmoil and distress. Behaviour 
is stereotyped. The patient paces restlessly, wrings hands, 
picks at skin or screws handkerchief. Retardation shows 
in decreased motor or mental activity. The appearance of 
the patient shows lack of spontaneity in movement and/or 
lack of emotional expression of the face. The patient's 
talk is characteristically slow, monotonous and unspon- 
taneous and thought processes lack originality; the initi­
ation of a simple act requires intense concentration. In 
some cases retardation may progress to depressive stupor 
with motor movement being slowed to the state of immobility 
and muteness.
Somatic symptoms : Insomnia is a salient feature and
delayed insomnia is characteristic of severe depression. 
Appetite is usually reduced with a consequent loss of weight. 
Patients may also show excessive fatigueability dispro­
portionate to performance. Sexual disorders (loss of libido, 
impotence, amenorrhoea) are also common features.
Cognition : Cognition impairment is common in depression.
The patient may complain of inability to concentrate and 
of poor memory. Objectively he is incapable of initiating 
simple tasks and requires intense concentration. His short­
term memory is defective and he cannot retain simple items 
of information for any length of time. He may show great 
indecisiveness and judgement failure. Insight and self­
appraisal are lost in severe cases.
1.2.2 Mania (based on Winokur et al, 1969)
Mood; Mood is slated and varies from cheerfulness to 
exaltation. Mood may show irritability and hostility. 
Transient depression is common. This is shown in fleeting
18
episodes of morbid preoccupation accompanied by weeping. 
Diurnal variation of mood is also common and is constant 
for a given individual.
Motor activity; Motor overactivity is present in 
almost every case and varies from a mild accentuation of 
normal activity to a constant wild overactivity leading 
to exhaustion. A few patients show posturing and stereo­
typed movements.
Thought processes : The stream of thought is.rapid and
the patient very commonly shows pressure of speech, a 
psychic equivalent to motor overactivity. The patient also 
shows flight of ideas, which is evident in frequent changes 
in subject of talk by a process of logical association 
which can be readily followed by the observer. Punning 
and rhyming may be present.
Thought content; Thought content is consistent with 
mood state. Thoughts reflect a grandiose self-image and 
the patient experiences ideas or delusions of grandeur.
Few patients experience grandiose auditory or visual hal­
lucinations .
Somatic symptoms ; Sleep and sexual disorders are 
common in mania. Marked insomnia is characteristic.
Energy is accentuated with a marked lack of fatigueability. 
Libido is increased with consequent increase in sexual 
demands within marriage or the emergence of heterosexual 
or homosexual promiscuity.
1.3 The classification of depressive illnesses
1.3.1 Historical background
In his perplexity and concern over the phenomena of 
mental illness, man has invoked numerous and varied ex­
planations, Models of mental illness varied from the
19
religious, supernatural and demoniacal to the strictly 
medical and biological. Depression as a disease entity 
has been recognised from time immemorial. Hippocrates, 
in the fourth century B.C., recognised melancholia as a 
form of madness. Its description, however, covered a 
wide range of behavioural abnormalities subsuming all 
forms of reduction of mental activity. Its relationship 
to mania was first observed by Aretaeus in the second 
century A.D. Manic-depressive illness, as we recognise 
it nowadays, was first discussed independently by Baillarger, 
'folie a double forme', and Farlet, 'folie circulaire' in 
1854. It was the German school that set the pace of 
systematic study of the clinical phenomena of mental ill­
ness, out of which the first classification had emerged. 
Kraepelin, its outstanding representative, perfected the 
classification of the functional psychosis, dementia 
praecox (schizophrenia), and manic-depressive psychosis on 
the basis of symptomatology and course of these disorders. 
Under the rubric of manic-depressive psychosis he included 
Farlet's folie circulaire and all melancholic and manic 
illnesses, be they single or recurrent, and the variety of 
morbid fluctuations of mood, be they intermittent or 
enduring and expanding into the realm of normal variation 
of mood.
Kraepelin and, for that matter, the German school sub­
scribed to the view that aetiology of mental illness is 
almost exclusively endogenous and gave very little import­
ance to exogenous or environmental factors. Concurrently 
with these developments another school of psychiatry was 
developing a totally different approach. The psycho­
analytic school, founded by Freud, addressed itself to 
the phenomena of less severe psychiatric disturbances.
It was against this background that the psychotic-neurotic 
distinction was born, a distinction that was also related 
to the practicalities of treatment: certification and 
asylum for the psychotic were rarely called for in the
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less severe illnesses, illnesses that invited psychological 
methods of treatment.
Out of this controversy two schools of thought had 
emerged; the unitarists' view that depressive illnesses 
are variants of one illness against the separatists' belief 
in validity of the psychotic-neurotic distinction. Separ­
atists like Ross, Gillespie and Rogerson, all successive 
directors of the Cassel Hospital that has a strong psycho­
therapeutic tradition, defended their claim on the basis 
of clinical experience. Unitarists like Mapother, Lewis 
and Curran, however, supported their claim by systematic 
observations (Kendell, 1968). The controversy over the 
psychotic-neurotic distinction continued when ardent 
phenomenologists like Roth defended the separatists' view 
by systematic investigations using multivariate analyses. 
Similar investigations that applied the same statistical 
techniques did not support that distinction (Kendell,
1968) .
Other clinical distinctions were less controversial.
The unipolar-bipolar dichotomy is widely accepted and 
stands on more solid grounds, well supported by genetic, 
physiological, biochemical, clinical, pharmacological, 
personality and life-time course differences between 
these types (Perris, 1966). The primary-secondary dichot­
omy has not commanded universal acceptance and has been 
essentially an American view.
Advances in neuropharmacology, neuroendocrinology and 
clinical psychopharmacology of depressive illnesses have 
been utilised in advancing and refining nosology and have 
given birth to biological classifications of these disorders
1.3.2 Clinical classifications of depression
Numerous classifications of depressive illness have 
been proposed. These classifications varied between
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typologies that were simple or tiered and those that were 
dimensional with a variable number of dimensions. Kendell 
(1976), in a comprehensive review, spoke of a 'contemporary 
confusion' in these classifications and indicated that the 
arguments over the clinical classifications of depression 
have been much more intense than those of other psychiatric 
disorders. Part of the reason for this was that the study 
of depression was an open area for most of the disputes 
about the nature and classification of mental illness as 
a whole: whether mental illnesses are diseases or reaction 
types, whether they are independent entities or arbitrary 
concepts, whether they should be classified on the basis 
of their symptomatology, their aetiology or their patho­
genesis and whether they should be portrayed by typologies 
or by dimensions.
1.3.2.1 The psychotic-endogenous/neurotic-reactive dichotomy
The terms 'psychotic' and 'neurotic' are incapable of 
precise definition and they usually mean little more than 
'severe' and 'mild' (Bowman and Rose, 1951). The consensus 
of workers in psychiatric nosology have come to regard 
'psychotic' and 'endogenous' as synonymous, and 'neurotic' 
and 'reactive' likewise. The psychotic-endogenous type 
refers to severe depressions, often with acute onset and 
accompanied by retardation, guilt, diurnal variation of 
mood, severe insomnia, weight loss and occasionally by 
psychotic symptoms (hallucinations, delusions and gross 
loss of insight). The neurotic or reactive type consists 
of milder illnesses often accompanied by anxiety, day-to- 
day variation, self-pity, histrionic outbursts and preceded 
by stressful events. Kendell (1976), to avoid unnecessary 
confusion, referred to these syndromes as simply Type A 
(psychotic-endogenous) and Type B (neurotic-reactive).
The nature of the relationship between these two types 
has been the cause of a most enduring controversy. Roth 
and his colleagues in Newcastle (Carney et al, 1965; Gurney
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et a l , 1972) found that these are distinct illnesses and 
that both are distinctly different from anxiety states.
This contention was supported by the results of dis­
criminant function analysis of clinical ratings of 
depressive patients. Diagnostic scores obtained for 
each patient by summing the 18 largest weighting co­
efficients showed an unequivocal bimodal distribution 
(Carney et a l , 1965). Further studies confirmed this 
finding (Carney and Sheffield, 1972; Andrews et al, 1973). 
Studies by Kendell (1968), however, using similar statis­
tical techniques, obtained a unimodal distribution of 
diagnostic scores. Furthermore, Kendell used the Newcastle 
Scale (Carney et al, 1965) to classify a subgroup of de­
pressive patients and failed to find a bimodal distribution, 
He argued that the bimodal distribution found by the New­
castle group was due to a selection effect, and further 
studies replicated his findings with the Newcastle Scale 
(Kendell and Gourlay, 1970; Post, 1972; Rao and Coppen,
1979; Bech et al, 1980a).
However, Kendell acknowledged that the differences in 
symptomatology, premorbid personality, treatment response 
and lifetime course between the two extremes were too 
extensive to be regarded merely as differences in severity 
and chronicity. Eysenck (1970), however, argued that two 
dimensions were necessary to represent the variation in 
symptomatology in depressed patients, and those were dimen­
sions of neuroticism and psychoticism. Finally, Foulds' 
conception of the relationship between Type A and Type B 
was a hierarchical one (Foulds, 1976), i.e. Type B is 
characterised by the absence of Type A features rather 
than by the presence of pathognomonic features of its own. 
Evidence bearing on this conception derived from the ques­
tionnaire responses of several hundred patients (Foulds and 
Bedford, 1 975) .
Multivariate analyses have provided evidence bearing
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on this dichotomy. Cluster analytic studies produced 
a cluster that corresponds to the Type A syndrome (Overall 
et al, 1966; Pilowsky et al, 1969; Paykel, 1971; Everitt 
et al, 1971) and earlier factor analytic studies also 
produced a factor that is clinically identifiable with 
this type (Hamilton and White, 1959). These studies, 
however, failed to produce a cluster or factor that could 
be confidently identified with Type B syndrome; they either 
produced two (Overall et al, 1966) or three (Paykel, 1971) 
clusters, suggesting greater heterogeneity at the neurotic 
end of the spectrum.
1.3.2.2 The unipolar-bipolar dichotomy
The distinction between endogenous affective dis­
orders with both depressive and manic phases (bipolar) 
and those disorders with recurrent depressive or manic 
episodes (unipolar depression or mania) was first sug­
gested by Leonhard, who described the clinical pictures 
and distinct courses of these illnesses (1957). He docu­
mented the influence of heredity in their causation and 
indicated the difference in temperamental characteristics 
between these types (Leonhard, 1963). He concluded that 
bipolar patients are characterised by cyclothymic tempera­
ments whilst unipolar depressive patients had subdepressive 
temperaments. Investigations by Perris (1966) and Angst 
(1966), carried out independently, supported this dis­
tinction. Unipolar mania is an extreme variety and shows 
a similar genetic profile to bipolar depression and thus 
has been regarded as a random form of mania.
The unipolar-bipolar dichotomy was supported by 
genetic, physiological, biochemical, clinical pharmaco­
logical, personality and natural history (age of onset, 
course and mortality) differences between these two types 
(Perris, 1966). Initially these disorders were found to 
breed true, i.e. the first degree relatives of bipolar 
patients had a greater risk for bipolar illnesses and the
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relatives of unipolar patients had a greater risk for 
unipolar illnesses (Perris, 1966). Angst (1966), however, 
showed that this genetic segregation is not quite so neat; 
the relatives of bipolar patients showed a greater risk 
for developing unipolar than for bipolar illness. Six 
further studies confirmed this finding (reviewed by Perris, 
1982) who argued that differences in familial morbid risk 
for unipolar depression were related to differences of 
definitions of this disorder. Perris (1966) defined uni­
polar depression as recurrent psychotic depression and 
required that the patient should have suffered from at 
least three episodes of illness separated from each other 
by an interval of complete symptomatic remission. Other 
investigators have used much broader definitions of uni­
polar depression. Winokur applied it to all patients 
meeting criteria for primary depressive illness, and Prien 
applied it to all patients with recurrent hospital admission 
for depressive illness of any type (Kendell, 1976).
Angst et al (1978) studied the change in diagnosis of 
unipolar to bipolar depression over an observation period 
of 20 years. After three depressive episodes 31% of bi­
polar patients and 16% of the total groups of affectively 
ill patients could not yet have been diagnosed because 
they switched in a later episode to mania. This diagnostic 
error cannot be reduced substantially by selecting patients 
with more and more episodes. This may be due to the fact 
that patients with many episodes have a higher chance of 
belonging to the bipolar group than patients with fewer 
episodes.
Bipolar illness has an earlier age of onset (peak 25-29 
years) than unipolar illness (peak 40-44 years) and shows 
greater morbidity over time with a median number of epi­
sodes of eight for bipolar and five for unipolar illness 
(Perris, 1966). The length of each cycle (time from onset
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of an episode to the time of the onset of the subsequent 
episode) is shortened by 10% in unipolar and 5% in bipolar 
illness by each episode and by 1% by each year of age.
The number of cycles increases up to an observation period 
of 20 years; after that the frequency of episodes drops 
off (Angst et al, 1973).
Short-term outcome of bipolar illness was shown to 
be good in only 50% of patients (50% of bipolar patients 
had no recurrence after three years follow-up: Winokur 
et al, 1969; Carlsson et al, 1974). Moreover bipolar 
patients tend to have greater shortening of life expectancy 
(26%) compared to unipolar depressive patients (4%) (Perris, 
1966; Rorsman, 1968) and their increased mortality is not 
due to any particular causes of death. Bipolar patients 
also have a higher rate of suicide than unipolar patients 
(Mayo, 1970) .
More recently, Angst studied the outcome of bipolar 
illnesses (outcome was defined as the state of the patient 
at the time of the last follow-up). The average period 
of observation in this study was 19 years for unipolar and 
26.7 years for bipolar illness. Fewer bipolar patients 
committed suicide than unipolar patients (3.3 versus 10%), 
and 36% of bipolar and 41.5% of unipolar patients showed 
full remission at the time of follow-up. The proportion of 
full remission versus partial remission was more favourable 
in the unipolar group. Outcome was also evaluated by the 
percentage of patients who remained relapse-free during 
the last five years of the follow-up period. Only 12% 
of bipolar and 31.4% of unipolar patients satisfied this 
criterion (Angst et al, 1978).
Coppen et al (1971) studied the morbidity of recurrent 
affective disorders in the context of a study of long-term 
lithium treatment in affective disorders (the details and 
methodology of this study will be described later). Patients
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suffering from affective disorders were observed over 11 2 
weeks in the context of open and double-blind trials of 
lithium. Patients who received placebo spent 46% of their 
time with affective episodes. Bipolar patients spent more 
time with episodes (57%) than unipolar patients (30%) .
Bipolar patients also showed higher morbidity over time 
during lithium treatment (17% of time with episode) than 
unipolars (5%).
Bipolar and unipolar illnesses have proved to be hetero­
geneous groups of disorders and few subclassifications have 
been proposed. Dunner et al (1976) suggested the distinction 
between manic I (severe mania necessitating admission) and 
mania II (hypomania). Finally, Angst (1978) subclassified 
bipolar psychosis into three types: predominantly depressed 
(Dm), manic (Md), and a nuclear group suffering from severe 
mania and severe depression (MD). Unipolar depression has 
been subdivided in several ways. Andreasen and Winokur
(1979) distinguished three subgroups: familial pure depress­
ive disease (first degree relative with depression but no 
first degree relative with mania, alcoholism or antisocial 
personality disorder), depression spectrum disease (first 
degree relative with alcoholism and.or antisocial personality 
disorder), and sporadic depressive disease (no first degree 
relative with any psychiatric illness). Other attempts to 
subdivide unipolar patients by positive or negative family 
history or by early or late onset were less successful.
1.3.2.3 The primary-secondary dichotomy
Robins and associates at Washington University in St. 
Louis proposed the distinction between primary and secondary 
affective disorders (Robins et al, 1972). Primary affect­
ive disorders are depressive or manic illnesses which 
are not chronologically preceded by any other psychiatric 
disorder, while secondary affective disorders are ill­
nesses which are either preceded by another psychiatric
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disorder (alcoholism, drug-addiction, schizophrenia, 
anxiety-neurosis, personality disorder, etc.), whether 
or not it still persists, or accompanied by a life- 
threatening or incapacitating physical illness. Primary 
affective disorders are subdivided into unipolar and bi­
polar types. Unipolar illnesses are subdivided further 
into ’pure depressive disease' and 'depressive spectrum 
disease' (Winokur, 1974). The distinction between these 
subtypes is based on observed differences in family history 
between patients developing their first depressive illness 
before and after the age of 40. Pure depressive illness 
disease refers to those patients who become ill after the 
age of 40 and who show a low incidence of psychiatric 
illness in their first degree relatives. Depressive 
spectrum disease refers to patients who become ill before 
the age of 40 (mostly women) and who show a high incidence 
of psychiatric illness in their first degree relatives.
In female relatives this is mainly depression, but in men 
alcoholism or sociopathy predominate.
The primary-secondary dichotomy has several advantages.
It avoids the issue of aetiology or the endogenous-reactive 
distinction and that of severity, thus avoiding the neurotic- 
psychotic distinction. It has also allowed for the provision 
of operationally defined diagnostic criteria for the diag­
nosis of psychiatric disorders (Feighner et al, 1972).
As a diagnostic approach it has a few shortcomings.
The first is that it makes an a priori distinction that 
entails an unvalidated assumption (Roth, 1981), misclassifies 
bipolar illnesses (by definition primary illnesses) that 
follow or are associated with alcoholism. Its avoidance 
of the endogenous-reactive issue involves 'forfeiting the 
valuable therapeutic and prognostic correlates of that 
dimension' (Kendell, 1976). Another shortcoming is related 
to the great heterogeneity of secondary affective dis­
orders and the ambiguities it entails in establishing the 
association between the 'primary' psychiatric or physical
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illness and the 'secondary' affective disorder (Roth, 1981). 
Some of these shortcomings have been rectified in the more 
recently introduced diagnostic criteria, Research Diag­
nostic Criteria (Spitzer et al, 1:978) , and in the third 
edition of the American Psychiatric Association's Diag­
nostic and Statistical Manual of Mental Disorders (DSM-III)
(1980) .
1.3.2.4 The International Classification (ICD)
The demand for an internationally accepted classifi­
cation of disease prompted the World Health Organisation 
(WHO) to respond and establish such a classification.
The sixth (1948) revision (ICD-6) contained three categories 
of depressive illness; manic-depressive reaction, depress- • 
ive type, involutional melancholia (subcategories of 
Affective Psychosis) and neurotic depressive reaction.
In the eighth revision (ICD-8, 1965) a fourth category 
was introduced, reactive depressive psychosis, at the 
request of Scandinavian psychiatrists. The ninth revision 
(ICD-9, 1978) contains 16 different subcategories of 
affective disorders listed under eight different categories. 
The category 'involutional melancholia' was abolished as it 
was shown not to have independent validity and to be genetic­
ally heterogeneous (Stenstedt, 1959).
The ICD-9 did not, however, take note of the findings 
of recent research, and the terms 'bipolar-unipolar' and 
'endogenous' only appear in the glossary, and the subcategory 
'schizoaffective disorder' is placed under the category 
'Schizophrenia*. ICD-9 contains nine categories (excluding 
schizoaffective disorder) defining Affective Psychosis.
The 'manic types' refers to unipolar mania while the 
'depressed type' refers to unipolar depression. There 
are four types of circular Manic-Depressive Psychosis, which 
is equivalent to bipolar disorder; currently manic, cur­
rently depressed, currently mixed, and currently unspecified. 
The Scandinavian concept of reactive depressive psychosis
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was placed under the heading 'Other Non-organic Psychoses'. 
This was defined as 'psychotic conditions that are largely 
or entirely attributable to a recent life experience'.
The milder forms of affective disorders are listed under 
Neurotic Disorders, Personality Disorders, Acute Reaction 
to Stress, and Adjustment Reaction-
The classification and its successive revisions were 
based on committee consensus to be acceptable to psychi­
atrists in different countries with divergent orientations 
and traditions (Kendell, 1976). It was not developed on 
the basis of reliability studies. It also does not provide 
operational criteria for making diagnoses.
Significant differences when using the ICD-8 were 
demonstrated between American and British psychiatrists 
concerning the diagnosis of schizophrenia (Cooper et al, 
1972). Significant differences were also found between 
European psychiatrists (British, French and German) con­
cerning the diagnosis of affective disorders. One of its 
merits, however, is that it has a high degree of coverage,
i.e. a large pool of patients is covered by the system 
and the number of unclassifiable patients is negligible.
1.3.2.5 The DSM-III classification
The third edition of the American Psychiatric Associ­
ation 's Diagnostic and Statistical Manual of Mental 
Disorders (DSM-III) (1980) is a radical and innovative 
development in psychiatric nosology. The approach is 
an expansion and elaboration of its predecessor classi­
fications: Feighner's criteria (Feighner et al, 1972) 
and the Research Diagnostic Criteria (Spitzer et al, 1978). 
Innovations include operational definitions of all diag­
nostic categories, the adoption of a multiaxial system of 
patient evaluation, and the revision of clinical concepts 
in the light of recent research findings. It disregarded
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the time-honoured distinction between the psychoses and 
the neuroses. Affective disorders are grouped together 
and subclassified into Major Affective Disorder (Major 
Depression and Bipolar Disorder), Other Specific Affective 
Disorders (Dysthymic Disorder and Cyclothymic Disorder), 
and Atypical Affective Disorders (Atypical Bipolar Dis­
order and Atypical Depression). Major Depression is sub­
divided into With Psychotic Features, and With or Without 
Melancholia (endogenous depression). Psychotic features 
could be mood-congruent or mood-incongruent. Other 
Specific Affective Disorders are characterised by milder 
symptoms (either depressive or hypomanie and depressive) 
than for the Major Affective Disorders, but of long duration 
(greater than two years).
1.4 Personality and affective disorders
The complexities of the relationship between person­
ality and psychiatric illness have intrigued physicians 
since the days of Hippocrates, who considered illness 
including psychiatric illness as an outgrowth of morbid 
characteristics (Adams, 1939),and Hippocrates believed 
that 'melancholia' was an outgrowth of the 'melancholic' 
temperament which he related to disturbance in bodily 
humours with excess yellow bile. Interestingly, von 
Zerssen (1982), in a recent review of the world literature 
on the relationship of personality and affective disorders, 
argued strongly for a specific predisposing personality 
type to melancholia (unipolar depressive psychosis) which 
he had called the 'melancholic type'. The complexity of 
interaction between personality and affective disorders 
was recently explored by Akiskal et al (1983): personality 
characteristics have been studied as predisposing factors, 
modifiers, complications and expressions of affective ill­
ness. The methodological difficulties involved in such 
studies are formidable: difficulties of definition, measure-
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ment and controlling for the influence of illness on 
personality characteristics.
1.4.1 Personality as a predisposing factor
Analytical formulations of depressive illness had 
suggested that proneness to such development was related 
to fixation at the 'anal' stage with high levels of 'oral' 
dependency, a formulation that was suggested for obsessional 
illness (Abraham, 1960; Chodoff, 1972). Other dynamic 
formulations focused on unsatisfactory intimacy in early 
attachment leading to' self-esteem that is vulnerable to 
adulthood emotional setbacks (Arieti and Bemporad, 1978), 
or to failure to negotiate the depressive position and 
the ambivalent attachment to the loved object (Klein, 1948).
These clinical anecdotes gave way to more systematic 
investigations using psychometric methods. These studies 
were invariably retrospective assessments and thus open 
to the confounding influences of illness. Kendell and 
DiScipio (1968), using the Leyton Inventory for Obsessional- 
ism, found that unipolar psychotic depressive patients had 
higher scores than normal controls and argued that obsession- 
alism per se is protective against mania, a notion that 
was not confirmed in a large multicentre collaborative study 
(Hirschfeld and Klerman, 1979) . The latter study found 
that obsessionalism was the only deviant personality measure 
in manic patients, Metcalfe(1968) used the Maudsley Person­
ality Inventory (MPI) and found that recovered depressive 
women compared with normal controls were characterised by 
increased worry and tenseness and by rigid, unimaginative 
and habit-bound attitudes. These findings were confirmed 
by Abe and Coppen (196 9) .
Personality characteristics were also studied in 
relation to the two main subdivisions of endogenous- 
neurotic and bipolar-unipolar depressive illness. Dépress­
ives with neurotic symptom patterns scored higher on
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neuroticism than those with endogenous patterns (Kendell 
and DiScipio, 1968; Garside et al, 1970; Paykel et al,
1976a). However, Snaith et al (1971) found no relation­
ship between personality and any pattern of depressive 
symptoms.
Eysenck's Neuroticism has repeatedly been shown to be 
mood labile (Coppen and Metcalfe, 1965; Kendell and DiScipio, 
1968), and it was shown that differences between unipolars 
and bipolars at discharge disappeared at follow-up (Perris, 
1971; Hirschfeld and Klerman, 1979) or when patients became 
euthymie (Liebowitz et al, 1979). Extraversion was found 
to be less sensitive to the effects of mood (Coppen and 
Metcalfe, 1965; Kendell and DiScipio, 1968; Liebowitz et 
al, 1979) and to belong to the universe of personality 
rather than to the universe of personal illness (Bedford 
et al, 1978) .
Perris (1966) found no difference between unipolars 
and bipolars on Extraversion on admission, discharge or 
at follow-up. Liebowitz et al (1979) showed moderately 
increased extraversion in bipolars compared with unipolars, 
and Hirschfeld and Klerman (1979) reported that depressives 
had significantly lower extraversion scores than manies 
at discharge and at follow-up. Studies that used the 
16 Personality Factors Questionnaire (16PF) by Cattell et 
al (1970) examined the endogenous-neurotic distinction. 
Endogenous depressive patients were characterised by more 
submissive, dependent personality characteristics (Pilowsky, 
1979), were found to be more gloomy, pessimistic, 
cautious and .conservative (Forbes, 1972) and to have 
higher 'superego strength' (Cadoret et al, 1971) than 
patients with neurotic depressive illness who were found 
to have similar 16PF profiles to chronically anxious 
patients (Murray and Blackburn, 1974).
In her study of the pattern of hostility in affective 
illness, Blackburn (1974) used the original version of the
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Foulds’ Personality Deviance Scale, the Hostility and 
Pattern of Hostility Questionnaire (Foulds, 1965), which 
had only two subscales of extrapunitiveness and intropunit- 
iveness. She found that ill manic patients had signifi­
cantly higher extrapunitiveness than ill depressive patients 
Recovered manies, however.., had similar extrapunitiveness 
scores to ill depressives but higher scores than normal 
controls. She also found that recovered unipolar patients 
had higher intropunitiveness and extrapunitiveness scores 
than recovered bipolar patients. Higher extrapunitiveness 
has been shown to protect against neurotic breakdown in 
dysthymic states, and was also shown to be associated 
with the psychotic classes of Foulds' Hierarchy of Personal 
Illness (Foulds and Bedford, 1977).
On Sjobring's personality factors as measured by the 
Marke-Nyman Temperament Scale (MNTS) (Coppen, 1966), de­
pressive patients were found to have low validity (routine- 
bound, neurasthenic, cautious, tense and meticulous) and 
high Solidity (rigid, steady and dependable) scores compared 
to normal controls, tendencies that were suggested as 
vulnerability factors to depression in middle age (Metcalfe 
et al, 1975). Unipolar depressive patients were shown to 
have lower validity but higher Stability (cool and self- 
controlled) (Perris, 1966) and to have higher solidity 
(Liebowitz et al, 1979; Bech et al, 1980b) scores than 
bipolar patients.
In conclusion, the following personality character­
istics have been suggested as predisposing factors to 
depressive illness: introversion, lack of self-confidence, 
non-assertiveness, deficiency in social adroitness, 
dependence, tendency to worry, obsessionalism and pessimism 
(Hirschfeld and Klerman, 1979). Introversion appears to 
be more specific to unipolar depression; extraversion and 
obsessionalism to bipolar depression.
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1.4.2 Personality as a modifying factor
Personality characteristics may modify the symptomatic 
expression of affective illness. In hospitalised de­
pressives or in women, obsessionality was associated 
with more severe depressive symptoms than those with 
hysterical characteristics (Lazare and Klerman, 1968).
High neuroticism on the EPI was found the 'most important 
predictor of long-term outcome in neurotic depressive 
patients' (Weissman et al, 1978) and treatment with anti­
depressants and psychotherapy had an ameliorating effect 
on the negative impact of neuroticism on outcome in these 
patients. Similar findings were reported by Akiskal et 
al (1978). Patients with 'double depressions', i.e. co­
existing depressive personalities and major depressive 
illness, were also shown to have poor outcome compared to 
those with 'pure' major depressive illness (Keller and 
Shapiro, 1982). In a longitudinal epidemiological in­
vestigation to predict psychiatric morbidity, a low score 
on MNTS validity proved an effective predictor of poor 
outcome particularly in depressive illness (Nystrom and 
Lindegard, 1975).
Personality factors have also been examined in relation 
to treatment compliance: bipolar patients with hyper­
thymic characteristics who tended to believe that they 
were particularly creative during illness 'highs' showed 
poor compliance with lithium therapy (Jamison and Alciskal, 
1983). Compliers and non-compliers showed no significant 
differences on EPI and other personality variables 
(Jamison and Goodwin, 1983). Personality characteristics 
may also have an impact on prognosis through their psycho­
social effects: interpersonal disturbance during illness 
episodes were found to alienate spouses and retard recovery 
from depression (Weissman and Paykel, 1974) .
1.4.3 Personality in the aftermath
Assessment of the damaging effects of affective illness
35
on personality is hampered by the powerful effects of 
illness itself on its characteristics (vide supra).
Full recovery from the illness is difficult to determine 
and residual symptoms often persist. Weissman and Paykel 
(1974) showed that social recovery lags behind clinical 
recovery and a case was made for short-term psychotherapy 
following clinical recovery in combination with anti­
depressant maintenance treatment (Paykel et al,1975) .Person­
ality disturbances complicating both unipolar and bipolar 
illnesses have been documented (Akiskaland Puzantian,
1979) . The effects of psychotropic medication on
personality have been largely ignored. Patients on lithium 
prophylaxis often complain of undesirable changes 
attributed to lithium, e.g. decreased energy, enthusiasm, 
sexuality and a perception that life is flatter and less 
colourful.
The effects of prophylactic lithium have been studied 
in an international collaborative study (Bonetti et al,
1977). Unipolar and bipolar patients completed the EPI 
and MNTS on recovery and after at least three months 
lithium treatment. They found a significant decrease 
in extraversion and neuroticism scores in bipolar and uni­
polar patients respectively in comparison with their pre­
lithium scores. There was a significant increase in 
solidity scores and a significant decrease in stability 
scores in bipolar patients following lithium treatment.
The authors argued that lithium influences the habitual 
personality characteristics in addition to its influence 
on residual affective symptoms.
1.5 Chemical pathology of affective disorders
1.5.1 Introduction
Interest in the biology of depression was stimulated 
in the early 1950s by several observations, Woolley and
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Shaw (1954) observed that 5-hydroxytryptamine (5HT) has 
a strong structural similarity to lysergic acid di­
ethylamide ( LSD ) .* LSD was already known to have 
hallucinogenic properties and to produce marked alter­
ations in mood states, They proposed that 5HT might be 
involved in the regulation of mood. This proposition 
received further support by the observation that reserpine, 
while being given to patients to treat their hypertension, 
could produce severe depression in 15% of these patients 
(Bunney and Davis, 1965). Evidence was subsequently 
obtained for the monoamine-depleting effects of reserpine 
in rat brain (Shore et al, 1955). Also during the early 
1950s, physicians treating patients with tuberculosis 
with the drugs iproniazide and isoni&zid observed that 
a few of them became euphoric. Subsequently Zeller et al (1955) 
showed that these compounds inhibit the enzyme monoamine 
oxidase and therefore inhibit the degradation of brain 
monoamines. These observations were the basis of the 
monoamine hypotheses in the chemical pathology of 
affective disorders (Schildkraut, 1965; Coppen, 1967).
1.5.2 Aetiology and pathogenesis
Investigators in the fields of biological psychiatry 
and psychopharmacology found it necessary to emphasise 
the importance of adopting some of the basic principles 
in medical nosology. They insisted that (1) disease 
pictures, in this case depressions, should be classified 
according to their symptoms, course and causation, and 
(2) the concept 'disease cause' should be divided into 
two components; aetiology and pathogenesis. Pathogenesis 
was defined as the constellation of cerebral dysfunctions 
which enable psychiatric symptoms or disorders to occur; 
aetiology was defined as all factors - hereditary, 
acquired, somatic, psychological and social - which have 
contributed to the occurrence of the cerebral dysfunctions 
(van Praag, 1978) .
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1.5.3 Approaches to investigation
Several approaches have been explored to investigate 
the biochemical changes which might occur in affective 
disorders.
1.5.3.1 Animal models of depression
(a) Models produced by amine-depleting drugs, e.g. 
reserpine and a-methylparatyrosine.
(b) Models based on psychological theories, e.g.. 
Seligman's 'learned helplessness',
(c) Models based on the behavioural effects of anti­
depressants .
(d) Models based on behavioural changes induced in 
non-human primates, e.g. mother-infant separation 
and monkey peer separation.
The use of these models proved to be unsatisfactory, 
mainly on the grounds that the behaviours selected for 
study bear little or no relationship to aspects of the 
clinical syndrome.
1.5.3.2 Studies on patients
Studies of biochemical changes in peripheral tissues 
of patients with affective disorders bring home several 
formidable problems.
(a) The problem of accurate diagnosis and valid classi­
fication of the psychiatric illness under study.
(b) Standardisation of conditions in which they are 
studied, e.g. inpatient/outpatient status, nut­
ritional status.
(c) The special importance of controlling for the 
effects of drugs the patient may have taken or is 
taking at the time of the investigation.
38
1.5.3.3 Direct studies on the brain
The use of post-mortem brain tissues is fraught with 
major difficulties;
(a) many neurotransmitter concentrations and enzyme 
activities change rapidly after death, and immediate 
freezing of tissue after death is almost impossible 
for social, ethical, legal and practical reasons;
(b) the cause of death can influence results, e.g. 
oxygen deficit altering enzyme activity because the 
subject died from bronchopneumonia;
(c) patients would almost certainly have received drugs - 
drugs which might influence neurotransmitters, enzyme 
and receptor function, e.g. the effects of neuro­
leptics on dopamine receptor function in brains of 
schizophrenic patients, changes that are similar to 
the proposed pathological biochemical changes associ­
ated with the illness.
1.5.3.4 Psychopharmacological approach
In this approach the effects of antidepressants on 
biochemical functioning of the brain in experimental 
animals are studied. The researcher is faced with the 
following problems.
(a) The biochemistry of brain function in the experimental 
animal could be markedly different from that of the 
human brain. There are problems in deciding the 
optimum dose of the drug under investigation.
(b) Drugs are given to a 'normal' brain, thereby perhaps 
changing it to an 'abnormal' state.
(c) Biochemical changes caused by drugs may have no 
therapeutic significance but may account for side 
effects of the drug, e.g. lack of correlation 
between inhibition of 5HT uptake by platelets and
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therapeutic response (Coppen et al, 19 78).
1.5.3.5 Neuroendocrine approach
In this approach, neuroendocrine 'challenge' tech­
niques are used to explore the function of neurotrans­
mitter pathways in depressive patients. While this 
indirect approach has advantages of investigating the 
live brain and of being non-invasive, it has the methodo­
logical shortcomings of the direct approach and is 
hampered by the complexity of the mechanisms involved in 
controlling neuroendocrine release.
1.5.4 The amine hypotheses
The main hypotheses in the pathogenesis of depressive 
illness have been the catecholamine (Schildkraut, 1965) 
and indolamine (Coppen, 1967) hypotheses: both suggest 
a reduction in functional activity, of these amines in 
association with depressive illness. Hypotheses impli­
cating other neurotransmitters have also been proposed, 
such as the cholinergic (Janowsky et al, 1972) and the 
gabaminergic (Roberts, 1973) hypotheses.
The cholinergic hypothesis proposes an imbalance 
between the cholinergic and noradrenergic systems: 
depression associated with increased cholinergic activity 
and mania with increased noradrenergic activity. The 
gabaminergic hypothesis proposes GABA deficiency in 
depression.
Other hypotheses involve electrolytes such as sodium 
and calcium. Coppen and Shaw (1963) used an isotope 
dilution technique and found an increase in residual 
sodium (intracellular and exchangeable bone sodium) in 
both depressed and manic patients, with the latter group 
showing greater abnormality.
A detailed review of these hypotheses is beyond the 
scope of this thesis, whose main focus is on the indol-
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amine (5HT) hypothesis. The supporting evidence for 
this hypothesis will be reviewed briefly in this Chapter 
and in Chapter 4 where receptor binding studies will be 
reviewed.
1.5,4.1 The indolamine hypothesis
As stated in the introduction to this section, the 
involvement of 5HT in depression was first suggested by 
Woolley and Shaw (1954). The bulk of supportive evidence 
comes from investigations of the 5HT metabolite, 5-hydroxy- 
indole acetic acid (5HIAA) in cerebrospinal fluid (CSF) , 
of 5HT and 5HIAA concentrations in post-mortem brain 
tissue, or 5HT precursors tryptophan and 5-hydroxytrypto­
phan, and their use in the treatment of depressive illness,
Ashcroft and his colleagues (1966) were the first to 
report a reduction in CSF 5HIAA in depressed patients.
This finding was confirmed by Coppen and his colleagues 
(1972a) but not by other investigators (Bowers et al, 1969). 
The study by Coppen found a similarly reduced CSF 5HIAA 
concentration in manic patients. Moreover these reduced 
concentrations were not restored to normal on recovery 
from depression, suggesting that low 5HIAA is a vulner­
ability factor for depression.
Further studies measured 5HIAA concentrations following 
probenecid administration (probenecid blocks metabolite 
egress from CSF) and found similarly reduced levels in
odepressed patients (van Praag, 1978). Asberg and her 
colleagues (1976) found a bimodal distribution of CSF 
5HIAA in depressed patients, suggesting two distinct sub­
groups. They found that patients with low levels were more 
likely to commit suicide and with more violent methods 
than those with higher levels of 5HIAA. Similar results 
were obtained by the same group (Traskman et al, 1981).
This association between low 5HIAA, depression and suicide 
is in line with the results from post-mortem studies of
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brains of depressive and non-depressive suicides (Pare 
ët al, 196 9). A more recent study by Cochran and his 
colleagues (1976) failed to find any differences in 
brain 5HIAA concentrations between suicides and controls.
There is a controversy as to the origin of CSF 5HIAA: 
depressive patients were found to have low lumbar but 
normal ventricular 5HIAA (Curzon et al, 1980), suggesting 
a spinal rather than a central origin of lumbar 5HIAA. 
Further supportive evidence of 5HT decreased functional 
activity comes from studies of tryptophan concentrations 
in plasma and CSF of depressive patients. Coppen and his 
associates reported significantly lower plasma free and 
CSF tryptophan concentrations in depressive patients 
compared with normal controls (Coppen et al, 1973a;1972b).
A recent review of the literature (Moller et al, 1983) 
indicated that low plasma tryptophan levels were found 
in 10 out of 21 studies. Low plasma tryptophan levels 
have been associated with unipolar depression and post­
menopausal status (Coppen et al, 1973a), and plasma 
tryptophan levels also show seasonal variations (Swade 
and Coppen, 1980) .
Curzon (1969) proposed that low plasma tryptophan 
levels in depression are caused by increased peripheral 
metabolism by the high circulating levels of cortico­
steroids in this illness. Corticosteroid administration 
stimulates peripheral metabolism of tryptophan (to 
kynurenine products) by inducing hepatic pyrrolase enzyme. 
Curzon and Bridges (1970) reported that L-tryptophan 
loading in depressive patients was associated with in­
creased urinary excretion of kynurenine, but this finding 
was not confirmed by Frazer et al (1973) . Plasma kynurenine 
concentrations were found to be normal in depressive 
patients and showed no relationship to therapeutic res­
ponse to antidepressants (Wood et al, 19 78) and to L- 
tryptophan (Moller et al, 1982).
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Less controversy has surrounded the therapeutic use 
of tryptophan in depressive patients. The antidepress­
ant effects of tryptophan have been evaluated in open, 
placebo-controlled, comparative with ECT and other anti­
depressants, and in combination with ECT and other anti­
depressants studies (see review by Chouinard et al, 1983). 
Significant differences in favour of tryptophan or its 
potentiation of other treatments were found in four out 
of eight open studies, in none of the placebo-controlled 
studies, in two out of four combination studies with ECT, 
in seven out of nine comparative studies with tricyclic 
antidepressants, in three out of six comparative studies 
with tryptophan combined with tricyclic antidepressants, 
in one of two comparative studies with tryptophan combined 
with ECT, and in all five comparative studies with trypto­
phan combined with monoamine oxidase inhibitors (MAOI).
All in all it may be concluded that tryptophan has 
relatively weak effects when used alone in more severely 
depressed patients but appears to have powerful potenti­
ating effects on other antidepressants, particularly 
MAOIs.
The 5HT hypothesis, supported by all the aforementioned, 
was seriously challenged recently by new neuropharmaco- 
logical findings: the effects of antidepressants on 5HT 
binding sites. Chronic administration of most anti­
depressants caused a down-regulation (reduction in maximum 
number of receptor sites, but not their affinity,
K(j) in 5HT2 binding sites in brain tissue from experimental 
animals (Peroutka and Snyder, 1980). The time course of 
these changes is consistent with the delayed antidepress­
ant effect (2-3 weeks) and is independent of the anti­
depressant effect on amine re-uptake. These findings 
reverse the 5HT hypothesis, and suggest that depressive 
illness is associated with 5HT functional overactivity.
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The functional significance of this down-regulation in 
51-IT2 receptors remains unclear. Indeed ECT, the most effective 
antidepressive treatment, causes an increase in 5HT2 receptor 
binding or up-regulation (Kellar et al, 1981). Further­
more, studies by De Montigny and Aghajanian (1978) and 
Gallagher and Bunney (1979), using microiontophoretic 
techniques, suggest an increased responsiveness of rat 
forebrain neurones to 5HT following repeated antidepress­
ant administration. Again the time course for this up- 
regulation is consistent with the delayed antidepressant 
response.
1.5.5 Neuroendocrinology of affective disorders
The origins of a hormonal theory of mental function 
can be traced back to Hippocrates, who considered that 
emotions and behaviour are determined by chemical sub­
stances (Beaumont, 1979). Its modern era started in the 
early years of this century when Laignel-Levastine intro­
duced the concept of an 'endocrinological psychiatry' 
in 19 08 as the science that studies endocrine disturbances 
in psychiatric disorders and psychiatric disturbance in 
endocrine disorders (Bleuler, 1982). The first stage of 
investigation was observational and anecdotal, complemented 
by wild speculations about the nature of association 
between endocrine and psychiatric phenomena. There 
followed a phase of systematic investigations that merged 
with the development of neuroendocrine techniques using 
pharmacological agents that provided an indirect open 
window into brain function.
Out of the neuroendocrine systems investigated, the 
hypothalamic-pituitary-adrenal (HPA) was the most exten­
sively studied. Other neuroendocrine systems such as the 
hypothalamic-pituitary-thyroid and human growth hormone 
responses to a variety of stimulant pharmacological agents 
were also investigated (Coppen et al, 1980).
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1.5.5.1 Tests of hypothalamic-pituitary-adrenal (HPA) function
The functional activity of the HPA system has been 
extensively investigated in depressed patients. Board 
et al (1957) were the first to report an elevated con­
centration of plasma 17-hydroxy-corticosteroids (17-OHCS) 
in depressed patients. There followed reports of high 
cortisol production rate (Gibbons, 1964), elevated urinary 
free cortisol (UFC) excretion (Carroll, 1972), high free 
cortisol levels in plasma and CSF (Coppen, 1967; Carroll, 
1972) and high nocturnal plasma cOrtisol levels (Sachar 
et al, 1973). UFC has also been studied in subgroups of 
depressed patients. Patients who were clinically classi­
fied as endogenous depressives had significantly higher 
UFC levels than those who had depressive neurosis (Carroll, 
et al, 1976). Recently, Milln et al (1981) have shown that 
patients suffering from primary depressive illness ex­
creted more free cortisol in their urine than control 
subjects. Patients were also classified on the Newcastle 
Scale into endogenous and non-endogenous depressives.
Patients who were classified as endogenous had a sig­
nificantly higher UFC than both control subjects 
and non-endogenous (neurotic-reactive) depressives. 
Non-endogenous depressives had similar UFC levels to 
control subjects.
The next stage in the investigation of HPA function 
was the dexamethasone suppression test (DST). Dexametha- 
sone (a synthetic corticosteroid) administration is 
normally followed by suppression of adrenocorticotropic 
hormone (ACTH) release from the adenohypophysis and 
secondary decrease in cortisol secretion from adrenal 
cortex. Stokes (1966) was the first to report impaired 
suppression of 17-OHCS following oral dexamethasone 
administration in psychiatric patients. Over the last 
15 years, Carroll has extensively investigated the value 
of the DST in the management of depressive illness, in­
vestigations that culminated in its standardisation and
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determination of its sensitivity and specificity for 
the diagnosis of endogenous depression (Carroll et al,
1981) .
Carroll (1982) pooled the DST results of 10 in­
dependent investigations, and showed that the DST has a 
specificity (i.e. the proportion of non-depressed patients 
with normal tests) of 96%, but that its sensitivity (i.e. 
the proportion of depressed patients with abnormal tests) 
was low at 45%. A more recent series of studies by Coppen 
and his colleagues (1983) showed that the DST is highly 
sensitive to the presence of endogenous depressive ill­
ness (81%), but that its specificity is low (70%).
Abnormal DST responses were found in 11% of control subjects, 
in 49% of patients with non-endogenous depression, in 44% 
of patients with non-depressive neurotic disorders, in 47% 
of patients with senile dementia, in 22% of patients with 
chronic schizophrenia, and in 28% of abstinent alcoholic 
patients. Furthermore, abnormal DST responses as deter­
mined by post-dexamethasone cortisol concentration showed 
a significant positive correlation with the 'endogenicity' 
of depressive illness as measured by the Newcastle Scale 
(Carney et al, 1965), but not with the severity of 
depression as measured on the Hamilton Rating Scale.
Further evidence for the lack of specificity of the 
DST in the diagnosis of depressive illness comes from 
reports of high prevalence of abnormal DST responses 
in hospital medical and surgical patients (Connolly et a l , 
1968), in basic trainees under stress (Blumenfield et al, 
1970), in paranoid schizophrenia (Carmen et al, 1981)., in 
chronic schizophrenia (Dewan et al, 1982), in mania 
(Graham et al, 1982), in patients with dementia (Spar 
and Gerner, 1982; Raskind et al, 1982; Abou-Saleh et 
al, 1985a), in patients with anorexia nervosa (Walsh et 
al, 1978; Abou-Saleh et al, 1985b), and in alcoholic 
individuals (Oxenkrug, 1978; Abou-Saleh et al, 1984).
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The prognostic value of the DST has been less well 
investigated. The results of studies bearing on this 
question suggest that DST non-suppression predicts a more 
favourable response to antidepressive therapies. An early 
study by McLeod (1972) found that patients with abnormal 
DST responses responded poorly to tricyclic drugs. Studies 
by Brown et al (1979) , Greden et al (1980) and Nelson et al 
(1982) showed more favourable responses to tricyclic drugs 
in those with DST non-suppression compared to those with 
suppression. Furthermore, Brown et al (1980) reported 
that non-suppressors respond more favourably to imipramine/ 
desipramine (specific noradrenergic uptake inhibitors) 
than suppressors, while the latter group was found to 
respond more favourably to amitriptyline/clomipramine 
(specific serotonin uptake inhibitors). Greden et al (1981) 
failed to show a relationship between DST status and 
specific response to antidepressant medication. In relation 
to response to ECT the evidence is again conflicting.
Albala et al (1981), in a series of six patients, showed 
an association between abnormal DST and a good response to 
ECT in five of these patients. Papakostas et al (1981) 
reported that five of their 14 non-suppressors treated with 
ECT did not improve, a higher than usual rate of non-response 
Coppen et al (1983) showed an association between the degree 
of DST abnormality and the rate of improvement on ECT and 
antidepressant medication. In their series of 3 0 non- 
suppressors, 16 patients became suppressors at discharge 
(53%) while 14 remained abnormal on the DST, DST suppress­
ors and non-suppressors at discharge were equally recovered. 
DST non-suppression in a variety of diagnoses has been 
generally related to a more favourable response to somatic 
and psychological treatment (Reus, 1982). In schizophreni­
form disorders, non-suppression was associated with favour­
able clinical outcome at six months (Targum, 1983).
The performance of the DST is not affected by most 
psychotropic drugs. Higher doses of benzodiazepines, e.g.
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diazepam 20”4 0mg were reported to prevent HPA hyperactivity 
(Langer et al, 1979). Factors bearing on this abnormality, 
such as stress, nutritional factors (weight loss) and ageing 
were explored and an integrated hypothesis has been pro­
posed (Abou-Saleh,1985b). DST non-suppression appears to 
reflect a biological dysfunction that cuts through the 
clinically established boundaries of psychiatric nosology. 
This lack of diagnostic utility does not forfeit its 
prognostic value and abnormal DST response may indicate 
or reflect a versatile component in psychiatric disturbance 
and could serve therefore to predict or monitor the effects 
of physical and psychological interventions.
1.6 The management of affective disorders
Good management starts with a comprehensive assessment 
of the patient and his social network. Assessment will 
involve thorough history taking and examination of physical 
and mental state, and enquiries into the social network to 
elicit any further relevant information and to determine its 
response to the illness and its resources to cope with it.
It is important to determine the symptom pattern, severity 
of illness, risk of suicide and the interplay of aetiological 
factors such as genetic, personality and psychosocial.
1.6.1 The management of acute depression
The decision to start formal treatment for acute 
depression depends on careful consideration of factors 
such as severity, duration and degree of incapacitation 
by the symptoms and the personal and social context in which 
they occur. Mild depressive mood merges insensibly with 
the normal mood of unhappiness and response to life stress, 
and depressive reactions to major life crises in normal 
or vulnerable individuals rarely warrant physical treat­
ment and are better managed by supportive psychotherapy 
with or without a minor tranquilliser, e.g. a benzodiaze-
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pine for night sedation and daytime tranquillisation. 
Symptoms that are persistent and show little fluctuation, 
even in the mild form, may require antidepressant medic­
ation. The choice of treatment will essentially depend 
on the severity of the symptoms rather than their pattern 
(Paykel, 1979a).
1.6.1.1 Electroconvulsive therapy (ECT)
Electroconvulsive therapy is a rapid and most effective 
treatment for severe depressive illness (Medical Research 
Council trial. Clinical Psychiatry Committee, 1965). It 
is particularly indicated in situations of high suicidal 
risk, extreme distress, depressive stupor and physical 
deterioration. Crow et al (1984) have conclusively argued 
that it is a highly specific treatment for delusional 
depression. ECT is also indicated in depressions that are 
refractory to antidepressant medication, particularly 
those with an endogenous pattern of symptoms. The risk of 
relapse following recovery by ECT is considerable (Johnstone 
et al, 1980) and there is a strong case for continuation 
treatment with antidepressants (Coppen et al, 1981). These 
latter authors showed that patients who had receovered by 
ECT and who had received lithium continuation therapy for 
one year had significantly less morbidity than those who 
received placebo. Investigations into its mechanism of 
action suggest that the convulsion is the effective thera­
peutic component (Freeman et al, 1978) and animal studies 
have indicated that this effect is mediated by enhancing 
the sensitivity of catecholamine (Modigh, 1975; Grahame- 
Smith et al, 1978 ) and 5HT receptors (Green et al, 1977).
Unilateral ECT applied to the non-dominant hemi­
sphere was found to be as effective as bilateral ECT and 
associated with less unwanted effects such as confusion 
and memory impairment (D'Elia and Raotma, 1975). Loss 
of memory is a transient development and disappears within 
a few weeks of the end of treatment, and controlled studies
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found no significant differences on memory test performance 
between patients treated by ECT and controls who had not 
received the treatment (Weeks et al, 1980; Johnstone et al,
1980) . Patients who had received ECT in the past and who 
persistently complained that they had suffered memory 
impairment from ECT did worse on some memory tests than 
control subjects (Freeman et al, 1980). It was noted, 
however, that these patients had residual depressive 
symptoms which may account for their memory impairment.
1.6.1.2 Antidepressant medication
Antidepressant medication is indicated in the majority 
of depressive illnesses with only a few exceptions (vide 
supra). The main classes of antidepressants are the cyclic 
antidepressants and the monoamine oxidase inhibitors (MAOIs). 
The usefulness of L-tryptophan as an antidepressant was 
reviewed earlier (page 42). Cyclic (tricyclic and tetra­
cyclic) antidepressants as the first choice from the 
numerous available drugs depends on the presenting clinical 
picture and on the likelihood of the occurrence of dangerous 
side effects or drug interactions. Antidepressants such as 
amitriptyline, doxepine, mianserin and trimipramine are 
more sedative than the others and are therefore particul­
arly useful in depression associated with marked anxiety, 
agitation and insomnia. Antidepressants such as imipramine, 
desipramine, maprotiline and nomefensin are less sedative 
and may well be more useful in retarded depressions. These 
drugs show differences in pharmacodynamic properties and 
have been classified into those which predominantly inhibit 
noradrenaline uptake, such as desipramine, maprotiline 
and nomefensin; those that predominantly inhibit 5HT 
uptake, such as clomipramine, zimelidine and fluoxetine; 
and those with mixed effects such as amitriptyline and 
imipramine. The commonest side effects of tricyclic 
antidepressants are the anticholinergic and cardiovascular 
effects. Anticholinergic side effects such as dry mouth.
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impaired visual accommodation , urinary retention, constipation 
are particularly noted, and cardiovascular side effects 
such as tachycardia and palpitation commonly occur, whilst 
cardiac arhythmias are more likely to occur in patients 
with pre-existing heart disease. These side effects, 
however, are less marked with mianserin and doxepine.
Tricyclics are very dangerous in overdose, which may 
have a fatal outcome. Toxic effects include ventricular 
fibrillation, conduction disturbances, respiratory depress­
ion, convulsions and coma. Important interactions are 
with monoamine oxidase inhibitors causing hypertensive 
crises, with antihypertensive agents such as bethanidine 
and clonidine,interfering with their effects.
The MAOIs are often used in depressions that prove 
refractory to tricyclic antidepressants and particularly 
in those characterised by marked chronic anxiety symptoms 
(Sargent and :Dally, 1962). Phenelzine is the most widely 
used drug and tranylcypromine is the most powerful and 
which has amphetamine-like stimulant effects. This class 
of antidepressants interacts with tyramine-containing 
foodstuffs such as extracts of meat and yeast, pickled 
herrings, chicken liver, cheeses, causing hypertensive 
crises. They also interact with sympathomimetic amines 
such as adrenaline, noradrenaline and' amphetamine; with 
antihypertensive drugs such as guanethidine, and with 
narcotic drugs such as morphine, pethidine and cocaine.
They are occasionally combined with tricyclic anti­
depressants in the treatment of resistant depressions.
The use of lithium in acute depression is referred 
to in Chapter 5.
1.6.1,3 Psychological treatments
Supportive psychotherapy is crucial for all depressed 
patients who require reassurance and encouragement.
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Dynamic and interpretative psychotherapy is mainly 
indicated following remission of illness, whilst cognitive 
psychotherapy has been suggested for the less severe and 
more neurotic depressive illness.
1.6.2 The long term management of affective disorders
1.6,2.1 Continuation treatment
Affective disorders are by definition recurrent 
and studies of their natural history show a variable ten­
dency towards recurrence. Angst and his associates (1973) 
found that only 50% of unipolar and 15% of bipolar patients 
had a single episode over 1-12 years follow-up. Lundquist, 
in a 10-13-year follow-up however, found that 61% of his 
unipolar and 55% of his bipolar patients had had only a 
single episode (Lundquist, 1945). Pooling results from 
several studies suggests a figure of 20-40% of single 
episode unipolar or bipolar depression. An episode of 
depression usually lasts from three to six months and the 
length of the first cycle is typically two to four years; 
cycle length tends to become shorter with increasing age 
and number of cycles.
It is against this background that the case for con­
tinuation (maintenance) treatment was made (Coppen et al,
1971 ;. Mindham et al, 1973; Paykel et al, 1976b). Anti- 
depressants have the effect of bringing forward the time 
of recovery from its natural occurrence after six months 
to 4-6 weeks, whilst the phase of vulnerability continues 
and without continuation therapy symptoms commonly re- 
emerge. In placebo-controlled studies of continuation 
therapy with imipramine and amitriptyline, patients who re­
ceived placebo had significantly greater relapse rates than 
those who had received active medication over six months 
(Mindham et al, 1973; Paykel et al, 1975) and one year 
(Coppen et al, 1978a). Similar results were reported in 
patients who had received continuation therapy with imipra-
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mine for six months following recovery after ECT (Seager 
and Bird, 1962) and with lithium over one year, also follow­
ing recovery after ECT (Coppen et al, 1981).
1.6.2.2 Prophylactic treatment
Prophylactic treatment for recurrent affective dis­
orders was introduced by the discovery of the prophylactic 
effects of lithium salts. Hartigan (1963) and Baastrup 
(1964) independently reported its prophylactic effect but 
the impetus for its further investigation came after Schou 
(1974), The first systematic study was by Baasttup and 
Schou (1967), who found that in unipolar and bipolar 
patients who had received lithium for periods up to five 
years, affective morbidity was reduced from an average of 
13 weeks a year prior to lithium to two weeks a year 
following lithium. Using the same design, similar results 
were reported by Angst and his colleagues (1970) in an 
international collaborative study, and by Hullin (1972). 
These studies were criticised on the grounds that they 
were open studies and thus open to clinicians' bias, and 
for the assumption that morbidity continues unabated 
(Blackwell and Shepherd, 1968).
The second phase of study employed the approach of 
the discontinuation trial. Baastrup and colleagues (1970) 
randomly allocated lithium-treated patients to continue on 
lithium or receive placebo. Clinicians treating these 
patients were kept blind about the nature of the patients' 
medication. At the end of five months on the trial, 54% 
of patients switched to placebo relapsed, whereas none of 
those who continued on lithium had a relapse. The results 
were similar for bipolar and unipolar patients. Several 
recent doscontinuation studies confirmed this high rate 
of relapse ( Sashidharan and McGuire, 1983).
The third phase of study used the prospective trial 
design. Coppen and his colleagues (1971) randomly alloc­
ated unipolar and bipolar patients to receive lithium or
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placebo for a period of 112 weeks. Patients who relapsed 
on the trial received conventional treatment including 
antidepressants or ECT. Unipolar and bipolar patients 
on placebo had considerable morbidity and spent 30% and 
57% of their time respectively with affective morbidity.
The corresponding figures for patients on lithium were 5% 
and 17% respectively. Moreover, patients on placebo 
received significantly more antidepressant and antimanic 
medication than those on lithium. None of the lithium- 
treated patients received ECT while 43% of the placebo 
group had one or more courses of ECT.
There followed a series of studies by Prien and his 
colleagues (1973a) that compared lithium treatment with 
placebo and imipramine. Lithium proved more effective 
than placebo in both unipolar and bipolar patients, and 
as effective as imipramine in unipolar patients and more 
effective than imipramine in bipolar patients who continued 
to suffer manic morbidity on the latter medication.
Similar results were obtained by other investigators 
(Fieve et al, 1976; Quitkin et al, 1978).
The efficacy of prophylactic lithium in unipolar 
depression has been questioned (Prien, 1979) and reference 
was made to the conclusion of the American Food and Drug 
Administration Advisory Committee and the American Psychi­
atric Association Task Force on Lithium that there was 
insufficient evidence to recommend the use of prophylactic 
lithium in unipolar illness. Preliminary findings of 
Prien's most recent trial (Prien et al, 1984) 
suggest that lithium is not significantly different from 
placebo in preventing relapse, whereas imipramine and 
imipramine-lithium combination are significantly more 
effective than placebo. Reviews of the efficacy of prophy­
lactic lithium in unipolar illness indicate that it is at 
least as effective as antidepressants such as imipramine 
and amitriptyline (Schou, 1979; Coppen and Abou-Saleh,
1983) . Lithium was shown to be more effective than mapro-
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tiline (Coppen et al, 1976b) and mianserin (Coppen et al, 
1978b). The Medical Research Council's latest multicentre 
trial (1981) found that lithium was as effective as ami­
triptyline and both were more effective than placebo.
On balance the majority of studies indicate that prophy­
lactic lithium is effective in unipolar illness and the 
main reason for this conflicting evidence may be related to 
its definition (vide supra). Prien (19 74) had applied a 
broader definition including any depressive illness that 
necessitated recurrent hospital admission,
1.7 National Institute of Mental Health (NIMH) researchproject on the psychobiology of depression__________
Advances in nosology, aetiology, pathogenesis and 
psychopharmacology of affective disorders prompted the 
staff at NIMH, Bethesda, Maryland to hold a conference in 
1969 (Katz and Klerman, 1979) to review progress. Con­
ference considered that affective disorders are hetero­
geneous in nature and aetiology, that subgroups of these 
disorders have a hereditary component and/or may be associ­
ated with biological disturbances, that diagnostic criteria 
are unreliable across various settings and that psycho­
social factors play an important aetiological role in these 
disorders. It recommended that a multicentre collaborative 
study be carried out to explore and examine the complex 
relationships between clinical, psychological, biochemical 
and pharmacological factors in these disorders. The 
clinical component of the project developed reliable tools 
to elicit psychopathology such as the Schedule for Affective 
Disorders and Schizophrenia (SADS) (Endicott and Spitzer,
197 8) and the Research Diagnostic Criteria (Spitzer et al,
1978). Moreover it studied the comparative validity of 
various nosological systems and the contribution of genetic, 
personality and psychosocial factors to these disorders.
The biological component of the project involved 
the study of neurochemical, neuroendocrine and psycho-
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pharmacological parameters in relation to nosological 
entities.
A preliminary report on progress of the clinical 
component of the project was provided in 1979. The SADS 
and Research Diagnostic Criteria (RDC) were used to 
define clinical entities, and the following findings were 
reported;
1. Schizophrenic symptoms in affective disorders have 
diagnostic and prognostic significance; the term 
'psychotic depression' should be limited to impaired 
reality testing without reference to degree of in­
capacitation; situational-nonsituational and 
endogenous-nonendogenous classifications are sepa­
rate depressive subtypes, and that it may not be true 
that patients with endogenous major depressive dis­
order have a better prognosis than patients with 
nonendogenous depression (Endicott and Spitzer,
1979) .
2. The clinical entity of neurotic depression with its 
six identified definitions should no longer be used 
for its vagueness: out of 90 inpatients studied, 
only 16 met four sets of criteria and a considerable 
overlap existed between its different meanings 
(Klerman et al, 1979). . .
3. The primary-secondary dichotomy should be retained: 
patients with secondary depression have a higher 
familial prevalence of alcoholism, affective dis­
order, drug abuse, and show few sociodemographic, 
behavioural and attitudinal differences as compared 
with patients with primary depression. These types, 
however, show no differences in symptomatology and 
response to treatment (Andreasen and Winokur, 1979).
4. On a series of personality inventories, depressive 
patients showed more neuroticism, introversion and 
obsessionality than manic patients and normal
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individuals? manic patients differed from normal 
persons only on obsessionality (Hirschfeld and 
Klerman, 1979).
The biological component of the project was described 
by Maas et al (1980) and Secunda et al (1980), and its 
findings were as follows;
1. Unipolar and bipolar depression shows differences 
in behavioural and drug-response characteristics: 
unipolar depressive patients have higher levels
of agitation, anxiety and somatisation than bipolar 
patients? levels of agitation and. anxiety tended 
to decrease in unipolar patients and increase in 
bipolar patients following 2-3 weeks of anti­
depressant treatment (Katz et al, 1982) .
2. Low pre-treatment urinary MHPG and low CSF 5-HIAA 
values were associated with a favourable response
to imipramine; there was no significant relationship 
between pre-treatment urinary MHPG, CSF MHPG, 5-HIAA 
or HVA values and response to amitriptyline (Maas 
et al, 1982) .
3. Unipolar depressive patients had higher urinary nor­
epinephrine and epinephrine concentrations than 
bipolar patients; compared with control subjects, 
depressive patients had higher CSF MHPG concen­
trations, women had higher 5-HIAA concentrations 
and men had lower HVA concentrations; all urinary 
metabolites were elevated in depression and mania 
with the exception of MHPG (Koslow et al, 1983).
4. Pre-treatment measures of HPA (morning plasma 
cortisol, urine free cortisol and CSF cortisol) 
and DST results were abnormal in both depressive 
and manic patients compared with normal controls ; 
there were no differences in rates of non-suppression 
between unipolar and bipolar patients, and DST non­
suppression did not segregate between melancholic.
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endogenous or psychotic depression subtypes; 
patterns of post-DST plasma cortisol concentration 
other than simple escape or non-escape from suppres­
sion were common ; there were significant differences 
in HPA measures of depressed patients studied at 
different centres; age correlated positively and 
body weight negatively with plasma cortisol level 
(Stokes et al, 1.984) .
A further report on the findings of the clinical com­
ponent of the project was presented at the 14th Congress 
of the Collegium Internationale Neuro-Psychopharmacologicum 
(CINP) in June 1984. These findings were as follows;
1. There were no differences in lifetime prevalence rates 
of affective disorders, in first degree relatives between 
endogenous and nonendogenous depressive patients . Defin­
ition of endogenous/nonendogenous depression included 
the RDS, DSM-III, Newcastle and Yale criteria.
2. Situational major depression is associated with 
significantly higher distress scores on the Paykel 
and Tennant measures and more birth events than non­
situational major depression. Non-situational 
depression is associated with more prior affective 
episodes and hospitalisations than situational 
depression. These subtypes are similar- in clinical 
and personality (17 measures) characteristics.
3. Depression with mood-congruent and mood-incongruent 
psychotic features had a poorer outcome at six 
months than non-psychotic depression; patients with 
psychotic features were more likely to have episodes 
with manic features, to have an earlier age of onset 
and psychotic depression tended to 'breed true', i.e. 
patients with psychotic depression tended to have 
relatives with psychotic symptoms when depressed.
4. Patients with double depression, i.e. major depress­
ive disorder superimposed on a pre-existing inter­
58
mittent depressive disorder or chronic minor de­
pressive disorder of at least two years duration 
had variable outcomes in relation to their sequence 
pattern of the major and minor affective disorder; 
patients whose dysthymia occurred first and who 
entered the study with their first episode of major 
depression had a significantly faster time to 
recovery than patients in whom a major depression 
preceded their first dysthymia. Patients whose 
dysthymia occurred first and who had at least 
two lifetime episodes of major depression had 
an outcome which was intermediate between these
two groups.
5. A pattern of decreasing prevalence (by interview
and history methods) of bipolar I disorder in first 
degree relatives of patients with schizoaffective- 
manic, bipolar I, bipolar II and primary major 
depression (unipolar) confirms Gershon's hierarchy 
of severity of illness (Gershon et al, 1982) except 
for schizoaffective-depressed patients whose first 
degree relatives had an excess prevalence of schizo­
phrenia. The rate of bipolar II illness was highest 
in the relatives of bipolar II and major depressive 
patients suggesting that bipolar II and unipolar ill­
nesses are heterogeneous, having one form related 
to bipolar I and another being a phenocopy, i.e. 
clinically indistinguishable but not related in 
aetiology to bipolar I illness.
In a double-blind, long term follow-up study, the 
efficacy of lithium carbonate, imipramine, or their com­
bination was evaluated in 117 bipolar patients and in 150 
unipolar patients, and was compared with placebo in the 
latter group. With bipolars, lithium carbonate and the 
combination were superior to imipramine in preventing manic 
recurrences and were as effective as imipramine in preventing 
depressive episodes. The combination treatment provided no
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advantage over lithium carbonate alone. With unipolars, 
imipramine and the combination were more effective than 
lithium carbonate and placebo in preventing depressive 
recurrences. The combination treatment provided no 
advantage over imipramine alone. The lithium carbonate- 
treated group had fewer manic episodes than the other 
groups. Lithium carbonate was equally as effective as 
imipramine with patients whose index episode was of moder­
ate severity but significantly less effective than imipramine 
in patients whose index episode was severe (Prien et al, 1984)
2. DISCUSSION OF THE REVIEW
This general introductory section is not meant to be 
an exhaustive review of the literature on affective dis­
orders , which is beyond the scope of this thesis. It is 
meant to be a selective review of aspects of affective 
disorders that are relevant to the subjects under investi­
gation such as nosology, personality, biochemistry and 
psychopharmacology.
This general introductory review is complemented by 
more detailed reviews of aspects of depression that are 
relevant to the studies described in this thesis, such 
as nutritional factors (folic acid) in Chapter 4, 5HT in 
Chapter 3, predictors of treatment response, particularly 
response to prophylactic lithium, in Chapter 5. The 
review suggests that depressive illnesses show great 
heterogeneity along several different dimensions: clinical, 
psychological, biological and therapeutic. The NIMH study 
took stock of the recent advances in psychiatric nosology, 
biochemistry and psychopharmacology of depression and set 
a precedent for the large multicentre and multisystem in­
vestigation. Its findings are not a final statement on 
those aspects, particularly the more controversial ones 
such as the contribution of genetic factors to the endo-
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genous-nonendogenous and the situational-nonsituational 
distinctions in depression, the relationship between 
personality and affective disorders, the diagnostic and 
prognostic value of the DST in the management of depression 
and the usefulness of lithium in the prophylaxis of uni­
polar depression. The NIMH project, however, is a monumental 
achievement and its findings are true approximations to 
valid and comprehensive formulation of the phenomena of 
depression. Concurrently with multicentre national studies, 
multicentre international collaborative studies were con­
ducted by the World Health Organisation (WHO). The short­
comings of the multicentre national study were only 
magnified in the international scene: differences in patient 
populations, difficulties in ensuring reliability and 
standardisation of diagnoses, differences of language and 
culture and varying traditions of psychiatric theory and 
practice.
This review provides the following observations :
1. Further studies of the clinical and psychological 
characteristics of patients with endogenous, nonendogenous 
and bipolar depressions are needed.
2. The findings of ligand-receptor binding studies are 
provocative and call for a revision of the monoamine 
hypothesis in the pathogenesis of depression. This notion 
must be set against the notion that changes in receptor 
number or affinity are not necessarily reflected in changed 
synaptic function; functional response to receptor 
stimulation or inhibition may be a more valid indicator
of the functional activity of a particular monoamine 
receptor.
3. Nutritional factors have been largely ignored in 
biological investigations of affective disorders.
4. Further studies are in demand on the prediction of 
response to antidepressive therapies, particularly response 
to prophylactic lithium. Potential predictors include 
clinical, psychological, biological and pharmacokinetic 
factors.
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3. AIMS AND HYPOTHESES
This thesis consists of a series of studies that 
explore the complex relationships between the main 
dimensions of the construct of depressive illness, 
clinical, psychological, biological and therapeutic, 
with the aim of determining correlates of the two main 
clinical distinctions; the endogenous-nonendogenous and 
unipolar-bipolar along these dimensions. Differences 
between these clinical subtypes on these dimensions would 
validate these distinctions.
In view of the notion that the thesis consists of a 
series of studies on the aforementioned aspects of depress­
ive illness, it was thought appropriate to present these 
studies separately under the particular aspects clinical- 
psychological, biological and response to treatment.
3.1 Clinical-psychological aspects
The aim of the study was to examine clinical and psycho­
logical characteristics of patients with endogenous, non­
endogenous and bipolar depression. Clinical variables 
studied were illness severity both subjectively and ob­
jectively rated, age of onset, the presence of family 
history of affective disorder, and number of previous epi­
sodes of illness. Psychological variables studied were per­
sonality factors assessed on five personality questionnaires 
The hypothesis was that endogenous depressive patients 
have more severe illnesses, later age of onset, higher 
prevalence of affective disorder in first degree relatives 
and greater number of previous episodes of illness com­
pared to nonendogenous patients ; patients with endogenous 
depression are similar to bipolar patients in their 
psychological characteristics, and both of these subtypes 
are less deviant in these characteristics than patients 
with nonendogenous depression.
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3 .2 Biological aspects
3.2.1 Peripheral 5HT receptor functional activity
The aim of the study was to investigate the functional 
activity of platelet 5HT receptors in acute, drug-free 
depressed patients, in recovered patients receiving long­
term lithium therapy, and in normal control subjects. The 
hypothesis was that platelet 5HT receptors are subsensitive 
in depressed patients compared with recovered patients on 
lithium and normal control subjects.
3.2.2 Folic acid
The aim of the study was to investigate the relation­
ship between plasma and red blood cell folate concentrat­
ions and depressive illness, and evaluate the antidepress­
ant effects of physiological supplements of folic acid in 
lithium-treated patients with low plasma folate concen­
trations. The hypothesis was that low plasma and red blood 
cell folate concentrations are associated with the presence 
of affective morbidity and that physiological supplements 
of folic acid have antidepressant effects in folate- 
deficient patients.
3.3 Response to antidepressive therapies
3.3.1 Response to ECT and antidepressants
The aim of the study was to investigate acute anti­
depressive responses to ECT and antidepressants in relation 
to endogenicity of depression. The hypothesis was that 
patients with more endogenous illnesses have better res­
ponses than those with less endogenous illnesses.
3.3.2 Response to prophylactic lithium
The aim of the study was to investigate clinical, 
psychological, biological and pharmacokinetic correlates of 
response to prophylactic lithium. The aims of hypotheses 
of this study are outlined in Chapter 5.
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4. DIAGNOSTIC PROCESS AND CRITERIA
4.1 Diagnostic process
Depressive patients admitted to the MRC Neuropsychi­
atrie ward for treatment and investigation were assessed 
by at least one clinician (M. T . Abou-Saleh) and often 
by another clinician (Dr. P. Milln then Dr. D. Saffer).
The admitting physician, following a general psychiatric 
assessment, examination of physical and mental states and 
interviews with relatives, would rate the severity of 
depressive illness on the Hamilton Rating Scale (HRS).
The patient is classified on the Newcastle Diagnostic 
Scale and the ICD within the first week of admission.
A senior clinical psychologist (Mrs. M. Metcalfe) would 
then make an independent clinical assessment on the New­
castle Scale and the HRS, and any differences were settled 
by discussion with the clinician or clinicians. The self- 
rated questionnaires such as the BDI and MAS., and subjective 
side-effects checklist were also administered within the 
first week of admission. All this information was presented 
at the ward's clinical conference when the diagnosis and 
classification were settled after consultation with Dr.
A. Coppen.
Clinical assessments continue throughout the patient's 
admission and these include weekly ratings on the HRS by 
the clinician and/or the senior clinical psychologist, and 
weekly self-ratings on the BDI and subjective side-effects 
checklist.
4 .2 Diagnostic criteria
4.2.1 Acute depressive illness
All acutely depressed patients studied in the present 
series of investigations fulfilled the diagnostic criteria 
for primary depressive illness (Clinical Psychiatry Report 
to the Medical Research Council, 1965) or the Research Diag­
nostic criteria for major depressive disorder (Spitzer et al, 
1978). All patients were also diagnosed in accordance with
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the ICD-9 and fulfilled a criterion of severity (a score 
of 16 or above on the first 17 items of the HRS).
4.2.2 Recurrent affective disorder
The diagnoses of recurrent affective disorders were 
based on the presence of at least three previous affect­
ive episodes. Recurrent affective disorders were sub­
divided into bipolar and unipolar illnesses. The diagnosis 
of bipolar illness was based on the presence of at least 
one previous or current undisputed manic episode that 
necessitated admission to hospital, and the diagnosis of 
unipolar depressive illness was based on the presence of 
at least three previous episodes of primary depressive 
illness. Prophylactic lithium was only started in the 
context of or following recovery from the third episode 
of illness in both bipolar and unipolar patients.
5. RATING SCALES USED IN THE STUDIES
5.1 Observer-rated scales
5.1.1 Affective Morbidity Index
Coppen et al (1973b) , in their double-blind and open 
prospective studies of lithium prophylaxis in affective 
disorders, have evolved a sensitive measure of affective 
morbidity over time. This is based upon a frequent 
assessment of the patient's clinical state - well or ill.
If the patient is ill, he will be assessed weekly; if well, 
at intervals of not more than 6- 8 weeks. On each occasion 
the patient is seen, his affective state is plotted on 
the special chart shown in Fig. 1.1, using a 4-point 
global scale as follows:
0 = no conspicuous affective disturbance
1 = mild depression or mania
2 = moderate depression or mania
3 = severe depression or mania.
This chart is also used to gather data on a self-
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rating inventory (Beck Depression Inventory? BDI). On 
this chart are recorded other medications, ECT, inpatient 
periods, outpatient episodes and plasma lithium levels.
The patient's weight and any concurrent physical illness 
and side-effects are also recorded. At each attendance 
the patient also completes a standardised side-effects 
checklist (see Appendix 1.) and the total side-effects 
score on this checklist is recorded on the chart.
From these charts an Affective Morbidity Index (AMI) 
is devised which includes both the time spent with and 
the severity of an episode. A line is drawn between the 
points indicating the degree of affective disorder (mania 
or depression) on each occasion. The area under the curve 
is then calculated and divided by the relevant time period. 
The Index is expressed as a mean clinical rating unit per 
unit of time. The unit time used is one week. For 
example, if a patient has an AMI of 0.5 for a 16-week 
period, this is equivalent to a mean clinical rating of
0.5 throughout the whole period. The AMI could also be 
calculated for any period of time, from months to many 
years. For example, if a patient has an AMI of 0.1 over 
one year, this would indicate that the patient had 
suffered 5.2 weeks of mild depression. An Index of 0.2 
over one year would indicate that the patient had suffered 
10.4, weeks of mild or 5.2 weeks of moderately severe 
depression.
5.1.2 The Newcastle Diagnostic Scale
This Scale was developed by the Newcastle School 
(Carney et al, 1965) who studied 129 inpatient depressives 
treated with ECT. Initially the patients were scored for 
the presence or absence of 35 features considered to 
discriminate between endogenous and neurotic depressives. 
Factor analysis of these features produced three signifi­
cant factors: a bipolar factor corresponding to the dis­
tinction between endogenous and neurotic depression; a
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general factor with high loadings for many features 
common to all depressive patients studied; and a paranoid 
psychotic factor. The bipolar factor, i.e. the factor 
that showed large negative as well as large positive 
loadings, was conceived as a dimension of endogenous- 
neurotic depression that was independent of the severity 
of depression (the general factor). Features with high 
positive loadings on this factor were adequate pre-morbid 
personality, absence of adequate psychogenesis, weight 
loss, pyknic body build, occurrence of previous depressive 
episode, early morning awakening, psychomotor disturbance 
(agitation or retardation), nihilistic, somatic and para­
noid delusions, and ideas of guilt. Features with high 
negative loadings were anxiety, aggravation of symptoms 
in the evening, self-pity, a tendency to blame others, and 
hysterical features. The positive and negative loadings 
correspond to clinical diagnoses of endogenous and neurotic 
depression respectively (Appendix 2 ).
The Newcastle Diagnostic Scale was developed by use 
of discriminant function analysis of these features and 
is based upon a weighted sum of scores on each of the 
10 items of the Scale (see Appendix 2 ) . A total scores 
of >6 indicates an endogenous category, while a total 
score of <5 indicates non-endogenous depression.
Carney et al (1965) also studied the frequency dis­
tribution of the patients' Newcastle Diagnostic Scale 
scores. They obtained a bimodal distribution which, in 
their view, supported the neurotic-endogenous dichotomy. 
Kendell (1968), however, obtained a unimodal distribution. 
Further studies also showed unimodal distributions (Rao 
and Coppen, 19 79? Bech et al, 1980a). The diagnostic scale 
was shown to have high inter-rater reliability for diag­
nostic category (90%) and interclass coefficients (r=0.82) 
(Bech et al, 1983). Davidson and colleagues (1984) found 
similarly high inter-rater reliability for diagnostic
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category (95%) with a K value of 0.66, and for individual 
items, agreement as to their presence or absence occurred 
between 69% of the time in the case of guilt and 1 0 0 % in 
the case of delusions. Inter-rater agreement on the item 
of adequate personality (an elusive concept that was 
ambiguously defined) was 8 6 % and this was achieved by 
redefinition of this item that emphasised the social mal­
adjustment component of Carney's definition focusing on 
the quality of close interpersonal relationship by the 
ability to establish stable caring relationships, 
stability of work history, use or abuse of alcohol and 
drugs.
5.1.3 The Hamilton Rating Scale for Depression
The Hamilton Rating Scale for Depression (HRS) is an 
observer rating scale for the measurement of depressive 
states. The original version of the HRS (Hamilton, 1960) 
consisted of 17 items covering depressive symptoms. In a 
later version (Hamilton, 1967), item no.9 (agitation) was 
redefined from the previous 3-point scale to a 5-point 
scale. This version of the HRS is the one used in the 
present study (see Appendix 3). it consists of nine 
items defined on 5-point ordinal scales and eight items 
defined on 3-point scales. As a symptom rating scale, 
they intend to cover the state of the patient's condition 
during the preceding three days. Evaluation of items of 
sleep disturbance was based upon the patient's retro­
spective estimate of the last three nights. The inter­
observer reliability of the HRS has been found adequately 
high in various settings (Hamilton, 1967; Bech et al, 1979). 
Its concurrent validity has also been established by 
correlating the total score with a global clinical assess­
ment of the depressive scale (Weiner, 1972; Bechet al, 1975),
with a clinician's global judgement of response to treat-*ment (Montgomery and Asberg, 1979), and with the Beck 
Depression Inventory (Bailey and Coppen, 1976) .
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5.2 Self-rated scales
5.2.1 The Beck Depression Inventory
The Beck Depression Inventory (BDI) was one of the 
first self-rating scales for depressive symptomatology 
(Beck et al, 1961). It contains 21 items. Each item 
consists of a graded series of statements and the patient 
is asked to select the single statement in the domain of
each item that corresponds most closely to his actual
condition. Numerical values from 0 to 3 are assigned to 
each statement to indicate the severity of depression.
The total score is obtained by adding the scores of the 
21 items; the BDI score is consequently 0 to 63.
The items were chosen on the basis on their relation­
ship to the overt behavioural manifestations of depression 
and do no reflect any theory regarding the aetiology of 
depression.
The concurrent validity of the BDI has been evaluated 
by correlating the total score on the BDI with global assess­
ment (Beck et al, 1961; Metcalfe and Goldman;, 1965;’ Bech et al, 
1975) and with the HRS (Bailey and Coppen, 1976; Bech et al,
1975).
5.2.2 The Eysenck Personality Questionnaire
The Eysenck Personality Questionnaire (EPQ) was 
based on the original Eysenck Personality Inventory with 
an added dimension of psychoticism (Eysenck and Eysenck,
1976). The other dimensions are extraversion-introversion, 
neuroticism, and a lie scale that is directed to detect 
subjects that fake good responses. The EPQ has been 
extensively employed in the study of abnormal psychology.
5.2.3 Foulds' Personality Deviance Scale
Foulds' Personality Deviance Scale (PDS) consists of 
three scales intended to measure extrapunitiveness (E),
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intropunitiveness (I) and dominance (D) (Foulds, 1976). 
Although the actual items differ, the PDS is in part a 
modification of the Hostility and Direction of Hostility 
Questionnaire (Caine et al, 1967), with some additions 
and omissions. The D scale was added and the format was 
changed from a simple Yes/No one to a 4-point scale of 
never, seldom, often, nearly always. The E scale consists 
of six items intended to assess hostile thoughts and six 
to assess denigration of other people. The I scale is 
made up of six items intended to measure lack of self- 
confidence and six to assess over-dependency, both of which 
at least strongly imply a self-critical attitude. The 
D scale consists of six items intended to assess dominance 
and six items to assess overt or uninhibited aggression.
5.2.4 The Marke-Nyman Temperament Scale
The Marke-Nyman Temperament Scale (MNTS) is a self- 
rated personality questionnaire that is based on Sjobring's 
theory of personality structure (Sjobring, 1973), and 
measures three dimensions of personality; validity, 
stability and solidity (Nyman and Marke, 1962). The 
Scale was translated into English by Coppen (1966).
Validity is a measure of available and effective 
energy: it ranges from the cautiousness and weakness of 
the subvalid individual to the high level of energy, self- 
confidence and adaptability of the supervalid.
Solidity is a measure of organisation and integration: 
it ranges from subsolidity (changeability, subjectivity, 
impulsiveness) to supersolidity (steadiness, dependability, 
rigidity).
Stability is a measure of emotional control: it 
ranges from substability (warmth, naivety, sociability) 
to superstability (self-control, coolness and sophistic­
ation) .
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5.2.5 The Crown-Crisp Experiential Index
The Crown-Crisp Experiential Index (CCEI) is a self- 
rated scale that consists of 48 questions which was designed 
so that a total score could be obtained to provide a 
measure of general emotionality or 'neuroticism' together 
with a profile of six subscale scores (Crown and Crisp, 
1966). The six subscales measure respectively free-floating 
anxiety (FFA), phobic anxiety (PHO), obsessionality (OBS), 
somatic concomitants of anxiety (SOM), depression (DEP), 
and hysterical personality (HYS).
5.2.6 The Salkind Morbid Anxiety Scale
The Salkind Morbid Anxiety Scale (MAS) is a self-rated 
questionnaire to measure trait anxiety (Salkind, 1973).
5.2.7 The subjective side-effects checklist
The subjective side-effects checklist (Ghose, 1977) 
is a 36-item list of symptoms/complaints commonly reported 
by patients receiving psychotropic medication: each item 
is rated on a 4-point scale from no symptoms = 0 to severe 
symptoms = 3 (see Appendix 1 ).
5.2.8 The Severity of Alcohol Dependence Questionnaire
The Severity of Alcohol Dependence Questionnaire (SADQ) 
was constructed by Stockwell and colleagues (1979) to 
measure the subjectively rated severity of alcohol depend­
ence.
CHAPTER 2
CLINICAL CLASSIFICATION OF DEPRESSION: 
CLINICAL AND PSYCHOLOGICAL CORRELATES
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j_. INTRODUCTION
The controversy over the clinical classification of 
depressive illnesses remains an unresolved one. Kendell 
(1976), in a comprehensive review, spoke of a 'con­
temporary confusion' in these classifications. Three 
dichotomies or distinctions have so far emerged; the 
psychotic-neurotic or the endogenous-reactive, the 
unipolar-bipoiar, and the primary-secondary. Out of 
these the psychotic-neurotic or endogenous-reactive has 
been the most controversial and the most elusive to 
define, despite its wide acceptance and use in clinical ’ 
practice.
Definitions of endogenous-nonendogenous depression 
include the two Newcastle scales (Carney et al, 1965; 
Gurney et al, 1972), the RDC (Spitzer et al, 1978), ICD, 
DSM-III, the Michigan Diagnostic Index (Feinberg and 
Carroll, 1982), and Klein's endogenomorphic depression 
(1974) .
The unipolar-bipolar distinction stands on more solid 
grounds, well supported by genetic, neurophysiological, 
biochemical, clinical pharmacological, personality and 
lifetime course differences between the types. A more 
comprehensive review of clinical classifications of 
depression is provided in the General Introduction.
This review provided the following observations :
1. The Newcastle definition of endogenous-nonendogenous 
depression has not been examined in relation to the 
ICD.
2. The frequency distribution of depressive patients' 
scores on the Newcastle Scale has not been studied 
in a sufficiently large series of patients success­
ively admitted to hospital for treatment.
3. The Newcastle distinction requires further investi-
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gation in terms of clinical and psychological 
characteristics.
2. AIMS AND HYPOTHESES
The aim of this study was to examine differences in 
clinical and psychological characteristics of depressive 
patients classified on the two dichotomies; endogenous- 
nonendogenous and unipolar-bipolar. The frequency 
distribution of patients' Newcastle scores in relation 
to the international classification (ICD-9) was also 
determined. Moreover the relationships between the 
Newcastle Scale and observer-rated severity of depression 
(HRS), self-rated depression (BDI) and self-rated, trait 
anxiety (MAS) were studied.
It was hypothesised that nonendogenous depressives 
have more abnormal psychological characteristics than 
endogenous and bipolar depressive patients; that patients' 
Newcastle scores have a unimodal distribution; that the 
Newcastle distinction endogenous-nonendogenous depression 
corresponds to respective ICD categories, and that 
greater endogenicity on the Newcastle Scale is associated 
with greater severity of illness on both observer- and 
self-rated scales and with lower trait anxiety scores.
3. PATIENTS AND METHODS
Two hundred and fifty-four female and 93 male 
depressed patients successively admitted to the MRC 
Neuropsychiatry ward were studied. They were all classi­
fied according to ICD-9 and the Newcastle Scale. One 
hundred and fifty-five of these patients were rated on 
the HRS, 97 patients completed the BDI, and 76 patients 
completed the MAS on admission and discharge.
3.1 Clinical correlates
The case notes of 196 monopolar (less than three
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recorded episodes) and unipolar, and 86 bipolar patients 
were studied, and information on age of onset, number of 
previous episodes and family history of depression in 
first degree relatives was obtained.
3.2 Psychological correlates
Unipolar and bipolar patients who were receiving 
long-term lithium therapy completed the following person­
ality questionnaires at a time when they showed no conspicuous 
morbidity; EPQ, PDS, MNTS and CCEI questionnaires.
4. RESULTS.
4.1 Clinical correlates
The distribution of the Newcastle scores of all 
patients was unimodal (Fig. 2,1). Patients classified 
under ICD-9 category of neurotic depression (300,4) 
segregated neatly around the neurotic end of the scale 
and had lower Newcastle scores than those classified as 
manic-depressive psychosis type (296,1).
Only 4% of patients with neurotic depression were 
misclassified on the Newcastle Scale while up to 33% of 
patients with manic-depressive psychosis, depressed type 
were misclassified as neurotic depressives on this Scale.
Patients with endogenous depression (Newcastle score 
>6 ) had a significantly higher mean age than those with 
nonendogenous depression (Newcastle score <5), Age showed 
a highly significant positive correlation with the New­
castle score (r = 0.38, p< 0,001). Patients with endo­
genous depression had a significantly higher mean age of 
onset, mean number of previous episodes of depression 
than those with nonendogenous depression (Table 2.1),
However, the two groups showed no difference in terms of 
the prevalence of family history of depression.
Patients with bipolar depression had a significantly
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lower mean age than those with endogenous depression and 
a. significantly lower mean age of onset that both the 
endogenous and nonendogenous groups. They also had a 
significantly higher number of previous episodes than 
those with nonendogenous depression. They had a higher 
prevalence of depression in their first degree relatives 
than both endogenous and nonendogenous patients. This 
difference, however, was not significant by analysis.
The Newcastle score showed a significant correlation 
with the HRS (0.41; p<  0.001) but not with the BDI (r = 0.19). 
There was a significant negative correlation between the 
Newcastle score and the Salkind score at discharge (r = -0.28; 
p<0.01), but not with the Salkind score on admission 
(r = 0 .04 ) .
On admission, endogenous and nonendogenous depressives 
had. similar MAS scores. At discharge, however, endogenous 
depressives had significantly lower MAS scores than non­
endogenous depressives (Table 2.2).
4 .2 Psychological correlates
On psychological variables there were no significant 
differences between endogenous and nonendogenous depress­
ives on the EPQ and PDS variables (Tables 2.3 and 2.4). 
Significant differences between these groups were observed 
on MNTS validity and on all CCEI subscales (Tables 2.5 
and 2.6). Bipolar depressives compared to nonendogenous 
unipolar depressives showed significant differences on 
MNTS validity, and CCEI FFA, DEP, PHO and SOM. Compared to 
endogenous unipolars, bipolar depressives showed signifi­
cant differences on the EPQ extraversion and lie scales, 
on the PDS extrapunitiveness and the MNTS solidity.
5. DISCUSSION
5.1 Clinical correlates
These results are in agreement with Kendell's view
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that the relationship between endogenous (Type A) and 
nonendogenous (Type B) illnesses is a dimensional rather 
than a categorical one (Kendell, 1968). The distribution 
of the Newcastle scores of all the 347 patients was un­
equivocally unimodal.
This is contrary to the findings of Carney et al 
(1965) and Kiloh and Garside (1977) who found a bimodal 
distribution of diagnostic scores, but is in harmony with 
the results of other investigators (Kendell, 1968; Rao and 
Coppen, 1979; Bech et al, 1980&). The Newcastle Scale 
classification showed remarkable correspondence to the 
ICD-9 classification except for the notion that the ICD-9 
definition of endogenous depression (296.1) was broader 
than that of the Newcastle Scale. The ICD classifications, 
despite their poor reliability, embrace simple clinical 
classifications adopted by most clinicians in their 
practice. A halo effect cannot be ruled out as both 
classifications were applied by the same clinician.
The validity of the Newcastle Scale was examined by 
comparing it with four other definitions of endogenous- 
nonendogenous depression: the RDC, DSM-III, the Michigan 
Diagnostic Index (MDI), and Klein’s endogenomorphic 
depression scale (EDS) (Davidson et al, 1984). Signifi­
cant associations were found between the Newcastle Scale 
and all these definitions. In comparison with the RDC 
and MDI, fewer patients were diagnosed as having endogenous 
depression, i.e. RDC and MDI more broad but more patients 
were diagnosed as having endogenous depression when 
compared with the DSM-III and EDS, i.e. DSM-III and EDS 
more narrow.
The significant but moderate correlation of Newcastle 
scores and HRS scores in the unipolar group confirmed the 
view that endogenous depressive illness is a more severe 
illness than neurotic depressive illness (Kendell, 1976). 
This finding is not in harmony with the results of other
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studies that found that severity as measured by the HRS 
was independent of the Newcastle Scale (Carney and 
Sheffield, 1972; Bech et al, 1980a). However, Davidson 
et al (1984) found an association between the Newcastle 
Scale and the Montgomery-Âsberg rating scale (Montgomery 
and Asberg, 1979) but not with the HRS.
The argument for summing the 17 items of the HRS 
to measure the severity of depression was based on the 
finding of a general factor in the HRS (Hamilton, 1967). 
However, in his earlier factor analytic study, Hamilton 
(1960) failed to find a general factor indicating severity. 
Bech et al (1975), using non-parametric analysis, found 
that only six of the 17 items on the HRS had concurrent 
validity and concluded that the summed item-score of this 
subscale is a measure of severity of the depression whilst 
the other items may have more diagnostic value.
The lack of a significant correlation between the 
Newcastle scores and the BDI in these patients could mean 
that endogenous depressives do not perceive themselves 
as more ill than nonendogenous depressives, given the 
tendency of the latter group to exaggerate their symptoms 
and the tendency of the former group to deny their symp­
toms, a notion that is confirmed in the present investi­
gation by this group's high lie scale scores on the EPQ.
The lack of significant correlation between Newcastle 
scores and MAS scores on admission and the significant 
negative correlation between these two sets of scores on 
discharge may be due partly to the negative loading of 
the presence of anxiety symptoms on the Newcastle Scale 
(Carney et al, 1965) and partly to the notion that the 
MAS is a measure of trait anxiety and neuroticism (Salkind, 
1973), and indeed endogenous depressives had similar MAS 
scores to nonendogenous depressives on admission but 
significantly lower MAS scores at discharge, which would 
suggest that the MAS measures both trait and state anxiety.
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Despite their later age of onset, endogenous de­
pressives had a significantly higher number of previous 
episodes than nonendogenous depressives. Note should be 
taken, however, that the endogenous group was of signifi­
cantly higher mean age than the nonendogenous group at the 
time of investigation. This association between endo­
genous pattern and age was further shown by the highly 
significant positive correlation between age and New­
castle scores in the whole group and is in line with the 
findings of other workers (Mendels and Cochrane, 1968;
De Alarcon et al, 1975; Price et al, 1984). In the NIMH 
study, nonsituational depressive patients had a higher 
mean age than situational depressives (Hirschfeld et al, 
1984) .
The association between a later age of onset and 
higher affective morbidity over time has been observed 
by several investigators (Pollock, 1931; Lundquist, 1945; 
Price et al, 1984). Difference between unipolar and 
bipolar depressives in terms of age of onset, and life mor­
bidity are in line with the findings of Angst et al (1973) . 
Surprisingly, there were no significant differences in 
the prevalence of depressive illness in first degree 
relatives of endogenous, nonendogenous and bipolar de­
pressives. Bipolars, however, showed slightly higher 
morbidity in first degree relatives than both unipolar 
groups who had very similar morbidity rates. A higher 
family morbidity observed in the bipolar group compared 
to the unipolar group is in agreement with reports by 
Angst (1966) and Perris (1966) .
In the NIMH study, the validity of various clinical 
distinctions of depression was investigated by family 
studies. All available first degree relatives of depress­
ive patients were interviewed and the prevalence of 
affective disorders was determined. The study surprisingly 
showed no significant difference in prevalence of any 
subtypes of affective disorders between endogenous (four
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definitions including the Newcastle Scale) and nonendo­
genous (Andreason et al, 1984), situational and non­
situational (Hirschfeld et al, 1984).
5.2 Psychological correlates
The results surprisingly showed no significant 
differences between endogenous and nonendogenous depressives 
on the EPQ. Very few studies have examined personality 
differences in relation to the endogenous-neurotic 
dichotomy. Depressives with neurotic symptom patterns 
scored higher on neuroticism than those with endogenous 
patterns (Kendell and DiScipio, 1968; Garside et al, 1970; 
Paykel et al, 1976a; Benjaminsen, 1981). However, Snaith 
et al (1971) found no relationship between personality 
and any pattern of depressive symptoms.
Eysenck's neuroticism has been repeatedly shown to 
be mood-labile (Coppen and Metcalfe, 1965; Kendell and 
DiScipio, 1968) and it was shown that differences between 
unipolars and bipolars at discharge disappeared at follow- 
up (Perris, 1971; Hirschfeld and Klerman, 19791 or when 
patients became euthymie (Liebowitz et al, 1979). Extra­
version was proved to be less sensitive to the effects of 
mood (Coppen and Metcalfe, 1965; Kendell and DiScipio,
1968; Liebowitz et al, 1979) and to belong to the universe 
of personality rather than to the universe of personal 
illness (Bedford et al, 1978). In the present investi­
gation, bipolars were shown to have significantly higher 
extraversion and significantly lower lie scale scores than 
endogenous unipolar depressives but there were no signifi­
cant differences in neuroticism and psychoticism between 
these types.
Studies that compared endogenous unipolars with 
bipolars on the Maudsley Personality Inventory (MPI) 
found no differences in neuroticism (Perris, 1966;
Liebowitz et al, 1979; Bech et al, 1980b; Benjaminsen,
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1981). Perris (1966) found no differences between 
endogenous unipolars and bipolars on extraversion on 
admission, discharge or at follow-up. Liebowitz et al 
(1979) showed moderately increased extraversion in 
bipolars compared with endogenous unipolars, and 
Hirschfeld and Klerman (1979) reported that primary 
depressives had significantly lower extraversion scores 
than manies at discharge and at follow-up.
The one study (Benjaminsen, 1981) that compared bi­
polar patients with melancholic (endogenous) unipolars, 
nonmelancholic (neurotic) depressives and secondary 
depressives (neurotic) showed no significant differences 
between bipolar and melancholic patients on neuroticism 
or extraversion. However, bipolars had significantly 
lower neuroticism than secondary neurotic depressives 
and nonmelancholic patients. Nonmelancholics had sig­
nificantly lower extraversion than bipolar patients.
On psychoticism, endogenous depressives were 
reported to have similar scores to neurotic depressives 
(Eysenck and Eysenck, 1976). Account should, however, 
be taken of the significantly higher lie scale scores 
of the present endogenous group compared with bipolars 
and controls. Psychoticism scores would have been 
higher in this group had they not dissimulated (Eysenck 
and Eysenck, 1976). The difference between female uni­
polars and bipolars on the lie scale is in agreement with 
that found by Bech (1980b) .
The results of the present investigation are at 
variance with the findings of the above reviewed 
studies: no significant differences on the EPQ measures 
were found between nonendogenous unipolars and endogenous 
unipolars or with bipolars, and significant differences 
on extraversion and the lie scale were found between 
bipolars and endogenous unipolars. These discrepancies 
might be related to the relative broadness of the
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Newcastle definition of endogenous depression in comparison 
with other definitions such as the DSM-III and Klein's 
definition of endogenomorphic depression (Davidson et al, 
1984) .
On Foulds' measures, endogenous and nonendogenous 
depressives had similar scores and bipolar depressives 
had significantly higher extrapunitiveness than endogenous 
depressives. Blackburn (1974), in her study of the 
pattern of hostility in affective illness, used the original 
version of the PDS, the Hostility Pattern of Hostility 
Questionnaire which had only two subscales of extra­
punitiveness and intropunitiveness. She found that ill 
manies had significantly higher extrapunitiveness than 
ill depressives. Recovered manies, however, had higher 
extrapunitiveness than ill depressives but similar scores 
to normal controls. Contrary to the findings of the 
present study she found that recovered unipolars had 
higher extrapunitiveness and intropunitiveness scores 
than recovered bipolars. Higher extrapunitiveness has 
been shown to protect against neurotic breakdown in dys­
thymic states and was shown to be associated with the 
psychotic classes of Foulds' Hierarchy of personal illness 
(Foulds and Bedford, 1977).
On the MNTS validity, bipolars and endogenous de­
pressives had similar scores and both had significantly 
higher scores than nonendogenous depressives. Non­
endogenous depressives' mean score of validity was 
exactly half that of normal controls. Endogenous de­
pressives had significantly higher solidity scores than 
bipolars and controls. These findings are in agreement 
with reports by Coppen (1966) and Metcalfe et al (1975). 
Perris (1966) similarly found endogenous unipolars to 
have lower validity but higher stability than bipolars 
and no difference on solidity. Studies by Liebowitz 
et al (1979) and Bech et al (1980b), however, found endo­
genous unipolars to have significantly higher solidity
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scores than bipolars. Subvalidity, which indicates 
lack of self-confidence, energy and adaptability, and 
supersolidity, which indicates rigidity, have been sug­
gested as vulnerability factors to depression in middle 
age (Metcalfe et al, 1975).
The MAS scale distinguished between endogenous and 
nonendogenous patients, with the former showing signifi­
cantly lower scores of trait anxiety than the latter 
group on discharge from hospital.
Out of all the psychological measures, the CCEI 
emerged the most sensitive to personality differences. 
Endogenous depressives had similar scores on all CCEI 
subscales to bipolars and both groups had significantly 
lower scores thsn nonendogenous depressives who were the 
most deviant group compared to normal controls. This 
finding only confirms the widely held view that neurotic 
depressives on recovery show more neurotic symptoms than 
psychotically or endogenously depressed patients.
Lithium has been shown to affect personality charac­
teristics. Bonetti et al (1977) showed that lithium, 
when given to bipolar and unipolar patients during re­
mission, caused a significant decrease in extraversion in 
bipolars and neuroticism in unipolars. On the MNTS, 
lithium caused a significant increase in solidity in 
bipolar but not in unipolar patients. If account is 
taken of these lithium-induced changes in personality, 
then the differences found on extraversion and solidity 
were underestimates of those before lithium was started.
Matussek and Feil (1983) recently studied personality 
characteristics of depressive subtypes in a state of 
remission of illness in comparison with normal control 
subjects. They found that depressive patients had 
stronger autodestructive-neurotic tendencies (depressive 
mood, anger, negative attitude towards life, self-reproach
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and suicidal thoughts) than normal subjects. The nonendo­
genous patients were overautonomous (defensive) , mis­
trustful and aggressive compared to endogenous unipolars 
who were lacking in autonomy (few opinions of their own, 
overadaptive, overdependent, submissive and avoided res­
ponsibility) . Bipolar depressives were characterised by 
a hypomanie drive for success and achievement and, 
compared with nonendogenous depressives, had a similar 
tendency to aggression towards others accompanied by 
strong guilt feelings and fears of loss but had signifi­
cantly lower auto-aggressive-neurotic tendencies than 
nonendogenous depressives. They argued that on the basis 
of these findings the psychological vulnerability of 
each of the subtypes is related to dysfunctional coping 
which increases the possibility of relapse. Nonendogenous 
depressives, with their defensive autonomy and outward 
and inward aggression,alienate their partners and become 
ill following loss by separation or death. Endogenous 
depressives, with tneir overdependence and submissiveness, 
overtax themselves constantly with the result that they 
cannot cope with more serious situations or life changes 
and, compared to nonendogenous depressives, become ill 
during an existing partnership rather than after separ­
ation. Bipolar depressives, being achievement orientated, 
are vulnerable to failures, tend to overwork and become 
manic on reaching a goal, or cause them to have conflicts 
with partners resulting in depressive illness. The con­
tribution of personality abnormalities to long-term 
outcome on lithium therapy will be studied in Chapter 5.
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CHAPTER 3
PERIPHERAL 5-HT RECEPTOR FUNCTIONAL ACTIVITY IN DEPRESSION
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1. INTRODUCTION
The amine hypotheses in the chemical pathology of de­
pression are based on two sets of observations; the first 
is clinical and the second is neuropharmacological. The 
clinical observations were that reserpine precipitates 
severe depression in 10-15% of hypertensive patients and 
that iproniazid (an anti-tuberculous drug) and imipramine 
(manufactured as a major tranquilliser) are antidepressants.
The neuropharmacological observations were that reserpine 
depletes brain monoamine whilst iproniazid and imipramine 
increase monoamine functional activity, the former by in­
hibiting monoamine oxidase and the latter by inhibiting 
monoamine uptake by the presynaptic neurone.
These hypotheses implicated mainly noradrenaline 
(Schildkraut, 1965) or 5-hydroxytryptamine (5-HT)(Coppen,
1967; van Praag, 1974) in the pathogenesis of depression: 
that depressive illnesses are associated with a functional 
deficiency in either of these amines in the brain (see General 
Introduction, p. 40). These hypotheses were modified in the 
light of the accumulating knowledge of the biochemistry of 
the brain, mainly by further investigations into the neuro­
pharmacology of antidepressant drugs.
Ashcroft et al (1 9 7 2 ) ., in a modified hypothesis, supposed that 
decreased functional activity of amine systems was related 
either to decreased amine input into the synaptic cleft or to 
a decreased sensitivity of the post-synaptic receptor. Further­
more, and by implication, the functional recovery from this 
disturbance would follow either from an increase in amine in­
put or from an increase in post-synaptic receptor sensitivity, 
a recovery that may be conducive to clinical recovery from 
depression.
The development of methods for measurement of cellular 
receptor sensitivity provided tests for this modified hypo­
thesis. Radioligand binding techniques have been used to
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characterise and quantify rat brain monoamine receptors 
(Snyder, 19 78). Indeed, two distinct 5-HT receptors have 
been identified in mammalian brain: those that are labelled 
with ^H-5-HT were designated 5-HTi receptors and those 
labelled with ^H-spiperone were designated 5 -HT2 receptors 
(Peroutka and Snyder, 1979). In general, 5-HT agonists 
show the highest affinity for 5-HTi binding sites, while 
5-HT antagonists, such as methylsergide, cinanserin and 
spiroperidol, show the highest affinity for 5 -HT2 binding 
sites; lysergic acid diethylamide (LSD) binds to both recep­
tors (Peroutka and Snyder, 19 79) . Ketanserin was shown to 
be a very selective 5-HT2 antagonist (Leysen et al, 19 81) 
and was used to investigate and to characterise 5-HT recep­
tor function (vide infra).
These two 5-HT receptor sites have no association with 
presynaptic receptors and are probably post-synaptically 
situated (Whitaker and Deakin, 19 81; Blackshear et al, 19 81). 
Investigations of the effects of chronic antidepressant medi­
cation on 5 -HT2 receptors showed a significant decrease 
(down-regulation) in the number of these receptors (Bmax) 
but no change in the affinity (Kd) of these receptors 
(Peroutka and Snyder, 19 80) . This down-regulation in 5 -HT2 
receptors in rat brain was observed after one week of treat­
ment and was maximal after 3-6 weeks, changes that are more 
compatible with the observed therapeutic response to anti­
depressant medication. These investigators, however, also 
reported a down-regulation effect for imipramine and monoamine 
oxidase (MAO) inhibitors on 5-HTi receptor activity. Similar 
findings were reported for zimelidine, a specific 5-HT up­
take inhibitor (Fuxe et al, 1981).
The third 5-HT receptor is the presynaptic uptake recep­
tor, the site where synaptic 5-HT is inactivated. This is a 
high affinity, energy-requiring transport system that is sus­
ceptible to inhibitory effects of tricyclic antidepressants 
(Coppen, 1967). This 5-HT uptake mechanism, in platelets and 
neurones (Todrick and Tait, 1969), is particularly inhibited
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by antidepressants such as clomipramine, zimelidine and 
fluoxetine, designated as specific 5-HT uptake inhibitors 
(Iversen and Mackay, 197 9). This pharmacodynamic effect, 
monoamine uptake inhibition, remains the most widely accepted 
mechanism of action of tricyclic antidepressants,
Coppen and his colleagues (1979b) studied 5-HT uptake 
characteristics in platelets from depressive patients 
treated with amitriptyline and zimelidine: they found no 
association between the degree of uptake inhibition caused 
by these drugs and clinical outcome. Related to the 5-HT 
uptake site is a high affinity ^H-imipramine receptor that 
has been demonstrated in human blood platelets (Briley et 
al, 1979) and human brain tissue (Rehavi et al, 1980). Both 
of these receptor sites have been shown to be down-regulated 
in depressive illness, a change that is not normalised on 
recovery from the illness (Briley et al, 1980; Coppen et al, 1978c). 
These changes have been suggested as vulnerability or state- 
independent factors in depression.
All these studies have been concerned with changes in 
receptor function; changes that are not necessarily reflected 
in changed synaptic function. Indeed, there is evidence of 
an association between decreased receptor binding and in­
creased post-synaptic function (Nelson et al, 1981).
2. THE HUMAN PLATELET AS A MODEL FOR THE NEURONE
The dynamics of 5-HT in platelets, especially of its up­
take, storage, release and metabolism, show similarities to 
those of cerebral 5-HT neurones. In other aspects, however, 
such as synthesis and turnover, the two cells show marked 
differences. Platelets have therefore been considered as 
limited models for 5-HT neurones of the brain (Sneddon, 1973; 
Pletscher, 1978). Wood and Coppen (1982), in an extensive 
review, showed the usefulness of the platelet in investi­
gations into the chemical pathology of depression. Mechanisms 
of transport for tryptophan and 5-HT, of storage and metabolism
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and high affinity binding sites show disturbances in 
platelets from depressed patients. Studies by Coppen and 
his colleagues show that platelets from drug-free depress­
ive patients compared with platelets from control subjects 
have a significantly enhanced transport mechanism for 
tryptophan (Wood et al , 1979) but significantly decreased 
active transport mechanism for 5-HT (Coppen et al, 1978c). 
This decreased 5-HT uptake/transport in depressive patients 
is essentially related to decreased V^ax not to dimin­
ished affinity (Km) of 5-HT for the platelet carrier. It 
is the affinity of this carrier that is significantly de­
creased by tricyclic antidepressants, particularly those 
which specifically inhibit 5-HT uptake, such as zimelidine 
(Coppen et al , 1979b). Short and long-term lithium therapy, 
however, enhances V^ax 5-HT uptake in depressive patients 
and restores it to normal (Coppen et al, 1978c).
Studies of platelet monoamine oxidase (MAO) activity 
in depressive patients have not been as rewarding. Plate­
let MAO is purely MAO type B (Donnelly and Murphy, 1977) 
which is sensitive to the inhibitory effects of deprenyl 
and selectively metabolises phenyl-ethylamine rather than 
noradrenaline and 5-HT. Platelet MAO activity was shown to 
be decreased in schizophrenic (Murphy and Wyatt, 1972) and 
in bipolar affectively ill patients (Murphy and Weiss,1972) 
but .interestingly significantly increased in unipolar 
patients (Reveley et al,1981). A report by Sullivan et al 
(1977) suggested that tricyclic antidepressants have in­
hibitory effects on platelet MAO. This was not confirmed 
by Reveley et al (1979). Reports that therapeutic plasma 
levels of lithium were associated with enhanced MAO (Bockar 
et al, 1974; Mann, 1979; Abou-Saleh, 1980) were not sub­
stantiated by Reveley et al (1981).
5-HT storage in platelets (5-HT content) was shown to 
be reduced in depressed patients compared with control sub­
jects, and was restored to normal on clinical recovery, 
particularly in those who received lithium (Coppen et al, 1976a) .
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The discovery of high affinity binding sites for 
imipramine provided for a further use of the platelet to 
study adrenergic and serotonergic receptor function in 
depressive patients. Wood and Coppen (1981) found that 
platelets from depressed patients have a reduced number of 
uz-adrenoreceptors, suggesting a subsensitive U 2“adrenergic 
system during depressive illness. Further studies either 
failed to find a difference in a 2-adrenoceptor sensitivity 
on platelets between depressed patients and controls (Daiguji 
et al, 1981) or conversely found a significant increase.in 
a 2“Adrenoceptor sensitivity on platelets from depressed 
patients which was reduced following effective treatment with 
tricyclic antidepressants (Garcia-Sevilla et al, 19 81; Healey 
et al, 19 83). Interestingly, however, Wood and Coppen (1983) 
showed that lithium treatment with remission of depressive 
symptoms was not associated with a restoration to normal of 
a 2"Adrenoceptor sensitivity, again supporting the hypothesis 
that a 2-receptor subsensitivity is perhaps a vulnerability 
factor in depression.
Finally, radioligand binding studies identified two 5-HT 
binding sites on human platelets: site A corresponded to 
5-HT receptors mediating platelet aggregation, and site B 
corresponded to the 5-HT uptake receptor (Peters and Grahame- 
Smith, 19 80). 5-HT binding site A was strongly inhibited by 
ketanserin, suggesting that it is a 5-HT2 receptor. Failure 
to find a binding site for spiperone (binding that character­
ises 5 -HT2 receptors) on human platelets casts doubt on this 
assumption (Schâchter and Grahame-Smith, 1982). 5-HT binding 
site A, however, provides a model for the investigation of 
5-HT-mediated functional or physiological systems of platelet 
aggregation, the model that is used in the present investi­
gation .
3. 5-HYDROXYTRYPTAMINE-INDUCED PLATELET ACTIVATION
Mammalian platelets, including human platelets, are 
activated and aggregate in response to many agents such as
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adenosine diphosphate (ADP), collagen, thrombin and 5-HT 
(Packhametal, 1973) . Human platelets from most normal individ­
uals respond to 5-HT with a shape change and only a weak, 
reversible aggregation (Baumgartner and Born, 1968; Boullin 
et al,1975a). Furthermore, 5-HT amplifies the human plate­
let aggregation induced by ADP, collagen and epinephrine 
(Baumgartner and Born, 1968; Ball et al, 1977) . 5-HT itself 
is actively stored in platelets in comparatively high con­
centrations against concentration gradient by a membrane 
transport system (Hardisty and Stacey, 19 55). •
5-HT may have a regulatory role in the haemostatic 
function of platelets and it has been suggested that 5-HT 
together with adenosine triphosphate (ATP) are released 
during aggregation, at least in vitro (Mills and Roberts,
196 7). 5-HT causes platelets to undergo a shape change: to 
transform rapidly from smooth disks to spiky spheres 
prior to aggregation (Born, 1970; Drummond, 1976).
Similar changes were observed with ADP (Michal and Motamed,
19 76). 5-HT analogues that cause platelet aggregation also 
cause shape change and both processes are inhibited by 5-HT 
antagonists, suggesting a common mediating mechanism or the 
same receptor (Born et al, 1972).
Initial observations of a paradoxical effect of 5-HT on 
platelet aggregation, that is aggregation velocity acceler­
ates with 5-HT concentrations up to lOuM and decelerates with 
greater concentrations, led to the hypothesis that a func­
tional relationship exists between 5-HT activation and up­
take sites (Baumgartner and Born, 1968). Subsequent 
extensive investigations with 5-HT analogues and antagonists 
established the existence of two distinct receptors on plate­
lets: the shape change-aggregation 5-HT receptor and the 
5-HT uptake receptor (Born et al, 19 72; Schick and McKean,
19 79). These studies showed that 5-HT uptake inhibitors 
such as imipramine and clomipramine were more effective in 
displacing bound 5-HT than 5-HT antagonists such as methy- 
sergide and cyproheptadine, while uptake inhibitors had very
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weak effects on the activation receptor compared to 5-HT 
antagonists. The study by Born et al (19 72) suggested 
that the platelet receptor concerned with shape change and 
aggregation in response to 5-HT is not as structurally 
specific as the 5-HT uptake receptor.
Drummond and Gordon (19 75) described the use of ^H- 
5-HT in labelling 5-HT receptors on rat platelets and 
defined three receptors with high, medium and low affinities 
for 3H-5-HT. Boullin et al (1978a), using a similar technique 
with human platelets, recognised high and low affinity recep­
tors probably corresponding to the high and medium affinity 
binding sites in the rat. Further studies confirmed the 
existence of these two binding sites for 5-HT (Peters et al, 
1979).
Radioligand binding studies have further established 
the presence of two 5-HT receptor sites on membranes from 
rat frontal cerebral cortex and these were designated 
5-HTi and 5-HT2 binding sites (Peroutka and Snyder, 19 79).
The next step was to characterise the 5-HT receptor that 
mediates 5-HT platelet aggregation in terms of the 5-HTi/ 
5-HT2 typology. Known 5-HT antagonists were found to bind 
to both 5-HTi and 5 -HT2 receptors (Leysen et al, 19 81), but 
ketanserin, a selective 5 -HT2 receptor antagonist, was found 
to have powerful inhibitory effects on 5-HT-induced platelet 
aggregation (Lampugnani and De Gaetano, 19 82; De Clerck et 
al, 1982; Schâchter and Grahame-Smith, 1982). The report 
by De Clerck et al (19 82) showed that ketanserin inhibited 
in a concentration-dependent way the aggregation of human 
platelets induced and amplified by 5-HT (5-HT enhancement 
of other aggregatory stimuli) both in vitro and ex vivo after 
oral administration to volunteers, but had no such effects on 
platelet aggregatory responses to other aggregatory stimuli 
such as ADP, collagen and epinephrine.
4. 5-HYDROXYTRYPTAMINE-INDUCED PLATELET AGGREGATION
4.1 Effects of psychotropic medication
As indicated earlier, in vitro studies of human platelet
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aggregation in response to 5-HT strongly'suggested that the 
shape-change aggregation receptor is relatively insensitive 
to the effects of 5-HT uptake inhibitors in .comparison with 
5-HT antagonists which have powerful inhibitory effects on 
this receptor (Born et al, 1972; Schick and McKean, 1979). 
Neuroleptic drugs such as chlorproraazine and haloperidol 
were shown in vitro to have inhibitory effects on 5-HT- 
induced platelet aggregation (Mills and Roberts, 1967;
Boullin and Glenton, 1978). The latter study found that 
neuroleptics (dopamine blockers) such as haloperidol and 
chlorpromazine had relatively weak inhibitory effects on 
5-HT-induced aggregation as compared with 5-HT antagonists 
such as methylsergide and LSD. Spiroperidol, however, had 
the most powerful inhibitory effects on 5-HT-induced aggreg­
ation, being many times more potent than haloperidol. An 
earlier report by the same group found that chlorpromazine 
studied in vitro, and seven of its major metabolites, had 
inhibitory effects on 5-HT-induced aggregation (Boullin et 
al, 1975b).
The next stage was to investigate the in vivo (ex vivo) 
effects of chlorpromazine and other neuroleptics on 5-HT- 
induced aggregation. Schizophrenic patients receiving chlor­
promazine maintenance therapy showed enhanced aggregation 
responses to 5-HT (Boullin et al,1975a). Similar findings 
were reported following fluphenazine (Orr and Boullin, 1976). 
These studies also found a temporal association between these 
changes in 5-HT-induced aggregation and clinical outcome: 
enhanced responses were associated with clinical improvement.
A further report found that in schizophrenic patients who 
were withdrawn from chlorpromazine, enhanced aggregation res­
ponses returned to normal when symptoms reappeared (Boullin 
et al, 1978a). However, two further reports by the same group 
failed to confirm these findings, suggesting that 5-HT- 
induced aggregation responses have little value in predicting 
clinical outcome (Boullin et al, 1978b; Orr et al, 1981).
There followed a report by Youdim et al (1981) re-affirming 
the original findings of enhanced aggregation responses in
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'first breakdown' schizophrenic patients who showed 
clinical improvement. A mechanism by which chlorpromazine 
causes enhanced 5-HT aggregation responses was suggested 
by Baldacci et al (19 80), who found similar in vivo changes 
in rabbit platelets, changes that were not caused-by ADP,
They suggested that these changes could be a consequence 
of chlorpromazine in vivo inhibitory effects on 5-HT recep­
tors leading to a compensatory increase in 5-HT receptors 
at the megakaryocyte stage. An alternative mechanism is 
that chlorpromazine increases the turnover of catecholamines 
in the circulation (Seeman, 19 77), which potentiates 5-HT- 
induced aggregation responses (Boullin et al, 19 78a),
The effects of lithium salts on platelet aggregation 
have only been investigated in vitro. Platelet aggregation 
to ADP in PRP is inhibited by therapeutic concentrations 
of lithium (Greil et al, 1972; Anderson and Foulkes, 1976; 
Hargreaves and Hayes, 19 78). Similar changes were reported 
with 5-HT-induced aggregation (Geerdink et al, 1972;
Anderson and Foulkes, 1976). Pre-incubation of PRP with 
therapeutic concentrations Of lithium, however, was associ­
ated with enhanced aggregatory responses to ADP and 5-HT 
(Geerdink et al, 1972; Iraandt et al, 1977) . Lithium in­
hibitory effects can be competitively counteracted by in­
creasing calcium concentrations in PRP (Greil et al, 19 72; 
Anderson and Foulkes, 19 76) . The supposed mechanism by which 
lithium exerts these inhibitory effects is through its in­
hibitory effects on adenylate cyclase (Dousa and Hechter, 19 70) 
to the effect of reducing cyclic adenosine monophosphate 
(cAMP) content. The response of blood platelets to aggreg­
ating agents is impaired by an increase in their cAMP content 
(Salzman, 1972) .
.4.2 Technical and methodological issues
Platelet aggregation techniques were described by Born 
(1962) , The general methodology involves the following:
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4.2.1 Preparation of platelet-rich plasma (PRP)
(a) Blood is collected and mixed with an anticoagulant 
(usually trisodium citrate) in plastic centrifuge tubes.
(b) Blood is centrifuged for up to 15 min at 120-250g to
sediment blood cells.
(c) Supernatant PRP is transferred to siliconised glass 
cuvettes/bottles and kept at room temperature; the 
residue is centrifuged further at 1500g to obtain 
platelet-poor plasma (PPP).
(d) Platelet concentration in PRP is determined,
4.2.2 Platelet aggregation
(a) Samples (0.1-lml) of PRP in cuvettes are warmed at 3 70C 
for several minutes and placed in the cell compartment 
of the aggregometer, also maintained at 3 7oc.
(b) Platelet aggregation is measured photometrically:
light transmittance through PRP is continuously recorded 
at fixed chart speed.
(c) Parameters of the aggregation curve are measured, e.g. 
rate of platelet aggregation measured as the tangent to 
the steepest slope in the light transmittance records 
during aggregation and expressed as aggregation velocity 
in cm/min (Baumgartner and Born, 19 68).
Breddin et al (1968) studied technical factors that in­
fluence platelet aggregation. They showed that ADP aggreg­
ation response is dependent on factors such as amount of 
collagen, pH of reaction mixture, reaction temperature, hours 
of storage of PRP at room temperature and amount of ethanol 
and acetylsalicylic acid added to PRP.
The reliability of 5-HT-induced aggregation techniques 
was investigated by Knox et al (19 81). This study was promp­
ted by their inconsistent results with enhanced aggregation 
responses to 5-HT in schizophrenic patients (vide supra).
They found that variations in incubation time, temperature,
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aggregometer stirrer speed and in the time interval be­
tween withdrawal of the blood sample and testing, had no 
significant effect on the consistency of responses. 
Decreased platelet concentration in PRP by dilution of 
PRP and over-centrifugation of blood samples during the 
preparation of PRP caused a decrease in the incidence 
of enhanced platelet aggregation responses.
5. THE PROBLEM
The findings of ligand-receptor binding studies that 
antidepressants down-regulate 5-HT receptors are provocat­
ive and call for a revision if not a reversal of the 
indolamine hypothesis in the pathogenesis of depression. 
This notion must be set against the notion that changes 
in receptor function, are not necessarily reflected in 
changed synaptic function, and functional response to 
receptor stimulation or inhibition may be a more valid 
indicator of the activity of a particular amine receptor. 
5-HT induced platelet aggregation provides a viable model 
or technique for investigation of the functional activity 
of this receptor.
6. AIMS AND HYPOTHESIS
The aim of the present study was to investigate the 
functional and physiological activity of platelet 5-HT 
receptors in depressive illness, during illness and on 
clinical recovery, using the technique of 5-HT induced 
platelet aggregation. The effects of haloperidol and 
lithium in vitro and ex vivo on platelet aggregatory 
responses were also studied. The hypothesis was that 
platelet 5-HT receptors are subsensitive in depressed 
patients, an abnormality that is retored to normal on 
clinical recovery.
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7. METHODOLOGY
7.1 Introduction
The following studies are described:
1. Studies in control subjects
(a) Preliminary work to determine the reliability of 
the platelet aggregation technique.
(b) Investigation of in vitro effects of haloperidol 
and lithium on platelet aggregation.
2. Studies in depressive patients
(a) Investigation of platelet aggregation in drug- 
free depressive patients.
(b) Investigation of ex vivo effects of lithium on 
platelet aggregation in affectively well patients 
receiving prophylactic lithium.
3. Study in schizophrenic patients
Investigation of ex vivo effects of haloperidol on 
platelet aggregation in schizophrenic patients re­
ceiving haloperidol maintenance therapy.
7.2 Platelet aggregation: technique employed
Blood samples for platelet aggregation responses were 
collected between 0 800 and 090 0 after overnight abstinence 
from food, drink and tobacco. Blood (20-30ml) was collected 
(via 19 gauge needle) and mixed with one-tenth its volume 
of 3.8% (w/v) trisodium citrate in plastic centrifuge tubes. 
The blood was centrifuged for 10 min at 350g at room temper­
ature to obtain PRP as a supernatant fraction and the 
residue was then centrifuged for a further 10 min at 1500g 
to obtain platelet-poor plasma (PPP). The concentration of 
platelets in the PRP samples was measured by diluting 50yl 
PRP with 5ml Lempbert-Kristenson's staining solution (Dacie, 
1950) and counting the platelets in an aliquot of this mix­
ture using an Improved Neubauer Haemocytometer- Platelet
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aggregation was monitored using a Payton dual-channel 
aggregation module, and the responses were recorded on a 
Rikadenki R22 electronic dual-pen recorder (both from 
Centronic Sales Ltd., Croydon). Aliquots (500^1) of PRP 
and PPP were dispensed into siliconised glass cuvettes 
(Sigmacote; Sigma Chemical Co., Poole, UK). Each sample 
was allowed to warm to 37°C in the aggregation module before 
addition of 5-HT. Both PRP and PPP were stirred at 900 
rpm and maintained at 37°C throughout the experiments.
The limits of platelet aggregation were defined for each 
subject using PRP as the baseline (0% light transmission) 
and PPP to indicate 100% aggregation (100% light transmission) 
(see Figures 3.1 and 3.2). The aggregation assays were begun 
approximately 50 min after venepuncture and completed within 
the following 60 min. Furthermore, in order to permit com­
parison of aggregatory responses produced by 5-HT with maxi­
mum responses attainable by each PRP sample, the response to 
adenosine 5'-diphosphate (ADP) was also determined and the 
results presented as the 5-HT/ADP ratio.
The aggregation responses were measured for 5-HT 
creatinine sulphate and ADP, sodium salt grade IX (Sigma 
Chemical Co., Poole, UK). All solutions were made up in 
0.9% (w/v) NaCl. For each aggregation response 50yl 5-HT 
or ADP were added to PRP samples to produce a final con­
centration of 20ymol/l.
For each aggregation response curve the maximum height 
was recorded as mm% (in comparison to PPP samples), the 
time taken to reach maximum height was recorded in seconds 
(s), and the angle of the slope was measured in degrees (°).
7.3 Control subjects
Eight male and 17 female affectively normal subjects 
were recruited from the MRC Unit and West Park Hospital 
staff for investigation. Their ages ranged between 23 and
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64 years (mean 44.6, s.e.m. 3.0 years). Ten of these subjects 
were regular smokers (40%) and 15 were non-smokers. None 
of these subjects had significant physical illness at the 
time of the investigation.
7.3.1 Platelet aggregation technique: results of reli- ability study________________________________ ______
The reliability of the platelet aggregation technique 
was investigated to determine the procedural factors that 
contribute to variations in aggregatory responses by ex­
periments on PRP prepared from blood taken from control 
subjects. The results of this study will be presented in 
the methodology section.
7.3.1.1 Optimum concentrations of 5-HT and ADP in PRP
Variation in micromolar concentrations of 5-HT and ADP 
in PRP were studied against aggregatory responses in two 
subjects (Tables 3.1 and 3.2), Optimum final concen­
trations for both 5-HT and ADP in PRP were determined 
as 20|iM. This 5-HT concentration has been widely used 
in platelet aggregation studies (Boullin et al, 1975a;
Michal and Motamed, 1976). ADP concentration, however, 
is greater than the 2nM concentration used in those 
studies. Higher concentrations of ADP in PRP did not 
affect aggregation responses.
7.3.1.2 Dilution factor of PRP
The relationship between platelet concentration in PRP 
and aggregatory responses was investigated. In a series of 
experiments on control subjects, PRP was diluted by PPP to 
give a reducing gradient of platelet concentrations in PRP 
from 100% to 25%. Platelet concentrations were estimated 
in diluted PRP to ascertain the reduction in platelet con­
centrations . The results of these experiments were combined 
and are shown in Tables 3.3 and 3.4. There was a significant 
reduction in aggregatory response to 5-HT and ADP at 25%
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TABLE 3.1
Relationship between 5-HT concentration in PRP and aggregation response in two control subjects
5-HT concentration in PRP Minutes from venepuncture Time(s) Slope(°) Height(mm%)
SUBJECT 1
2]iM 96 34 49 12
10]iM 88 32 51 14
20yM 80 32 49 13
50yM 70 32 45 11
lOOyM 60 30 43 10
200yM 51 28 33 7
SUBJECT 2
2yM 117 31 52 14
10 yM 112 28 61 19
20yM 130 31 57 17
5 OyM 105 28 59 16
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TABLE 3.2
Relationship between ADP concentration in PRP and aggregation response in two control subjects
ADPconcentration in PRP Minutes from venepuncture Time(s) Slope(O) Height(mm%)
SUBJECT 1
0 .5nM 145 28 63 21
lyM 141 40 71 36
5yM 136 82 79 84
10 uM 131 120 75 91
20yM 125 72 79 86
50|iM 120 98 74 80
lOOyM 110 100 76 84
SUBJECT 2
5yM 104 106 75 91
.lOfiM 98 88 78 93
20ulM 91 86 79 95
50HM 85 80 79 94
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platelet concentration. This suggested that PRP platelet 
concentrations of 1.5-2.0x 10®/ml are unreliable. Knox 
et al (1981) reported a similar finding.
7.3.1.3 Interval between venepuncture and beginning of aggregation procedure______________
In a series of experiments on control subjects, PRP 
was kept at room temperature for increasing time intervals 
between venepuncture and the aggregation procedure. 
Aggregation responses to 5-HT and ADP were studied at 
25-min intervals up to 175 min from venepuncture. Results 
are presented in Table 3.5, Increasing time between vene­
puncture and beginning of aggregation to ADP showed little 
change. However, aggregation responses to 5-HT showed 
statistically significant enhancement after 125 min from 
venepuncture. Previous investigations which considered 
this factor reported little change in aggregatory responses 
after prolonged intervals (up to 6h) (Born et al, 1972;
Knox et al, 1981).
7.3.1.4 Conclusion
On the basis of these experiments the aggregation 
technique employed was standardised: optimum 5-HT and ADP 
concentration in PRP was established at 20ym; the maximum 
interval between venepuncture and beginning of the aggreg­
ation procedure was established at 110 min (50 min before 
the aggregation procedure starts and 6 0 min as a maximum 
time during which aggregatory responses were studied); 
and optimum PRP platelet concentration was established 
at 2.0X 10^/ml and above (all PRP preparations with 
platelet concentration below this value were not used).
None of the undiluted preparations of PRP from control 
subjects or patients had a platelet concentration below 
this value.
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7.3.2 Platelet aggregation: results of studies on influence of haloperidol and lithium (in vitro)__________________
7.3.2.1 Influence of haloperidol
Haloperidol was incubated with PRP for 1-3 min to give 
final concentrations of lyM. Seven experiments involving 
seven control subjects were carried out, 5-HT aggregation 
responses following incubation were compared with the 
respective baseline responses (prior to incubation). As 
shown in Table 3.6, aggregatory responses showed statis­
tically significant diminution after incubation with halo­
peridol: .there was a significant increase in time to reach 
maximal aggregation (p<0.03, one-tailed t-test).
7.3.2.2 Influence of lithium
Lithium salts (chloride and carbonate) were incubated 
with PRP for 1-3 min to give final concentrations of 1-5 
mmol/1/ Six experiments involving six control subjects 
were carried out. Platelet 5-HT induced aggregation res­
ponses showed no change following PRP incubation with 
lithium at these concentrations (Table 3.7).
7.4 Drug-free ill depressive patients
Four male and 16 female patients admitted to the 
Research Ward for a major depressive disorder (Spitzer 
et al, 1978) and who had no history of manic or con­
current significant physical illness were studied. Their 
ages ranged from 25 to 74 years (mean 51.8, s.e.m. 3.0 
years). Ten of these subjects were regular smokers (50%) 
and 10 were non-smokers.
On admission the patients were withdrawn from any 
antidepressant or neuroleptic medication for an assessment 
period of 7-10 days. No other medication such as aspirin 
or formulations containing aspirin were allowed. Occasional 
diazepam (daytime anxiolytic) and chloral hydrate (hypnotic) 
were allowed. At the end of this drug-free period the
TABLE 3.6
Aggregation responses to 20yM 5-HT in PRP following incubation with lyM haloperidol
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5-HT aggregation
PRP n Time(s) Slope(O) Height (mm% )
Baseline 7 27.7 10.8 45.8 ±5.3 13.9 ±2.1
Followinghaloperidol 7 30.1±0.5* 50.0 ± 4.7 14.6 ±1.8
Mean ± s.e.m.
*Significantly higher than baseline (p <0.03)
TABLE 3.7
Aggregation responses to 20yM 5-HT in PRP following incubation with l-5mm lithium
117
5-HT aggregation
PRP n Time(s) Slope(O) Height • (mm%)
Baseline 6 28.5 ±1.1 48.3 ±5.5 11.3 ±1.3
Followinglithium 6 26.2 ±1.4 53.3 ±4.9 16.0 ± 2.2
Mean ± s.e.m.
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patients were assessed for the severity of their symptoms 
by the Hamilton Rating Scale (HRS) for depression (Hamilton, 
1967) and only patients who scored 16 or more on the first 
16 items in the scale were included in the present in­
vestigation (mean HRS score 19.7, s.e.m. 0.8 ) . After this 
time patients were treated with tricyclic antidepressants 
and during this treatment phase they were classified using 
the Newcastle Scale (Carney et al, 1965). Ten of the 
patients had endogenous (Newcastle scores > 6 ) and 10 had 
non-endogenous depression (Newcastle scores < 5).
7.5 Lithium-treated patients
Eleven male and nine female patients with recurrent 
affective disorders who had been attending the lithium 
clinic for periods between 1.3 and 9.5 years (mean 5.3, 
s.e.m. 0.5 years) were studied. Eight of these patients 
had bipolar and 12 had unipolar affective disorders. They 
all received lithium carbonate (Priadel; Delandale Labora­
tories, Canterbury, UK) as their only psychotropic medic­
ation to achieve plasma lithium levels of 0 -6 - 1 .2mmol/l 
12h after the last dose. They were all investigated when 
they showed no conspicuous affective disturbance and their 
meant s.e.m. plasma lithium level at the time of investigation
was 0.83± 0.04mmol/l 12h after their last dose of lithium. 
Seven of these patients were regular smokers (54%) and 13 
were non-smokers.
7 .6 Chronic schizophrenic patients
Ten female chronic schizophrenic patients on haloperidol 
maintenance treatment and who were in long-term hospital 
care were studied. Their ages ranged from 44 to 80 years 
(mean 64.7 , s.e.m. 1.9 years) . Seven of these patients were 
also receiving antiparkinsonian medication at the time of 
the investigation. Seven of these patients were regular 
smokers (70%) and three were non-smokers. Their psychopathe-
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logy was not assessed and all exhibited residual schizo­
phrenic symptoms. They were primarily investigated to 
assess the ex vivo effects of haloperidol on 5-HT and 
ADP-induced platelet aggregation.
7.7 Data evaluation and statistical analyses
Platelet aggregation responses were compared between 
control subjects and patient groups and subgroups. Statis­
tical significances of any differences were determined 
using the unpaired Student's t-test. All correlations 
between variables were product moment correlations. Un­
less specified, all t-tests were two-tailed. Differences 
were considered statistically significant at the 5% level.
8 . RESULTS
Tables 3.8 and 3.9 show the platelet aggregation 
characteristics in responses to ADP. There were no signifi­
cant differences in any of the aggregatory parameters (time, 
slope and height) between control subjects and any of the 
patient groups and subgroups.
Aggregation responses to 5-HT, however, showed several 
significant differences between control and patient groups. 
For the slope variable, recovered depressives on lithium 
had significantly greater responses than controls ( p < 0 .0 1 ) 
and drug-free ill depressives (p<0.03). For the height 
variable the recovered patient group had significantly 
higher scores than controls (p<0.02) (Table 3.10). 
Aggregation characteristics (5-HT/ADP) showed similar 
statistically significant differences; for the slope vari­
able the recovered group had significantly higher scores 
than controls (p<0.01). For the height variable, again 
the recovered group had statistically higher scores than 
controls (p<0.02) (Table 3.11).
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There were no significant differences between these 
groups in terms of smoker/non-smoker status, sex dis­
tribution and mean age. It was noted that mean platelet 
concentration in PRP was lower in the control group than 
in the other groups, differences that were not statistic­
ally significant. Platelet concentration in PRP showed 
no significant correlation with any of the aggregatory 
variables (ADP, 5-HT, 5-HT/ADP). Age only showed a sig­
nificant positive correlation with the slope variable of 
5-HT/ADP response and only in depressive patients (r = 0.6,
p < 0 .0 2 ) .
Newcastle scores showed a significant positive correl­
ation with the slope of the 5-HT/ADP response (r = 0.69, 
p <  0 .0 0 1 ), which suggested an association between ' endo- 
genicity' of depression and augmented aggregatory responses, 
In view of the significant positive correlation between 
age and the slope of the 5-HT/ADP response, partial cor­
relations between these three variables were calculated. 
Partial correlation between slope (5-HT/ADP) and Newcastle ’ 
scores remained significant after exclusion of the influence 
of age (r = 0.5, p < 0.04) , whilst the correlation between 
age and slope (5-HT/ADP) was no longer statistically sig­
nificant after exclusion of the Newcastle scores (r = 0.2).
In ill depressive patients, again the slope variable 
of the 5-HT/ADP response showed a borderline significant 
positive correlation with HRS (r = 0.5, p <0.07, one-tailed 
t-test). In lithium-treated patients no significant cor­
relations were detected between any of the aggregatory 
variables and their plasma lithium levels at the time of 
investigation.
5-HT and 5-HT/ADP aggregatory responses showed several 
significant differences between endogenous depressives 
and the other two groups (controls and non-endogenous 
depressives) (Table 3.12). Endogenous depressives had 
significantly higher scores then these groups. Control
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subjects and non-endogenous depressives had very com­
parable mean scores on all aggregatory variables except 
in the 5-HT time variable where non-endogenous depressives 
had significantly higher scores than controls. Endogenous 
depressives had significantly greater mean age than both 
controls and non-endogenous depressives (p<0.01) and 
had significantly higher mean HRS scores than non-endogenous 
depressives (p<0.02).
Comparisons between schizophrenic patients and 
control subjects showed no significant differences in 
any of the aggregatory variables (Table 3.9). Schizo­
phrenic patients had significantly greater mean age than 
controls (p<0.01).
9. DISCUSSION
9.1 Influence of haloperidol on platelet aggregation
The results of the in vitro study of the effect of 
haloperidol on platelet 5-HT induced aggregation suggests 
an inhibitory effect on these responses. This finding is 
consistent with previous reports that suggested inhibitory 
effects for haloperidol on 5-HT-induced aggregation (Boullin 
and Glenton, 1978; Boullin et al, 1978c). It is worthy of 
note that spiroperidol, a more potent butyrphenone, has a 
powerful inhibitory effect on 5-HT-induced aggregation 
(Boullin et al, 1978c). Furthermore, spiroperidol binding 
to brain 5-HT receptor sites characterises 5-HT2 receptors 
(Peroutka and Snyder, 19 79) and 5 -HT2 receptors, labelled 
selectively by ketanserin, are suggested to mediate 5-HT- 
induced platelet aggregation (De Clerck et al, 1982). This 
reasoning must be qualified, however, by the notion that no 
specific binding sites for spiroperidol have been identified 
in human platelets (Schâchter and Grahame-Smith, 19 82).
Haloperidol showed no ex vivo effects on platelet 5-HT-
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induced aggregation: chronic schizophrenic patients on 
haloperidol maintenance treatment had similar responses to 
those of control subjects. One previous study by Orr et al 
(19 81) suggested that acute and chronic schizophrenic 
patients on haloperidol had augmented 5-HT-induced aggregat­
ory responses, responses that have been repeatedly reported 
for patients receiving chlorpromazine and other phenothiaz- 
ines (Boullin et al,1975a; Orr and Boullin, 1976). This 
notion, however, must be tempered by this group's later 
finding that 5-HT-induced aggregatory responses were shown 
to be inconsistent in chronic patients (Orr et al, 19 81). 
Furthermore, augmented 5-HT-induced aggregation responses 
were mainly shown in patients who responded favourably 
to their medication (Boullin et al, 19 78a).
Schizophrenic patients in the present group were not 
rated on their psychopathology and differences could emerge 
if they were classified into relative responders or non­
responders to haloperidol. It was noted that the schizo­
phrenic group had a significantly higher mean age than the con­
trol group. Age, however, only showed a moderate positive 
correlation with 5-HT-induced aggregation (vide supra) 
and if anything this would have been expressed in augmented 
responses in the schizophrenic group as compared with 
control subjects.
9.2 Influence of lithium on platelet aggregation
Lithium salts in 1-5 molar concentrations showed no 
in vitro effects on 5-HT induced aggregation. This find­
ing is inconsistent with previous reports which either 
found inhibitory (Geerdink et al, 1972; Anderson and 
Foulks, 1976) or stimulatory (Geerdink et al, 1972) effects 
on 5-HT aggregatory responses. These discrepancies were 
related to whether lithium was incubated with PRP and, 
more importantly, to incubation time (Imandt et al, 1977).
In studies which showed enhancement of aggregatory responses
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to 5-HT (Geerdink et al, 1972) and to ADP (Imandt et al, 
1977), lithium (1-5mmol/l) was incubated for 90-120 min 
before the aggregation procedure. In the present study 
lithium was incubated for only 1-3 min.
Platelets from patients on prophylactic lithium 
therapy showed enhanced aggregatory responses to 5-HT 
as compared with platelets from control subjects and drug- 
free ill depressive patients. The suggestion that this 
enhancement is simply a lithium effect could not be re­
conciled with the notion that there was no significant 
correlation between these responses and plasma lithium 
levels at the time of investigation. The lithium-treated 
group was essentially symptom-free and the contribution 
of affective morbidity to 5-HT aggregatory responses in 
addition to a lithium effect per se could not be determined
This question could be resolved in another cross- 
sectional study of patients on lithium and who show a 
variation in affective morbidity or, ideally, by in­
vestigating patients before and after the commencement 
of lithium treatment. A lithium effect does suggest it­
self given the findings of previous reports of an enhance­
ment in aggregatory responses following prolonged PRP 
incubation with lithium, a condition which simulates the 
ex vivo situation.
9.3 5-HT induced platelet aggregation in depression
The findings of the present investigation failed to 
verify the proposed hypothesis that the functional response 
to 5-HT receptor activity of platelets is decreased in 
depressed patients compared with platelet responses from 
control subjects. On the contrary, platelets from 
patients with endogenous depression showed significantly 
enhanced aggregatory responses to 5-HT compared with con­
trol subjects and non-endogenous depressive patients.
The situation was complicated further by the finding that
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recovered depressives on lithium had enhanced aggregatory 
responses to 5-HT as compared with control subjects. 
Lithium-treated patients showed significantly greater 
enhancement of 5-HT induced aggregation than drug-free 
ill depressives on one variable only, slope of 5-HT 
response.
An important notion to invoke in this context is that 
of the heterogeneity of depressive illness (see Chapters
1 , 2  and 3 for review of clinical and biological classi­
fications of depression). Again, it is the endogenous 
group of depressives that shows an abnormality of function 
in comparison both with control subjects and with non- 
endogenous depressives. Worthy of note is that the majority 
of patients in the recovered group had endogenous illnesses.
Few other differences between the study groups need 
accounting for. Firstly, there was a trend for lower 
mean platelet counts in PRP in control subjects compared 
with the patient groups, but platelet counts in PRP 
showed no significant correlation with any of the aggreg­
atory variables. Secondly, there was a significant cor­
relation between age of patients and 5-HT induced aggregatory 
responses, and thirdly there was a trend for an association 
between greater severity of depression (HRS score) and en­
hanced aggregatory responses. Greater age and higher HRS 
score are strong correlates of greater ’endogenicity' of 
depression as measured by the Newcastle Scale (see Chapter 
2). Indeed, partial correlation calculations showed that 
the association between age and aggregatory response was 
a second-order relationship: it was mediated by Newcastle 
Scale scores.
The results of the present study are inconsistent 
with findings in the stidy by Healey et al (1983) , the 
only study that investigated 5-HT induced platelet aggreg­
atory responses in depressive illness. Healey and his
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colleagues studied depressed patients ,before and during 
treatment with amitriptyline and trazodone in comparison 
with control subjects. Before treatment patients showed 
significantly lower aggregatory responses than those of 
control subjects. During treatment patients who responded 
well to treatment showed enhanced responses in comparison 
with their responses before treatment, responses that 
became similar to those of the control group, while those 
who failed to respond to treatment showed little change 
in their aggregatory responses, responses that remained 
significantly lower than those of control subjects. Their 
method of measuring platelet aggregatory responses appears 
similar to that used in the present investigation, essenti­
ally with reference to ADP-induced aggregation, 'the 
response to serotonin was expressed as a percentage of the 
maximum ADP response', which appears to correspond to the 
height parameter of the aggregation curve. It must be 
noted, however, that the use of three parameters to 
determine aggregation response may highlight subtleties 
of aggregation characteristics. For instance, it is in­
triguing to find that endogenous depressives have aug­
mented 5-HT aggregatory responses as expressed by slope 
and height of both 5-HT and 5-HT/ADP responses, suggesting 
receptor supersensitivity, and have perhaps decreased 
responsiveness in terms of the time to reach maximum 
aggregatory response, suggesting relative subsensitivity.
Healey et al (19 83) provided no information as to how 
endogenous their group of depressives was, and the mean age 
of the patients was 39 years, a lower mean that that of 
depressives in the present investigation (51.8 years). The 
present study does suffer from the disadvantage of not having 
investigated the same patients during illness and on recovery 
or before and after treatment to assess the contribution of 
morbidity and antidepressant medication to the variation of 
5-HT-induced aggregatory responses.
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9.4 Implications for the chemical pathology of depression
The findings of the present investigation suggest that 
endogenous depressed patients show peripheral (platelet)
5-HT receptor functional supersensitivity as compared 
with affectively normal controls and patients with non- 
endogenous depression. Furthermore, this relative super­
sensitivity was also found in euthymie patients on pro­
phylactic lithium.
There is good evidence that platelet 5-HT-induced 
aggregatory responses are mediated by 5-HT2 receptors (see 
introduction to this Chapter), and if we accept the platelet 
as a model for the 5-HT neurone, then the present results 
suggest an association between depression and 5-HT2 
receptor supersensitivity. Recently, Stanley and Mann 
(19 83) reported a significant increase in the number of 
5 -HT2 but not 5-HTi receptors in the frontal cortex of 
suicide victims when compared to control brains. The 
authors did stress, however, that speculation about this 
finding should be tempered by the fact that only 50% of 
suicides tend to be due to depressive illness (Barraclough 
et al, 1974). They also reported a negative correlation 
between 5-HT2 receptor density and imipramine binding sites, 
suggesting an association between 5-HT presynaptic input 
(estimated by imipramine binding)and a 'compensatory' in­
crease in the number of post-synaptic 5-HT2 binding sites. 
The authors had reported previously a significant decrease 
in the number of presynaptic imipramine binding sites in 
the brains of suicides (Stanley et al, 1982). Briley et 
al (1980) reported a significant decrease in imipramine 
binding sites on platelets from depressive patients, a 
decrease that persisted after clinical recovery. Coppen 
and his colleagues ( 1978c) showed significantly reduced 
5-HT transport (uptake) in platelets from depressive 
patients, an abnormality that persisted after recovery 
from illness. Imipramine binding sites on platelets and
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on neurones have been linked with the 5-HT uptake receptor 
(Rehavi et al, 1980).
Owen et al (1983), in their post-mortem study of 
suicide victims, however, found a trend towards a decrease 
in 5 -HT2 receptor activity which they related to the 
effects of antidepressant medication these patients had 
received before death. Antidepressant medication has 
been shown to down-regulate 5 -HT2 receptors in rat brain 
tissue (Peroutka and Snyder, 1980) .
How does all this fit in with the amine hypothesis 
of depression in its original (Coppen, 1967) and modified 
(Ashcroft et al, 1972) forms? At face value these find­
ings could not be integrated with the amine hypotheses in 
their static formulations. Elements of an apparent para­
dox could be resolved by a dynamic synthesis: notions of 
adaptive or compensatory change could be invoked. Post- 
synaptic supersensitivity becomes an adaptive or compen­
satory change to diminished presynaptic output.
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CHAPTER 4
THE BIOLOGY OF FOLATE IN DEPRESSION
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1. INTRODUCTION
1.1 Nutritional abnormalities in psychiatric illness
The contribution of nutritional abnormalities to 
the phenomena of psychiatric illness has been a neglected 
area of investigation. Investigations have mainly 
focused on the relationships between various vitamin 
deficiencies and organic brain syndromes whilst func­
tional major or minor psychiatric disorders have received 
little attention. It has been noted that vitamins A, C,
D, E, K, pantothenic acid, biotin and riboflavin were not 
associated with any psychiatric symptoms. Deficiencies 
in the vitamin B group, however, have been strongly 
associated with neuropsychiatrie syndromes. Thiamine 
Vitamin B1) deficiency is the causative factor for beri 
beri, Wernicke’s encephalopathy, Korsakoff's psychosis.
In the early stages the picture is that of neurasthenia 
manifesting with generalised weakness, anorexia, fluctu­
ating irritability, insomnia and depressive mood. Later 
on in the course and on the imposition of a sudden acute 
deficiency on top of the chronic incomplete one, Wernicke's 
encephalopathy might set in and could resolve in Korsakoff's 
amnesic syndrome. Niacin (vitamin B3) deficiency is also 
associated with a neurasthenic picture, fatigue, irrit­
ability, poor sleep and depressive symptoms. In more 
severe cases an acute brain syndrome might develop or 
occasionally agitated depression or schizophrenia.
Vitamin B12 deficiency rarely presents with psychiatric 
pictures such as brain syndromes, affective and schizo­
phrenic illnesses (see review by Crammer, 1983).
1.2 Folate deficiency in psychiatric illness
Folic acid deficiency was shown to be a common occur­
rence in the general population in the United Kingdom, 
particularly in the elderly mentally ill (Editorial,
British Medical Journal, 1968). Surveys showed that up
135
to 80% of those admitted into old people's homes or 
psychiatric hospitals had low plasma folate concentrations 
(Read et al, 1965; Shulman, 1967). Folic acid deficiency 
was reported to be a causative factor in certain types 
of dementia (Lishman, 19 78) and lower plasma concentrations 
of folic acid, ascorbic acid and total tryptophan were 
found in patients with senile dementia in comparison with 
control subjects (Shaw et al, 1984). However, Bober 
(1984) found that folic and ascorbic acid deficiencies 
are common findings in a variety of psychiatric diag­
noses in the elderly, including organic, functional and 
mixed states.
In a recent study of patients with dementia, folate 
deficiency was observed in 35% of patients and was associ­
ated with increased age and greater 'metabolic strain' 
as determined by increased erythrocyte sedimentation rate 
and increased plasma thyroxine concentrations (Abou-Saleh 
et al, 1985a). Folate deficiency was not associated with 
classification of dementia, the degree of cognitive 
impairment or cortical dysfunction.
Folate deficiency was also observed in schizo­
phrenic patients, particularly those with chronic illness 
(Carney, 1967), Reynolds (1968) has suggested that the 
later occurrence of schizophrenia-like illnesses in 
patients with temporal lobe epilepsy was related to 
folate and vitamin B12 deficiencies induced by anticon­
vulsant therapy. Epileptic patients with psychiatric 
symptoms are more likely to have folate deficiency than 
those without such symptoms (Snaith et al, 1970). In a 
series of four patients with homocystinuria caused by 
methyltetrahydrofolate reductase deficiency, one patient 
developed schizophrenia that responded to folate treat­
ment (Freeman et al, 1975) .
Surveys of folate deficiency in psychiatric patients
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found variable rates of low serum folate ranging from 
10% of patients attending a psychiatric clinic (Hallstrom, 
1969) to 50% of hospital patients including alcoholic 
patients, drug-dependent individuals and epileptic 
patients receiving anticonvulsant drugs (Hunter et al, 
1967). Carney (1967) investigated the prevalence of 
folate deficiency in 423 successive admissions to a 
general hospital psychiatric unit and found a rate of 
23%. He then looked closely at the folate-deficient 
group and found that 14% also had vitamin B12 deficiency, 
75% had received drugs (anticonvulsants, barbiturates 
and antibiotics) in the three weeks preceding admission, 
23% were grossly undernourished, 17% were physically ill 
on admission and 44% had been continuously ill for more 
than three years. The proportion of folate-deficient 
patients in various diagnostic groups were 8 6 % of
epileptic patients, 30% of depressed patients, 25% of
organic psychotic patients and 2 0 % of schizophrenic 
patients. The normal control group was significantly 
younger (mean 39 years) than the patients (mean 54 years) 
and no association was found between age and serum folate 
levels.
In a study of 100 consecutive admissions with severe 
depression, low serum folate and vitamin-B1 2 concen­
trations were found in 24% and 13% respectively of cases 
(Reynolds et al, 1970). Folate-deficient patients had 
more severe illnesses, lower validity (psychic energy) 
scores on admission and discharge, greater neuroticism
scores on discharge and responded less well to ECT and
antidepressants than those who showed normal serum folate 
concentrations. Surprisingly, folate and vitamin B12 
deficiencies were not related to poor nutritional history 
in these patients.
In a study of the neuro-psychiatric status of 84 
consecutive admissions with megaloblastic anaemia
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secondary to pure folate of vitamin B12 deficiencies, 
patients with folate-deficient megaloblastosis had sig­
nificantly higher prevalence of affective disorders (56%) 
than those with vitamin B12 megaloblastosis (20%) (Shorvon 
et al, 1980) .
Factors contributing to folate deficiency were in­
vestigated: drug intake, physical illness and poor nut­
ritional status. Three studies found poor association 
between dietary histories and serum folate levels on ad­
mission to hospital (Shulman, 1967; Reynolds et al, 1970; 
Thornton and Thornton, 1978). One study, however, found 
an association between increasing rates of low folate 
levels and increasing rates of physical disability, sug­
gesting that dietary deficiency was responsible for the 
low folate levels. Interestingly, folate deficiency was 
more related to psychological factors such as loneliness, 
apathy and depression than to poverty and physical dis­
ability (Hurdle and Williams, 1966).
Other supportive evidence for an association between 
folate deficiency and psychiatric illness comes from 
therapeutic trials of folic acid therapy. The earliest 
studies were on epileptic patients receiving anticonvuls­
ant therapy and showed striking improvement in patients' 
mood, drive and sociability (Reynolds, 1967). Botez et 
al (1976) described a syndrome of long-standing functional 
gastrointestinal disorder, abnormal diet, occult mal­
absorption and folate deficiency associated with fatigue, 
lassitude and depressive symptoms that have proved unrespons­
ive to conventional antidepressant therapy. They there­
fore explored the usefulness of folate therapy in the 
treatment of these folate-deficient neuropsychiatrie 
patients. Patients were treated with oral folic acid 
(lOmg daily) for three months; this dose was gradually 
reduced during the following six months to a maintenance 
dose of 5-1Omg weekly. Results showed very good improve-
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ment in mood (assessed by both subjective and objective 
criteria) in 56% of the patients? good improvement was 
observed in 3 0% of the cases, fair improvement in 10% 
and no improvement was observed in 4% of the patients. 
Psychiatric symptoms required 2-3 months of treatment 
before resolution, whereas the gastrointestinal and 
neurological symptoms only improved after five months 
of treatment. Significant improvement was also shown on 
several psychometric measures including verbal and per­
formance intelligence tests.
Carney (1979) observed that folate-deficient patients 
with schizophrenia, endogenous depression and organic 
psychoses who had received folate supplements showed more 
improvement in their mental state on discharge and spent 
significantly less time in hospital than similar patients 
with low folate levels who received no folate supplement.
In a recent study Botez et al (1984) explored the 
value of long-term therapy with folic acid in folate 
deficiency-related disorders, including 49 patients with 
mild depression, 12 patients with folate neuropathy and 
37 patients with soft neurological signs who had low 
serum and CSF folate concentrations. 6 8 % of these 
patients showed evidence of cerebral atrophy on computer­
ised axial tomography and/or radio-nucleide cysternograms 
in association with cognitive impairments on psychometric 
tests. Patients showed significant improvement following 
one year of folate therapy in their cognitive functioning, 
particularly on the block design and digit symbol sub­
tests, and in five patients who had their radio-nucleide 
cysternograms repeated, three showed improvement in 
cerebral atrophy.
1.3 Folate deficiency in the pathogenesis of depression
Recent studies have suggested that folate synthesis.
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transport and metabolism might be implicated in the 
pathogenesis of a variety of neurological and psychiatric 
disorders (Levi and Waxman, 1975). Folate is involved 
in the metabolism of biogenic amines, in processes of 
méthylation and hydroxylation (Turner, 1977). Folate 
is involved in the biosynthesis of methyl donors :
5-methyltetrahydrofolate (5-MTHF) and S-adenosylmethio- 
nine (SAM), and the former metabolite (5-MTHF) is in­
volved in the biosynthesis of the latter (SAM). The 
methyl group from 5-MTHF is transferred to homocysteine 
to form methionine. The enzyme for this reaction is 
5-MTHF-homocysteine methyltransferase and requires 
vitamin B12 and SAM in catalytic amounts (Spector et al, 
1980). Finally, methionine is converted to SAM by the 
enzyme methionine adenosyltransferase. SAM is the main 
methyl donor in mammalian brain; 5-MTHF however was found 
to be a much more efficient donor to biogenic amines 
than SAM (Banerjee and Snyder, 1973) .
Aberrant méthylation processes have been suggested 
in the pathogenesis of schizophrenia and affective dis­
orders. An early hypothesis for schizophrenia - the 
transmethylation hypothesis by Osmond and Smythies (1952)
- suggested that schizophrenic disorders are akin to 
hallucinogenic psychoses induced by hallucinogens such 
as mescaline. This was based on their observation that 
there are structural similarities between these hallucino­
gens and aberrantly methylated neurotransmitter metabolites 
that could be psychotogenic, and they postulated the 
production in brains of schizophrenic patients of abnormal 
methylated toxins. After 25 years of research such 
compounds have not been demonstrated (Smythies, 1977).
The role of folate in the pathogenesis of depressive 
illness involved both processes of méthylation (Reynolds 
et al, 1984) and hydroxylation (Reynolds et al, 1970).
The méthylation hypothesis suggests that depressive illness
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is associated with folate deficiency that leads to SAM 
deficiency and deficient méthylation. This is based on 
the finding that SAM has antidepressant properties, an 
observation that was made in the context of using SAM to 
study the transmethylation hypothesis of schizophrenia 
(Fazio et al, 1973).
The antidepressant effects of SAM were confirmed in 
double-blind placebo-controlled trials (Agnoli et al,
1976), and in comparative double-blind trials with clom­
ipramine and amitriptyline (Miccoli et al, 1978). SAM 
was administered parenterally in doses up to 2 0 Omg per 
day and was observed to act more rapidly than conventional 
antidepressants; patients showed significant improvement 
after 4-7 days of treatment. Furthermore, SAM in these 
doses was found to be remarkably free of side-effects; 
however, occasional increases in anxiety or emergence of 
manic symptoms were observed. Manic symptoms rarely 
occur during folic acid therapy (Reynolds and Stramentinoli, 
1983) .
The administration of SAM increases the turnover of 
serotonin (5-HT) and noradrenaline in rat brain and 
decreases méthylation of neuronal membrane phospholipids, 
an initial common pathway for the transduction of many 
receptor-mediated biological signals through membranes 
(Reynolds and Stramentinoli, 1983).
An alternative mechanism for the effects of folate 
on amine metabolism is one that involves the hydroxylation 
of tyrosine and tryptophan, the rate-limiting step in the 
biosynthesis of catecholamines and 5-HT respectively.
Folate reductase and pteridine reductase are both in­
volved in the regeneration of tetrahydropterine (BH4 ), 
an essential co-factor in this hydroxylation process in 
mammalian brain tissue (Spector et al, 1977). The bio­
synthesis of BH4 is stimulated in rat brain preparations 
by 5-MTHF and vitamin B12 (Leeming et al, 1982) and in
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human temporal cortex preparations including those from 
depressed patients (Blair et al, 1984). In the latter 
study it was shown that brain BH4 synthesis was signifi­
cantly reduced in postmortem temporal cortex samples from 
four patients with histories of severe depression in com­
parison with samples from controls. Moreover, they found 
significantly reduced concentrations of total biopterines 
in morning urine samples from patients with recurrent 
affective disorders, particularly those with bipolar 
illness and who were euthymie than in normal controls. 
Curtius et al (1983) administered BH4 to a patient with 
chronic resistant depression of 10 years duration who 
had once responded to 5-HTP, They observed a dramatic 
response to BH4 , particularly in combination with tyro­
sine and tryptophan which caused an elevation in CSF 
amine metabolites. Successful treatment of depression with 
BH4 was also reported by Levine and Lovenberg (1984).
Other supportive evidence for this mechanism is 
provided by the studies of Botez and his colleagues.
Botez et al (1979a) have shown that the concentration 
of 5-HT metabolite (5-HIAA) was low in the lumbar CSF 
of folate-deficient patients who had folate-responsive 
neuropsychiatrie symptoms. They argued that these lower 
levels of 5-HIAA were not due to precursor deficiency, 
as CSF tryptophan levels were normal. Studies in 
psychiatric patients (Bowers and Reynolds, 1972), in 
demented patients (Shaw et al, 1971) and in patients 
receiving anticonvulsants (Reynolds et al, 1975) showed 
no association between CSF folate and 5-HIAA. Botez et 
al (1979a) argued that low folate concentrations per se 
are not necessarily associated with neuropsychiatrie 
symptoms which are responsive to folate therapy. More 
supportive evidence comes from their animal studies 
(Botez et al, 1979a). They found that rats given folate- 
deficient or folate over-supplemented diets had low 
brain 5-HT levels, while noradrenaline and dopamine were
142
unchanged. They argued that excess folate might compet­
itively inhibit folate reductase and therefore impair 
the formation of tetrahydrobiopterine with a consequent 
decrease in the hydroxylation of tryptophan. Folate 
given in pharmacological doses (15mg daily) to healthy 
volunteers was associated with toxic effects such as 
altered sleep patterns, malaise, irritability and over­
activity (Hunter et al, 1970).
Swade and Coppen (1980) have studied the seasonal 
variation in 5-HT uptake by platelets and the serum 
folate concentrations in depressed patients, factors 
that have been related to depressive illness (Coppen et 
al, 1978). Interestingly, both 5-HT uptake and serum 
folate showed significant reductions in the months of 
May and June, months when patients showed less favourable 
responses to antidepressant medication.
1.4 The problem
The weight of the reviewed evidence suggests that 
folate deficiency is a fairly common occurrence in 
depression and other psychiatric disorders. The nature 
of this association remains to be determined and the 
relationship between folate deficiency and factors such 
as the classification of depression and its severity in 
a variety of clinical settings has been poorly examined. 
Moreover, the usefulness of folate in the management of 
depression has not been adequately explored.
2. AIMS AND HYPOTHESIS
The aims of the study were to investigate the 
relationship between serum and red blood cell folate 
concentrations and depressive illness, and to evaluate 
the antidepressant effects of physiological supplements 
of folic acid in lithium-treated patients with low
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plasma folate concentrations.
It was hypothesised that depressive illness is 
associated with lower folate concentrations and that 
physiological supplements of folate are associated with 
significant improvement in affective morbidity.
3. PATIENTS AND METHODS
3.1 Control subjects
Thirty-four male and 26 female affectively, normal 
subjects were recruited from the MRC Unit and West Park 
Hospital staff and had their plasma folate concentrations 
estimated. Red blood cell folate concentrations were 
estimated in a subgroup of eight male and three female 
subjects. Their ages ranged between 32 and 57 years 
(mean 44-7, sem 2.1 years). None of these subjects had 
any significant physical illmess at the time of the in­
vestigation .
3.2 Drug-free ill depressive patients
Twenty-six male and 6 9 female patients suffering 
from major depressive disorders (Spitzer et al, 1978) 
were studied. Their ages ranged from 45 to 73 years 
(mean 59.5, sem 1.5 years). They consisted of 75 in­
patients admitted to the MRC research ward for treatment 
and 20 patients assessed and treated in the outpatients 
clinic. All patients were classified on ICD-9 and 90 
patients were classified on the Newcastle Diagnostic 
Scale. The severity of their depression was rated ob­
jectively on the Hamilton Rating Scale for Depression 
(HRS) and subjectively self-rated on the Beck Depression 
Inventory (BDI). Their anxiety symptoms were rated on 
the Salkind Morbid Anxiety Scale. All these ratings were 
carried out within the first week of admission or 
assessment in the outpatients clinic.
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Plasma folate concentrations were estimated, also 
during the first week of admission. Red blood cell 
folate concentrations were estimated concurrently with 
their plasma folate concentrations in a subgroup of 11 
female and one male patient. Plasma folate estimations 
and the HRS were repeated on a subgroup of 17 inpatients 
prior to their discharge from hospital to determine the 
effects of clinical recovery on plasma folate concen­
trations .
3.3 Lithium-treated depressive patients
Thirty-six male and 71 female patients (81 unipolar 
and 26 bipolar), who had been attending the lithium clinic 
for periods between 2 and 14.5 years (mean 5.9 years), 
were studied. Their ages ranged from 21 to 83 years 
(mean 55.6, sem 3.7 years). All patients had received 
lithium carbonate in the form of sustained release tab­
lets (Priadel, Delandale Laboratories, Canterbury).
Lithium was given once daily at night to achieve plasma 
lithium levels 12 hours later of 0.8-1.2mmol/l. The 
affective morbidity of these outpatients varied, but 
none was severely depressed or manic. Affective morbidity 
was measured objectively on a global scale from 0 to 3 
and subjectively by the BDI. These clinical ratings 
w ere performed when the sample of blood for folate 
estimation was obtained and was termed the 'spot rating'. 
Furthermore, patients' affective morbidity over the 
preceding two years (AMI) was also calculated. Blood was 
taken between 09 0Oh and lOOOh when they attended the 
clinic for their regular follow-up appointment. Plasma 
folate was estimated in 107 patients..
3.4 Alcoholic patients
Twenty-nine male and 12 female patients suffering 
from alcoholism who satisfied the criteria for the diag-
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nosis of alcohol dependence syndrome on the ICD-9 were 
studied. These patients were investigated during their 
admission to the Regional Alcoholism Unit at Epsom 
District Hospital. Patients were admitted when they 
were 3-6 weeks abstinent from alcohol after having been 
detoxified as inpatients in other wards or as outpatients. 
During their stay they received group psychotherapy and 
social rehabilitation. While they were being treated 
they completed the BDI and the Severity of Alcohol 
Dependence Questionnaire (SADQ) (Stockwell et al, 1979), 
Their mean age was 42, sem 1.6 years. Blood was taken 
on the same day for the estimation of plasma folate con­
centrations .
3.5 Chronic schizophrenic patients
Nine female chronic schizophrenic patients in long­
term hospital care were studied. Patients were receiving 
chronic neuroleptic therapy (haloperidol). Their mean 
age was 6 5.4, sem 3.6 years. Plasma folate concentrations 
were determined before and after they received physio­
logical doses of folic acid (300|ig/day) .
3.6 Clinical trial of folic acid in lithium-treatedpatients___________________________________________
The antidepressant effects of physiological supple­
ments of folic acid were investigated in the context of 
a double-blind prospective trial in patients with re­
current affective disorders on long-term lithium therapy 
who had low plasma folate concentrations. Nine male 
and 15 female lithium-treated patients (22 unipolar and 
4 bipolar), who had low plasma folate concentrations 
(<5.0ng/l), were randomly allocated to receive physio­
logical supplements of folic acid (300|ig nocte) or 
identically-appearing placebo tablets, in addition to 
and concurrently with their lithium, for at least six 
months. Affective morbidity over the six months of the
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trial was measured by the AMI and the mean BDI over 
this period. For intra-group comparisons, patients’
AMI and mean BDI were measured for the six months pre­
ceding the trial. Plasma folate concentrations were 
estimated at the end of the trial. Red blood cell 
folate concentrations were estimated in 24 of these 
patients: 12 patients were receiving placebo folic acid 
and 12 were receiving active folic acid therapy. The 
Dexamethasone Suppression Test (DST) was carried out on 
21 patients to determine their affective vulnerability 
during the trial. The DST procedure is described in 
Chapter 5.
3,7 Folate estimations
Plasma and red blood cell folate concentrations 
were estimated using a quanta-count Folate Kit (Bio-Rad 
Laboratories, Watford, UK).
4. RESULTS
4 .1 Plasma folate concentrations
4.1.1 Control subjects and psychiatric patients
Table 4.1 shows plasma folate concentrations in control 
subjects and patient groups; drug-free ill depressives, 
lithium-treated depressives, and alcoholic patients. 
Drug-free ill depressive patients and lithium-treated 
depressives, particularly unipolar patients, had sig­
nificantly lower plasma folate concentrations than con­
trol subjects; the former group also had significantly 
lower levels than the lithium-treated and alcoholic 
patients. It was noted, however, that drug-free depress­
ives and lithium-treated patients were significantly 
older and had higher proportions of females than the 
other two groups. There was a significant negative 
correlation between age and plasma folate concentration 
in the control group (r = -0.4, p<  0.03) but not in
TABLE 4.1
Plasma folate concentrations in control subjects, drug-free depressives, lithium-treated and alcoholic patients: intergroup comparisons
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Group
n
M F Age Plasma folate (ng/ml)
Control subjects 34 26 44.7 ± 3.0 7.02 ± 0.34
Drug-freedepressives 26 69 59.5 ± 1.5 5.28 ± 0.27*
Lithium-treateddepressives 36 71 55.6 ±1.7 6.15± 0 .2 1 **
Bipolar 14 12 53.8 ±2.5 6.96 ± 4.5
Unipolar 22 59 56.2 ± 1.3 5.86 ± 0.23***
Alcoholicpatients 29 12 42.0 ± 1.6 6.90 ±0.50
Mean ± sem,
*significantly lower than control subjects (p< 0 .0 0 1 ),than lithium-treated patients (p < 0.025) , and thanalcoholic patients (p < 0 .0 1 ) .
**significantly lower than control subjects (p<0.03).
***significantly lower than control subjects ( p < 0 .0 1 ).
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drug-free ill depressive patients (r = 0.09) or in 
lithium-treated patients (r = 0.14). There were no 
significant differences in plasma folate concentrations 
between males and females in any of these groups.
Table 4.2 shows percentages of folate-deficient 
(plasma folate levels< 2 .5ng/ml) individuals in controls, 
drug-free ill depressives, lithium-treated patients and 
alcoholic patients. As shown, drug-free depressives 
with endogenous and nonendogenous depressions, as 
defined by ICD or Newcastle Scale, had significantly 
higher percentage of folate-deficient patients than con­
trol subjects. Lithium-treated and alcoholic patients 
had slightly higher percentage of folate-deficient 
patients than control subjects. These differences were 
not statistically significant.
4.1.2 Drug-free ill depressive patients
Table 4.3 shows comparisons of plasma folate con­
centrations between control subjects and drug-free ill 
depressive patients classified on ICD-9: patients with 
endogenous depression (ICD 296 . 1 ) and particularly males 
had significantly lower plasma folate concentrations than 
control subjects. Among patients with neurotic depression 
(ICD 300.4) only male patients had significantly lower 
plasma folate levels than male control subjects, and the 
difference for the whole group was not statistically 
significant.
It is worthy of note that male patients with neurotic 
depression had a near-identical mean age to male control 
subjects. Patients with endogenous depression were 
significantly older than the groups of patients with 
neurotic depression and control subjects. This Table 
also shows that there were no significant differences in 
plasma folate levels between males and females in any of 
these groups. It is to be noted also that plasma folate
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TABLE 4 .2
Percentage of folate-deficient patients (plasma folate < 2 .5ng/ml) in drug-free depressives, lithium- treated and alcoholic patients and control subjects
(X^  analyses)
Group n Folate-deficient
Control subjects 60 2 %
Endogenous depressives
ICD 296. 1 71 16%*
Newcastle score > 6 52 14%**
Non-endogenous depressives
ICD 300.4 24 13%**
Newcastle score < 5 38 18%**
Lithium-treated
Bipolar 26 4%
Unipolar 81 6 %
Alcoholic patients 41 7%
*Significantly greater than control subjects, p < 0.01**Significantly greater than control subjects, p < 0.05
TABLE -4 ..3
Plasma folate in depressive patients comparisons with control subjects
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Group n Age Plasma folate (ng/ml)
Endogenous Males 18 61.9 ±2.8 4.70± 0.57*depressives Females 53 64.4 ± 1.7 5.13± 0.38(ICD 296.1) Total 71 63 .8 ± 1.5**** 5.04 ± 0.31** -
Neurotic Males 8 41.1±2.7 4 .66 ± 0.71***depressives Females 16 50.1±4.1 6.65 ± 0.66(ICD 300.4) Total 24 46.4±2.9 5.99 ± 0.53
Control Male 34 41.6 ±3.6 7.41 ± 0.49subjects Female 26 46.5±2.3 6.52 ±0.43
Total 60 44.7±3.0 7.02 ± 0.34
Mean ± sem.
* significantly lower than male controls (p< 0 .0 0 1 ).
**significantly lower than total controls (p< 0 .0 0 0 1 )
***significantly lower than male controls (p<0.04).
****significantly higher than control and neurotic depressive groups (p < 0 .0 0 1 )
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levels showed no significant differences between the 
two depressive groups.
Table 4.4 indicates that depressive patients who 
had lost weight had similar plasma folate concentrations 
to those who had not lost any weight, as determined on 
the Newcastle Scale. Table 4.5 shows plasma folate con­
centrations and HRS scores on admission and on discharge 
for a subgroup of these patients. Patients had a very 
significant reduction in their HRS scores on discharge 
and a non-significant trend for lower plasma folate con­
centrations on discharge compared with admission levels.
Other analyses were also carried out. Percentage 
change in HRS at four weeks of treatment was determined 
for these patients. This was calculated by subtracting 
HRS score at four weeks from the baseline score and 
dividing by the baseline score. Patients were treated 
with EOT and/or antidepressant medication. Patients were 
then divided in terms of their plasma folate concentrations 
into those with low (<5ng/l) and into those with high 
(> 5ng/l) folate concentrations. Patients with low plasma 
folate showed similar percentage change (mean 46.0%, sem 
7.07) to those with high plasma folate concentrations 
(mean 57.4%, sem 6.54). There was no significant correl­
ation between percentage change and HRS and percentage 
change in plasma folate between admission and discharge 
(r = 0.1) . There was a significant negative correlation 
between plasma folate concentration and HRS (r = -0.32; 
p<0.01). There were no significant correlations 
between plasma folate concentrations and patients' 
scores on the Newcastle Scale (r = 0,12), their scores 
on the BDI (r = 0.18) and their scores on the Salkind 
Morbid Anxiety Scale (r = 0.04) .
4.1.3 Lithium-treated patients
Plasma folate concentrations were significantly
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TABLE 4.4
Plasma folate in depressive patients with and without weight loss (on Newcastle Scale)
Group n Plasma folate (ng/ml)
Depressives with weight loss 
Depressives without weight loss
58
37
5.01± 0.29 
4.98 ±0.38
Mean ± sem .
TABLE 4.5
Plasma folate and HRS on admission and on discharge.
n Plasma folate (ng/ml) HRS
Admission 17 4.7 ± 0.43 22.5 ± 1.3
Discharge 17 4.1±0.45 9 .6 ± 1.5*
Mean ± sem.
*significantly lower than admission score (p< 0 .0 0 1 ) by paired comparison.
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lower in the whole group of lithium-treated patients 
than in the group of control subjects (Table 4.1).
These patients were divided into three groups according 
to their plasma folate concentrations; <3.9; 4.0-7.9;
> 8 . Ong/ml. The morbidity of the patients as a whole was 
low, but the patients with the highest folate concen­
trations had significantly lower morbidity than the 
patients with low and medium folate levels. This was 
true both with 'spot rating' (i.e. the morbidity at the 
time of blood collection), and the affective morbidity 
index calculated for the preceding two years (Table 4.6).
Of the 26 bipolar patients, three had low folate 
levels, 14 had medium and nine had high folate levels.
Two of the three bipolars in the low folate group had 
mild manic morbidity, one of the 14 bipolars in the 
medium folate group was rated as having mild manic morbid­
ity, but none of the nine bipolars with high folate levels 
exhibited manic morbidity. The groups with low (< 3.9ng/ml 
and high ( > 8 . Ong/ml) plasma folate concentrations were 
compared in terms of their change in weight between their 
attendance when their plasma folate was estimated and the 
preceding attendance. The group with low plasma folate 
had a mean (0.4 ± 0.3kg) weight gain while the group with 
high folate had a mean (0.68 ± 0.5kg) weight gain. This 
difference was not significant. A proportion of patients 
had other psychotropic medication (anxiolytics, anti­
depressants, neuroleptics). The percentages of patients 
who received psychotropic extra medication were 56, 6 5 
and 57% in the low, medium and high folate groups res­
pectively .
4.1.4 Alcoholic patients
Plama folate concentrations of alcoholic patients 
were similar to those of control subjects (Table 4.1). 
Table 4.7 indicates the relationship between plasma
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TABLE 4.7
Plasma folate. Beck Depression Scores (BDI) and Severity of Dependence Questionnaire (SADQ) scores in alcoholic patients
Plasma folate n BDI SADQ
< 7ng/ml 23 2 1 . 0 ± 2 .2 * 33.2 ±2.7
^ 7ng/ml 18 10.8 ± 1.9 30.1±2.9-
Mean ± sem.
*Patients with serum folate < 7ng/ml had significantly higher BDI scores (p< 0.001)
TABLE 4.8
Plasma folate in female schizophrenic patients comparison with female controls
Group n Age Plasma folate (ng/ml)
Controls
Schizophrenics
26
9
46.5±2.3 
65.4 ± 3.6**
6.52± 0.43 
3.51± 0.37*
Mean ± sem.
*significantly lower than controls (p < 0 .0 0 2 ).
**significantly higher than controls (p< 0 .0 0 1 )
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folate concentrations and the patients' scores on the 
BDI and the SADQ. Patients were divided into those with 
a folate level above (>7ng/ml) and those with folate 
levels below the mean (< 7ng/ml) (the mean for the con­
trol subjects). As shown, the mean morbidity score 
(BDI) for the low folate group was approximately twice 
as high as that for the high folate group? the SADQ 
scores did not differ significantly between these two 
groups. Liver function jbests were also carried out 
on these patients, There was no association between 
abnormal liver function tests and plasma folate' concen­
trations .
4.1.5 Chronic schizophrenic patients
Table 4.8 indicates that female chronic schizophrenic 
patients had significantly lower plasma folate concen­
trations than the female control subjects. It was noted 
that schizophrenic patients were significantly older than 
control subjects.
4.2 Red blood cell folate levels
4.2.1 Control subjects and drug-free ill depressive patients_________________________________________
Table 4.9 shows comparisons of red blood cell folate 
concentrations between control subjects, drug-free ill 
depressive and lithium-treated patients, subdivided into 
those who were receiving placebo folic acid and those 
who were receiving active folic acid (vide infra). Drug- 
free ill depressive patients and lithium-treated patients 
receiving placebo folic acid had significantly lower 
folate concentrations than control subjects. Lithium- 
treated patients receiving placebo folic acid also had 
significantly lower folate concentrations than those 
receiving active folic acid, and the latter group had 
significantly higher folate concentrations than control
TABLE 4.9
Red blood cell (RBC) folate concentrations in control subjects, drug-free depressive patients and lithium-treated patients receiving placebo and active folic acid supplements
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Group
n
M F Age RBC folate (ng/ml)
Controls
Drug-freedepressives
Lithium-treated;
on placebo folate
on active folate
1 11
5 7
4 8
43 .4 ± 4.7
56.3 ± 5.1
52.2±3.2
51.5 ±4.5
360.4± 29.5
224.7 ± 26.0*
213.0± 20.4**
505.8 ± 23.9***
Mean ± sem.
*significantly lower than controls ( p < 0 .0 1 ). 
**significantly lower than controls and active folate(p < 0 .0 0 1 ) .
***significantly higher than all groups (p< 0 .0 0 1 ).
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subjects. Drug-free ill depressive patients were classi­
fied on the Newcastle Scale into endogenous and non­
endogenous subgroups. They were also classified in terms 
of whether they lost weight or not (according to that 
item on the Newcastle Scale). Red blood cell folate con­
centrations showed no association with either classific­
ation (Tables 4.10, 4.11).
4.2.2 Lithium-treated patients
As indicated above, lithium-treated patients receiving 
placebo folic acid had similar folate concentrations to 
drug-free ill depressive patients and significantly 
lower concentrations than control subjects. The 'spot' 
morbidity rating (global morbidity rating at the time 
of blood collection) and the change in weight between 
patients' attendance when their red blood cell folate 
was estimated and the preceding attendance were determined 
for both groups: those on placebo and on active folic acid. 
There were no significant differences in 'spot' morbidity 
between the group receiving active folic acid (mean 0.35, 
sem 0 .1 ) and the group receiving placebo folic acid (mean
0.18, sem 0.1). The group receiving active folic acid 
had a mean change in weight of -0.5 ± 0.7 5kg versus a mean 
change in weight of -1.4 ±0.67kg for the group receiving 
placebo folic acid. Red blood cell folate concentrations 
showed no significant correlation with HRS (r = -0.07) or 
with BDI (r = 0.15). Red blood cell folate concentrations 
showed a significant positive correlation with plasma 
folate concentrations in the full group of lithium- 
treated patients (r = 0.73, p <  0.001) and for the full 
group of lithium treated patients, drug-free depressive 
patients and control subjects (r = 0.82, p <  0 .0 0 1 ).
159
TABLE 4.10
Classification of depression and RBC folate
Group n RBC folate (ng/ml)
Endogenous(Newcastle score è 6 ) 6 236 .8 ± 41.4
Non-endogenous(Newcastle score Û 5) 6 212.8 ±26.9
Mean ± sem. .
TABLE 4.11
Relationship between weight loss (according to Newcastle classification) and RBC folate in depression
RBC folateWeight loss n (ng/ml)
Present 6 256.5 ± 35.2
Absent 6 191.5 ± 30.5
Mean ± sem.
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4.3 Clinical trial of folic acid
4.3.1 Open trial of folic acid supplement in chronic schizophrenic patients____________________________
Nine female chronic schizophrenic patients who had 
low plasma folate concentrations received physiological 
doses of folic acid (300|ig per day) to determine the 
effects of such doses on their plasma folate concentrations 
Table 4.12 shows folate concentrations of patients at 
baseline and at the end of weeks 1, 2, 3 and 4 on the 
trial. As shown, by the end of week 1 the group had 
significantly higher folate concentrations than at base­
line, concentrations that showed little variation over 
the next three weeks.
4.3.2 Double-blind trial of folic acid supplement in lithium-treated patients________________________
Table 4.13 shows clinical outcome after 6 months 
treatment with physiological supplements of folic acid 
in comparison with placebo. The two groups had similar 
baseline plasma folate concentrations and mean BDI scores. 
Their baseline affective morbidity index (AMI) over 6 
months was lower in the group that received folic acid 
treatment. This difference was not statistically sig­
nificant .
Patients who received folic acid treatment had a 
significantly higher mean plasma folate concentration at 
6 months compared with baseline concentrations. Patients 
who received placebo had only a very minimal increase in 
their plasma folate concentrations. Intra- and intergroup 
comparisons showed no significant changes in morbidity 
as measured by mean BDI scores and AMI over the 6 months 
of the trial. Paradoxically, the group on placebo had 
a 60% reduction in AMI and the group on folic acid had 
a 20% increase in AMI during the 6 -month trial period.
These changes were not statistically significant. Four
TABLE 4.12
Open trial of folic acid supplements in 9 female schizophrenic patients; effects on plasma folate concentrations
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Weeks after trial Plasma folate (ng/ml)
Baseline 3.51± 0.37*
Week 1 8.71± 0.80
Week 2 8.23±1.12
Week 3 11.44 ± 1.44
Week 4 10.63 ± 1.47
Mean ± sem.
*significantly lower than after trial (p< 0 .0 0 1 )
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out of 10 patients who had received folic acid had ab­
normal DST responses (40%) versus one patient out of 
11 in the placebo group (9%). This difference is not 
statistically significant.
5. DISCUSSION
These results substantiate previous reports of high 
prevalence of low plasma folate concentrations in depress­
ive patients (Carney, 1967; Reynolds et al, 1970; Carney 
and Sheffield, 1978). Indeed, the prevalence of very low 
plasma folate concentrations (<2.5ng/ml) in the acutely 
ill depressive patients was 15%, a lower rate than the 
previous report from this laboratory of 24% (Reynolds et 
al, 1970). Only 6 % of the lithium-treated group, 7% of 
alcoholic patients and 2 % of control subjects had such low 
plasma folate concentrations.
Both plasma and red blood cell folate concentrations 
were significantly lower in drug-free acutely ill depress­
ive patients and in patients on long-term lithium therapy 
than in control subjects . Among the acutely ill group 
those with more endogenous illness (ICD-9) had the lowest 
plasma folate concentrations compared with control sub­
jects and those with non-endogenous illnesses. Surpris­
ingly there was no association between either plasma or 
red blood cell folate and 'endogenicity' as defined by 
the Newcastle Scale, given the notion that it provides 
a narrower definition than ICD-9 (see Chapter 2). It is 
conceivable that folate deficiency is associated with 
both endogenous and non-endogenous depressions. Indeed, 
the percentage of folate-deficient patients was similar 
in endogenous and non-endogenous depressions, as defined 
by ICD and the Newcastle Scale.
Affective morbidity was associated with plasma 
folate concentration but not with red blood cell folate
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concentration in both groups: acutely ill depressives 
and lithium-treated patients. This finding is intriguing 
in view of the significant positive correlation between 
plasma and red blood cell folate concentrations. The 
relationship between these two estimates of folate to 
brain tissue folate concentration, as determined by CSF 
folate, was previously investigated. Plasma folate con­
centrations were strongly positively correlated to CSF 
folate concentrations (Reynolds et al, 1972; BOtez et al, 
1979b). The relationship between plasma, CSF and red 
blood cell folate concentrations, however, was shown to 
be unidirectional; low red blood cell folate concentrations 
were associated with low plasma and CSF folate concen­
trations but the reverse was not true in many cases 
(Botez et al, 1979b).
In lithium-treated patients lower plasma folate con­
centrations were associated with increased morbidity over 
the previous two years, perhaps indicating the continuing 
vulnerability of the group with low plasma folate con­
centrations. Indeed, the subgroup with low plasma folate 
concentrations that received placebo during the folic 
acid trial showed little change in these concentrations 
after 6 months on the trial, whilst those who received 
folic acid supplements had a significantly greater plasma 
folate concentration during the trial. The notion that 
lithium treatment per se may contribute to lower plasma 
folate concentrations by the release of folate-binding 
proteins in granulocytes (Herbert and Colman, 1980) and 
in one case the occurrence of megaloblastic anaemia 
(Prakash et al, 1981) is inconcistent with the observed 
association between lower plasma folate concentration 
and higher AMI in lithium-treated patients when they 
are maintained on similar plasma lithium concentrations. 
Extra medication (extra to lithium) showed no association 
with plasma folate concentrations.
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Changes in weight were not associated with plasma 
or red blood cell folate concentrations, thus confirming 
the findings of the previous investigation in depressive 
patients (Reynolds et al, 1970) and in psychiatric patients 
in general (Shulman, 1967; Thornton and Thornton, 1978).
The reliability, and hence the validity, of taking 
dietary histories from psychiatric patients must be 
questioned. Furthermore, weight change is a crude in­
dicator of nutritional status. Alcoholic patients, a 
most vulnerable group for nutritional deficiencies, had 
remarkably similar plasma folate concentrations to control 
subjects. This may be related to the fact that these 
patients had undergone detoxification and had been abstin­
ent for 3-6 weeks by the time their plasma folate concen­
trations were estimated, when any pre-existent nutritional 
deficiencies may have been rectified. Among them, however, 
those with lower plasma folate concentrations (lower than 
the mean folate concentration for the control group) had 
significantly higher affective morbidity than those with 
higher concentrations. No association was found between 
plasma folate concentrations and the severity of their 
alcohol dependence or their liver function disturbance.
The association between increased affective morbidity 
and lower plasma and red blood cell folate concentrations 
would imply that folic acid may have therapeutic effects. 
This hypothesis was tested by observing the effects of 
clinical recovery on plasma folate concentrations and 
more stringently by observing the effects of therapeutic 
folic acid supplements on morbidity over time: changes 
in morbidity in both situations were not associated with 
changes in plasma folate concentrations. Paradoxically, 
patients receiving placebo had a 60% reduction in their 
morbidity over six months, whilst those who received 
folic acid had an increase of 2 0 % in their morbidity 
during the trial, It was noted that the morbidity of
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these patients was minimal if not residual: none of the 
patients suffered an affective episode (i.e. at least 
moderate morbidity) during the six months preceding or 
whilst on the trial. Seven patients in each group were 
euthymie in the six months preceding the trial (baseline) 
and five of these in both groups remained euthymie during 
the trial. Furthermore, in each group there were only 
two patients who had plasma folate concentrations of 
< 2.5ng/ml, a very low baseline, and three of these four 
were euthymie at baseline and one had mild morbidity.
On follow-up the three euthymie patients experienced no 
morbidity and the one with mild morbidity became euthymie 
and this patient was on placebo.
Furthermore, more patients onfolic acid had abnormal 
DST responses during the trial (40%) than those on placebo 
(9%). If an abnormal DST response is accepted as an in­
dicator of continuing vulnerability or poor prognosis, 
then the group on folic acid appears to have experienced 
a more vulnerable phase of illness whilst on the trial 
than the group on placebo. This, however, was not borne 
out on evaluating the difference in AMI in the six months 
preceding and the six months during the trial; out of the 
four patients with abnormal DST results and who were on 
folic acid, two had no change in morbidity, one had an 
increase and one had a decrease in morbidity.
In the previous investigation (Reynolds et al, 1970) 
those with similar very low folate concentrations had 
significantly higher self-rated morbidity, and had less 
favourable response to antidepressant therapy than those 
with higher folate concentrations. In the group which 
had their morbidity rated and plasma folate estimated on 
admission and on discharge, no trend was noted for those 
with lower plasma folate concentrations to have a worse 
outcome that those with higher concentrations. Only one 
of these 17 patients had plasma folate concentration
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below 2.5ng/ml on admission, and this patient had a 78% 
reduction in HRS score by the time he was discharged.
Folic acid was given in physiological doses (300|ig/ 
day) in view of the reported toxicity of pharmacological 
doses (Hunter et al, 1970). Patients who received folic 
acid in the trial had significantly higher plasma folate 
concentrations (mean 13.1 ± 1.5 ng/ml) , which is nearly 
double the mean for control subjects (7.02 ± 0.3 ng/ml) , 
and the question arises as to whether 300|ig/day was 
possibly too high a dose to prescribe in this situation. 
The literature on the antidepressant effects of folic 
acid in affective disturbance is scanty. Therapeutic 
trials of folic acid in pharmacological doses showed it 
to be of value in the treatment of neuropsychiatrie symp­
toms including depressive symptoms in epileptic patients 
on anticonvulsant therapy (Reynolds et al, 1966; Reynolds, 
1967) and in folate-deficient patients with long-standing 
functional gastrointestinal disorders associated with 
neuropsychiatrie symptoms (Botez et al, 1976,1979b).
The only investigation that involved primary depressive 
patients was a retrospective one which found that folate- 
deficient depressive patients who had received folate 
supplements showed more improvement in their mental 
state on discharge and spent less time in hospital than 
similar patients who received no folate supplements 
(Carney, 1979).
Folate supplements may have therapeutic value in 
a percentage of folate-deficient patients with long­
standing functional gastrointestinal disorders associated 
with neuropsychiatrie symptoms (Botez et al, 1979b), 
probably in those with susceptibility to affective dis­
turbance. Indeed, in one investigation as many as one- 
third of patients with a deficiency severe enough to 
produce megaloblastic anaemia showed no nervous system
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complications (Shorvon et al, 1980). Along the same 
lines, one could argue that among primary depressive 
patients with folate deficiency, only a certain percent­
age of them respond or improve on folic acid supplement, 
probably those whose affective disturbance was aggravated 
by the folate deficiency consequent to poor nutrition,
i.e. those with a particular susceptibility to folate 
deficiency.
Botez et al (1979a) showed that low CSF 5-HIAA was 
associated not so much with folate deficiency itself as 
with the neuropsychiatrie effects of folate deficiency 
that were responsive to folate therapy. After all, 
depressive illnesses show biochemical heterogeneity and 
one relevant distinction is that of 5-HT-deficient de­
pressive illness as evidenced by characteristically low 
CSF 5-HIAA concentrations (Asberg et al, 1976).
In the light of all these findings, Botez and his 
colleagues (1979b) proposed an interesting hypothesis 
on the pathogenesis of the neuropsychiatrie syndrome 
associated with folate deficiency: anxiety-depression 
causes or is associated with colitis which in turn 
causes folate deficiency that in turn has neuropsychiatrie 
effects including depression that aggravates the colitis, 
and a vicious cycle is created.
Another subgroup vulnerable to folate deficiency 
among depressive patients is the group suffering from 
endogenous psychotic illnesses. These patients tend to 
have appetite disturbance with consequent weight loss.
It was shown in the present investigation that those who 
had more severe and endogenous illnesses (ICD-9, 296.1) 
had significantly lower plasma folate concentrations com­
pared with control subjects. These patients were older, 
a factor which showed a significant negative correlation
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in the control group but not in the depressive groups.
Age did not account for the differences in plasma 
folate concentfations: male neurotic depressives had 
significantly lower plasma folate concentrations than 
male control subjects, yet they had a very similar age.
This finding confirms a previous report by Carney (1979) , 
who showed that increasing age had no effect on plasma 
folate concentrations in psychiatric patients. Botez and 
his colleagues (1979b) found a high, proportion (6 8 %) of 
cerebral atrophy in folate-deficient patients, which con­
firmed an earlier report by Reynolds et al (1973) that 
showed that 75% of non-alcoholic patients with severe 
folate deficiency had organic brain syndromes. Furthermore, 
patients with inborn errors of metabolism have cerebral 
atrophy and mental retardation (Luhby et al, 1961; Arakawa 
et al,. 1963) . Severely depressed patients were found to 
show evidence of cerebral atrophy and enlarged ventricles 
by pneumoencephalography and computerised axial tomography 
(Standish-Barry et al, 1982; Jacoby, 1982). This latter 
finding is intriguing and the possibility could be enter­
tained that folate deficiency that accompanies or compli­
cates these severe depressive illnesses may be a con­
tributory factor to this cerebral atrophy.
6 . FURTHER RESEARCH
These findings strongly suggest that depressive illness 
is associated with low plasma and red blood cell folate 
concentrations. Although this association does not appear 
to be mediated by weight loss, the contribution of this 
factor could not be ruled out and indeed must remain a 
plausible hypothesis that could stand the test of further 
and better designed studies. The lithium-treated group 
was not the ideal group to study in this respect, given 
the well-documented effects of lithium on body weight.
This notion applies to many other antidepressants and
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neuroleptics shown to stimulate appetite and cause weight 
gain. The ideal group would therefore be drug-free 
depressive patients whose weight changes could be monit­
ored with their mood changes and their plasma, CSF and 
red blood cell folate concentrations, i.e. placebo-treated 
patients during clinical trials.
With regard to the therapeutic effects of folic 
acid, these could hardly be ruled out in the light of 
the negative findings of the present study. The case for 
further clinical trials of folic acid in probably even 
lower and more physiological doses (e.g. 1 0 0 |ig/day) is even 
stronger in view of the fact that there have been no 
clinical trials of folic acid in primary depressive patients 
The finding that 5-adenosylmethionine (see Introduction 
to this Chapter) has significant antidepressive effects 
would prompt clinical trials of folic acid in acutely 
ill patients and in those receiving prophylactic therapy 
such as lithium. In a prophylactic situation, clinical 
outcome must be evaluated over an extended period of time, 
perhaps at least for a year, given the relatively low 
morbidity of this group of patients. Furthermore, the 
value of folic acid in the treatment of depressive illness 
that is refractory to conventional antidepressant therapy 
should also be explored.
Folic acid could be particularly effective in 
clinically or biochemically defined subgroups of depressive 
patients. This could be studied in the context of clinical 
trials in depressive patients carefully classified on 
clinically established distinctions combined with bio­
logical investigations such as dexamethasone suppression 
test, platelet 5HT uptake, plasma and CSF tryptophan,
CSF 5-HIAA, etc.
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CHAPTER 5
TREATMENT OUTCOME IN DEPRESSION: CLINICAL, PSYCHOLOGICAL, BIOLOGICAL AND PSYCHOPHARMACOLOGICAL CORRELATES
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1. INTRODUCTION
Depressive illnesses show great heterogeneity along 
several dimensions: clinical, psychological, genetic and 
biochemical. The study of the ranges of these heterogen­
eities is particularly important in relation to treatment 
outcome or response: characteristics that predict or deter­
mine future response to treatment are of paramount importance 
in clinical practice. Ultimately the aim is to define 
meaningful subgroups of depressive patients that respond 
or do not respond to specific psychological or physical 
treatments. It was the discovery of physical treatments 
such as electroconvulsive therapy, antidepressant medication 
and lithium that refined the nosology and the present-day 
classifications of affective disorders whose further refine­
ment depends on more extensive studies of clinical charac­
teristics of depressed patients in relation to biochemical 
and psychopharmacological variables. Several factors must 
be considered when predictors of treatment outcome are 
studied (Paykel, 1979a). The first factor is the strong 
tendency of depressive illnesses for spontaneous recovery 
in the absence of treatment. Secondly, non-specific factors 
such as changes in precipitant events, in social support, 
in provision of professional help and the benefit of hos­
pital admission make their contribution to outcome.
Thirdly, there are placebo effects and the 
effects of specific treatment: the essence of clinical 
trials research. The contribution of all these factors is 
particularly relevant to long-term treatment outcome when 
their effects are least likely to be ruled out.
In studies of determinants of treatment outcome, two 
contrasting approaches have been used: the dimensional and 
the typological. The dimensional approach, advocated by 
Kendell (1968),argues for a linear dimension or a diagnostic 
index derived from many variables as being a better predictor 
of outcome than a typological distinction (Kendell, 1976).
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The typological or categorical approach relates the member­
ship of a discrete category of illness or diagnosis to 
outcome of the specific treatment (Paykel, 1979a). Studies 
of predictors of treatment outcome in affective disorders 
have centred on two main distinctions; the endogenous 
(psychotic)-nonendogenous (neurotic) and the unipolar- 
bipolar illnesses. The primary-secondary dichotomy has been 
shown to be of little use in determining treatment outcome.
1,1 Clinical predictors of response to ECT
Studies of clinical outcome of delusional and non- 
delusional depression antedated the introduction of ECT 
(Hoch and McCurdy, 1922; Lewis, 1934); these studies showed 
that most severely depressed patients, excluding those 
with delusions, make spontaneous recoveries. Studies of 
treatment outcome with ECT examined the endogenous-nonendo­
genous distinction and showed that endogenous illnesses 
have more favourable responses than nonendogenous illnesses. 
Several predictive diagnostic indices were constructed and 
were shown to have good predictive validity (Hobson, 1953; 
Carney et al, 1965; Kendell, 1968; Carney and Sheffield, 
1972). These findings were not confirmed by other investi­
gators (Hamilton and White, 1960; Abrams et al, 1973;
Crow et al, 1984). The study by Crow et al (1984) examined 
the predictive validity of all the known scales that pre­
dict response to ECT in the context of a trial of real 
versus simulated ECT: none of these scales predicted res­
ponse to real ECT and the most salient predictor of such 
response was the presence of delusions. A few studies 
investigated the relationship between the unipolar-bipolar 
distinction and response to ECT. In one study unipolar 
depressives were found to require more treatment than bi­
polar patients (Perris, 1966), and two studies found no 
difference in response between these two groups (Stromgren, 
1973; Abrams and Taylor, 1974).
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1.2 Clinical predictors of antidepressant therapy
Kuhn (1958), who discovered the first tricyclic 
antidepressant, imipramine, observed that endogenous 
depressive patients showed particularly favourable res­
ponses to the drug. This area was critically reviewed by 
Bielski and Friedel (1967) and Paykel (1979a). Overall 
the balance of the evidence strongly suggests that tri­
cyclic antidepressants are more effective in the treatment 
of endogenous than in non-endogenous depression.
Greenblatt et al (1964), in a large collaborative study, 
showed a clear differential effect for imipramine compared 
with placebo in manic depressive and involutional depressive 
patients but not in those with neurotic depression. In 
neurotically depressed patients tricyclic antidepressants 
were found to be more effective than placebo in a few 
controlled trials (Ball and Kiloh, 1959; Wittenborn et al, 
1962; Covi et al, 1974). Paykel, in his review (1979a), 
raised the question of differential response to placebo 
in these subgroups of depressive patients. He noted that 
in the study by Greenblatt et al (1964) neurotic depressive 
patients showed a very high improvement rate on placebo 
(83%)as compared with those with involutional melancholia 
(25%). He also noted that the advantage of imipramine in 
psychotic depressives only became apparent on comparing 
imipramine with placebo. Furthermore the rate of improve­
ment in neurotic depressive patients on imipramine was 
higher than in those with psychotic illness.
A major difficulty in evaluating the effects of treat­
ment in neurotic depressive illness is the heterogeneity 
of this disorder. Overall et al (1966) derived 
two meaningful subgroups that could be subsumed clinically 
under neurotic depression - the anxious-tense and hostile 
depressions. They found that anxious-tense depression 
responded better to thioridazine than to imipramine. Paykel 
(1971), using cluster analysis, obtained three clinically 
meaningful neurotic depressive subgroups; anxious, hostile,
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and young depressive patients with personality disorder.
This typology was examined in relation to response to 
amitriptyline (Paykel, 19 72). He found that anxious 
depressives had the worst response, a finding that was 
replicated in a further study (Prusoff and Paykel, 1977).
Endogenous depressive illness also shows some hetero­
geneity and of importance is the particular standing of 
delusional depression in relation to response to anti­
depressant therapy. Several studies indicated that delus­
ional depressive illness is less responsive to tricyclic 
antidepressants than non-delusional depression (Friedman et 
al, 1961; Angst, 1961; Hordern et al, 1965; Glassman et al, 1975)
1.3 Predictors of lithium response in affective disorders
The use of lithium salts in the management of affective 
disorders has provided one of the most dramatic developments 
in clinical psychopharmacology. Lithium salts have an 
established anti-manic and prophylactic effects but its place 
in the management of acute depression remains to be substanti­
ated (see reviews by Cpppen and Abou-Saleh, 1983; Abou-Saleh 
and Ghodse, 1983).
Prediction of lithium anti-manic response is far less 
important than its prophylactic response in view of the 
availability of equally effective treatments such as pheno- 
thiazines and butyrophenones. It is important that sub­
groups of affectively ill patients responsive and non- 
responsive to lithium be identified in advance: the group of 
non-responders who tend to run a course of high morbidity 
could be spared, exposure to long-term lithium therapy and 
its unwanted effects.
1.3.1 Predictors of anti-manic response
The overall favourable response rate of manic patients 
to lithium is in the order of 70-80% and both typical and 
atypical manic patients respond equally well (Schou, 1959).
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The presence of symptoms such as delusions and gross 
hysterical symptoms is associated with poor response 
(Schou, 1959). Manic patients with paranoid-destructive 
features have less favourable responses than those with 
the typical euphoric-grandiose characteristics and the 
former subgroup tend to suffer considerably more depressive 
symptoms (Murphy and Beigel, 1974). Psychotic manies with 
severe excitement tend to respond favourably to treatment 
even when they have paranoid delusions, visual and olfactory 
hallucinations, catatonic and first rank Schneiderian 
symptoms (Taylor and Abrams, 19 75). Their study does not 
allow the data for patients treated with lithium alone to 
be evaluated separately from the results obtained in patients 
who received neuroleptic drugs with or without lithium.
They found, however, that good response was associated 
with euphoric mood, grandiose delusions and cyclothymic 
premorbid personality and poor response in those who had 
incomplete auditory hallucinations and depressive withdrawn 
premorbid personality. Sullivan (19 77) reported an associ­
ation between low platelet monoamine oxidase (MAO) activity 
and poor response. The lithium-refractory subgroup which 
comprised 25% of the total sample of 24 manies remained 
essentially unchanged in their clinical manic state after 
three weeks of lithium treatment, with plasma levels between 
1.4-1.8mmol/l. The only significant difference between the 
lithium-responsive and non-responsive subgroups was a 
significantly higher incidence of psychiatric illness in the 
families of lithium-refractory patients.
1.3.2 Predictors of antidepressive response
Patients with bipolar depression respond better to 
lithium that those with unipolar illness (Goodwin et al,
1972), and characteristic personality traits of lithium 
responders within the unipolar group were reported to be 
similar to bipolar patients' personality profiles (Kupferetal, 
1975). Depressed patients with a schizoid pattern of 
response to the Hopkins' Symptom Checklist show poor responses
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to lithium (Mendels et al, 1979). Those with an endogenous 
symptom profile respond best to lithium which emphasises 
that patients with neurotic depression are poor candidates 
for lithium treatment (Dyson and Mendels, 1968). . Psycho­
logical variables have also been studied in relation to 
lithium response. High Depression and Psychasthenia 
profiles on the Minnesota Multiphasic Personality Inventory 
(MMPI) (House and Martin, 19 75? Donnelly et al, 1978) and 
higher scores on the Ego Over-Control Scale (Donnelly et 
al, 1978) were associated with a favourable antidepressant 
response to lithium.
1.3.3 Predictors of prophylactic response
The overall response rate is about 65-80% which is 
similar to the response rate in acute mania. The evalu­
ation of long-term outcome of treatment, as in lithium 
prophylaxis, is fraught with difficulties; it is likely 
to be biased in favour of the treatment due to the non­
specific treatment factors and the tendency of affective 
disorders for spontaneous recovery. This notion must be 
balanced against the tendency of these disorders to recur 
more often with increasing age. Another methodological 
difficulty is the measurement of long-term treatment out­
come. Most studies determined outcome by the rate of
relapses and fewer studies used global measures of clinical
state. The definition of relapse and lithium-modified 
episodes are not standardised to make meaningful comparisons 
between the results of different studies.
1.3.3.1 Clinical
The evidence for the efficacy of lithium in the treat­
ment of bipolar affective illness is overwhelming; seven 
placebo-controlled studies involving 4 00 patients showed 
that it definitely reduces the occurrence of depressive 
episodes (Baastrup et al, 19 70; Coppen et al, 1971; Cundall
et al, 1972; Fieve et al, 1976; Hullin et al, 1972? Prien
et al, 1973a",b) . The evidence for efficacy in unipolar
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affective illness was thought to be inconclusive (Prien,
1979; Report of the American Psychiatric Association Task 
Force, 1975). Several studies found lithium to be superior 
to placebo in unipolar illness (Baastrup et al, 1970;
Coppen et al, 1971; Fieve et al, 1975; Prien et al, 1973a; 
Quitkin et al, 1978), and the reason for the foregone 
conclusion may be the heterogeneity of unipolar illness 
(see Introduction, p. 24).
In schizoaffective illness, the case for lithium 
therapy is difficult to determine, given the contemporary 
confusion over its nosology: it is conceived as a variant 
of schizophrenia (ICD-9), as more closely related to affect­
ive illness or as a mixture of the two illnesses (Brockington 
and Leff, 1979). In three double-blind studies, lithium 
was found to be equally effective to chlorpromazine 
(Prien et al, 1972; Brockington et al, 1978) and less 
effective than chlorpromazine (Johnson et al, 1971). In the 
study by Prien and his colleagues (1972), however, lithium 
was found less effective than chlorpromazine in the highly 
active patients but as effective in the mildly active group.
Among bipolar patients, those with frequent episodes 
(rapid cycling patients) show a greater incidence of 
prophylaxis failure (Stancer, 1970; Dunner and Fieve,
1974; Misra and Burns, 1977) than those with non-rapid cycling 
illness. Prien et al (1974) similarly found that patients 
with a higher frequency of recent hospital admissions had 
higher incidence of treatment failure on lithium. More­
over, the occurrence of a relapse within one year of 
starting lithium predicted future relapses, Dunner et al 
(1976) studied clinical predictors of prophylaxis failure 
in non-rapid cycling bipolar patients. Whilst none of 
the clinical variables studied predicted outcome, they 
observed that patients who received lithium had a similar 
failure rate to those on placebo in the first six months 
of treatment, A quarter of their patients had early fail­
ure of treatment (within three months) and this tended to
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predict earlier failure during their continued lithium 
treatment.
It has been argued that rapid cycling illness may be 
an iatrogenic phenomenon induced by exposure to anti­
depressant medication (Kukopulos et al, 1975) which leads 
to the suggestion that withdrawal of antidepressant medic­
ation would cause a better response to lithium. Indeed, 
this group of workers has provided evidence to that effect 
(Reginaldi et al, 1981) . Kukopulos and Tondo (1980) have shown 
the course of affective illness in relation to outcome 
and delineated subgroups with variable responses to 
treatment. Patients with mania-depression-interval course 
were found to respond better (60% good response) than those 
with depression-mania-interval course (33% good response) 
and those with continuous circular course (2 2 % good response) 
Comparatively, unipolar patients in their group had a 
high rate of good response at 58%.
As regards the prediction potential of clinical 
features, the evidence is inconclusive. Several studies 
have shown that factors such as age of onset, number of pre­
vious affective episodes (excluding rapid cycling patients), 
age at starting lithium therapy have no predictive value 
(Dunner et al, 1976; Coppen et al, 1979a; Abou-Saleh, 1980, 
1983).. Among the clinical features of affective state in­
vestigated , marked psychomotor retardation was found to be 
associated with better response (Ananth et al, 1979) and 
the presence of paranoid features to be associated with 
poor response (Dunner and Fieve, 1974; Abou-Saleh, 1980). 
Several studies reported an association between the pre­
sence of family history of bipolar illness and favourable 
response to lithium (Mendlewicz, 1973; Stallone et al, 1973; 
Prien et al, 1974; Maj et al, 1984). Other studies failed 
to confirm this finding (Dunner et al, 1976; Misra and 
Burns, 1977). The presence of a family history of non- 
bipolar affective disorder was not, however, associated with 
a more favourable response (Mendlewicz et al, 1973; Dunner
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et al, 1976; Coppen et al, 1979e; Abou-Saleh, 1980). In 
a combined group of bipolar and unipolar patients, Svestka 
and Nahumek (1975) noted that a family history of endo­
genous psychosis or suicide in first-degree relatives 
was significantly associated with good prophylactic res­
ponse. The most convincing evidence that genetic hetero­
geneity affects response to lithium was presented by 
Mendlewicz (1979) in a study of twins. A high concordance 
rate was found in bipolar monozygotic and dizygotic twin 
pairs where one twin has experienced a good long-term 
response to lithium. In a related study, prophylactic 
response was better in the concordant than in the dis­
cordant twins (Mendlewicz et al, 1978).
1.3.3.2 Psychological
Psychological factors have been studied mainly in 
relation to short-term response to lithium (vide supra). 
Two studies examined MMPI profiles of lithium responders 
and non-responders in a prophylactic situation (Ananth 
et al, 1979; Burdick et al, 1980) and had conflicting 
results. Responders had higher scores on scales of hypo­
chondriasis and psychasthenia , whilst non-responders had 
higher scores on scales of psychopathic deviance and 
paranoia; differences, however, were not statistically 
significant (Ananth et al , 1979) and support the 
findings of Donnelly et al (1978) in relation to short­
term response. The other study used the lithium-response 
scales derived by the aforementioned group and failed to 
predict outcome (Burdick et al, 1980).
On the Eysenck Personality Questionnaire, responders 
to lithium had significantly lower neuroticism scores 
than non-responders in both unipolar (Coppen et al, 1979a) 
and bipolar (Abou-Saleh, 1980) patients and, more recently, 
in a combined group of unipolar and bipolar patients (Maj 
et al, 1984 ) .
181
On the Crown-Crisp Experiential Index (CCEI), 
responders to lithium had significantly higher obsession- 
ality scores than non-responders (Maj et a l , 1984), which 
confirmed a similar finding by an earlier study in relation 
to short-term response (Kerry and Orme, 197 9). This was 
interpreted in terms of better compliance in those with 
obsessional tendencies and thus more likelihood of 
favourable response. Indeed, on the MMPI, favourable 
short-term antidepressant response was associated with 
higher scores on the acquiescence scale indicating greater 
conformity with a pill-taking regime (Steinbrook and 
Chapman, 1970). On the Foulds' Personality Deviance 
Scale, responders to prophylactic lithium had significantly 
higher dominance scores than non-responders (Abou-Saleh, 
1983) .
It has been claimed that responders show premorbid 
mood lability whilst non-responders have premorbid traits 
of chronic anxiety and obsessiveness (Kupfer et al, 1975; 
Ananth et al, 1979). On the MNTS, responders had sig­
nificantly higher validity and significantly lower stability 
scores than non-responders (Bech et al, 1976).
The difficulties in investigating personality charac­
teristics in relation to response to lithium are formidable. 
Firstly, assessment and measurement of premorbid person­
ality characteristics is rarely possible. Secondly, the 
presence of affective symptoms affects these character­
istics; e.g. neuroticism and validity (Coppen and Metcalfe, 
1965; Kendell and DiScipio, 1968; Bech et al, 1976).
Thirdly, assessment during euthymie periods is subject to 
the influence of medication on these characteristics 
(Bonetti et al, 1977).
1.3.3.3 Biological
Physiological and biochemical correlates of prophy­
lactic response were the least investigated. One important
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factor has been the Lithium Index (ratio of erythrocyte 
to plasma lithium concentration). Out of 10 studies 
(reviewed by Carroll, 1979) only three showed a definite 
tendency for patients with low ratios to relapse. Lithium 
index may be related to bipolar status rather than lithium 
response per se (Frazer et al, 1978). Carroll (1979), in 
the only study that employed the newer in vitro transport 
measures, found that those with the best long-term outcome 
on lithium had the lowest lithium efflux.
Erythrocyte membrane ATPases have been investigated 
in relation to lithium prophylactic response. Naylor et 
al (1976) postulated that a rise in Na^/K+-ATPase activity 
with lithium correlates with a good response to lithium. 
Hasketh (1976) found a significant increase in the activi­
ties of all the ATPases after one year of lithium therapy.
On classifying his patients into lithium successes and 
failures, it emerged that the lithium failure group had 
only an increase in Mg+-ATPase activity with no changes 
in Ca+- and Na+/K+-ATPases. These findings, together with 
the notion that calcium inhibits Na+/K+-ATPase (Skou, 1957), 
prompted investigations of Ca"*" binding by erythrocyte 
membranes (Glen et al, 1978), and these authors reported 
that lithium treatment increases calcium binding to ery­
throcyte membranes during the acute treatment stage. McLeod
(1979), however, found no significant difference in Ca+ 
binding to erythrocyte membranes between depressed patients 
on lithium and controls. In relation to lithium prophy­
lactic response, no differences in Ca"^  binding between 
responders, non-responders and control subjects were 
detected (Abou-Saleh, 1980). However, this study found a 
trend for an association between higher calcium binding 
ratio (active/inactive Ca"*" binding) and better response 
in responders and the opposite trend in non-responders.
Platelet MAO was investigated in relation to lithium 
prophylactic response in three studies (Abou-Saleh, 1980;
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Reveley et al, 1981: Maj et al, 1984), and no significant 
association was found.
1.3.3.4 Subjective side effects of lithium
The occurrence of subjective side effects during 
lithium therapy is well documented (Schou et al, 1970:
Ghose, 1977? Vestergaard et al, 1980). Commonly reported 
side effects in the early stage (within six weeks of 
starting lithium) include nausea, loose stools, fatigue, 
muscle weakness, polydipsia, polyuria and hand tremor.
During maintenance, weight gain, mild memory impairment 
are common complaints, and hand tremor, polydipsia and 
polyuria may persist from the early stage. It is generally 
considered that the rate of occurrence of these side effects 
and their severity are related to plasma lithium concen­
trations .
Similar complaints, however, have been reported in 
patients who had received placebo (Pogge, 1963? Shapiro 
et al, 1974; Prien et al, 1974), and the suggestion was 
made that such 'side effects' are also symptoms of 
depression (Schulterbrandt et al, 1974),
Another complicating factor is the contribution of 
extramedication to the occurrence of these side effects.
Bech et al (1976) showed that patients who received anti­
depressants and neuroleptics complained of more side 
effects than those on lithium alone or patients who dis­
continued their lithium. Moreover, patients who received 
lithium only had less affective morbidity than those who 
received extramedication or those who discontinued their 
lithium. Similar findings were reported by Bone et al
(1980) . In a cross-sectional and longitudinal survey of 
side effects in a lithium clinic, Lynkowski et al (1982) 
found that the presence of additional medication and mood 
disturbance contributed to the occurrence of side effects 
in the cross-sectional but not in the longitudinal study.
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They found a trend for dry mouth to increase and for 
fatigue, sleepiness and confusion to decrease with time 
on lithium.
In a more recent longitudinal study of subjective 
side effects of lithium, again no association was found 
between side effects and the presence of mood disturbance 
(Duncarage et al, 1983). The contribution of personality- 
factors has not, however, been investigated.
1.3.3.5 Pharmacokinetic
The widely accepted prophylactic therapeutic range of 
serum lithium concentrations of 0 .8 -1 .2ramol/l was an extra­
polation from the range required for adequate antimanic 
effect (Baastrup and Schou, 1967; Schou, 1968). Coppen 
et al (1971) provided empirical evidence that within the 
range 0.77 to 1.3mmol/l no relationship existed between 
average plasma in each patient and clinical response.
Other investigators recommended a range of 0.4-0.8mmol/l 
for effective prophylaxis (Gershon, 1970; Brown, 1973).
Several studies attempted to determine the minimal effect­
ive dose/serum level of lithium in prophylaxis using a 
retrospective (Prien and Caffey, 1976; Marchetti and Cabras, 
1980; Sarantidis and Waters, 1981; Decina and Fieve, 1981; 
Sashidharan et al, 1982) and prospective (Jerram and McDonald, 
1978; Waters et al, 1982) design.
Prien and Caffey (1976), in a multicentre collaborative 
study, examined the relationship between lithium dose/serum 
level in a high-risk group of lithium responders and non­
responders, i.e. patients with one previous episode of 
illness in the previous two years or two previous episodes 
in the previous five years. They found that 55% of 
patients maintained on lithium levels < 0.7mmol/l and 
14% on levels > 0.7mmol/l were non-responders. Furthermore, 
they observed that relapses occurred fairly quickly and 
could not be prevented by increasing their lithium dosage.
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In a retrospective study, Marchetti and Cabras (1980) 
found that manic-depressive patients maintained on levels 
between 0.4 and 0.8mmol/l had a significant reduction in 
morbidity, i.e. 5 0% reduction in recurrences on lithium 
compared with the pre-lithium period, whilst patients 
maintained on levels below 0.4mmol/l had a significantly 
higher rate of relapse. Sarantidis and Waters (1981) 
found that in a group of bipolar and schizoaffective 
patients, fair response (less morbidity than prior to 
lithium) was associated with levels below 0.7mmol/l, 
and lithium levels were highest in the non-responder group 
who suffered the same or greater morbidity on lithium than 
before it was started.
Decina and Fieve (1981) reviewed the follow-up charts 
of 14 unipolar patients on prophylactic lithium: they found 
that the seven patients who had treatment success had a 
significantly lower serum lithium level (mean 0.59, SD 0.1) 
than the seven patients who failed to respond (mean 0.99,
SD 0.09). The last retrospective study was carried out by 
Sashidharan and colleagues (1982) on 53 bipolar and uni­
polar patients observed over four years. They found that 
responders spent significantly more time at lithium levels 
below 0.9mmol/l than non-responders.
Jerram and McDonald (1978), in an open prospective 
investigation over one year, studied the efficacy (relapse 
rates) in groups of bipolar and unipolar patients main­
tained at three lithium levels; below 0.49, between 0.5 
and 0.6 9 and above 0.7mmol/l. Relapse rates of these 
groups were 18%, 13% and 20% respectively. To determine 
the minimal effective levels, these workers carried out 
a further study over one year and allocated patients to 
one of three groups with ranges of 0.25-0.39, 0.4-0.59 
and 0.60-1.OOmmol/1 (Hullin, 1980). Relapse rates for 
these groups were 62%, 15% and 18% respectively, a marked 
increase in the group maintained at levels between 0.25
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and 0.39mmol/l and thus indicating that a lithium level 
of 0.4mmol/l is the minimal effective serum lithium con­
centration. It was noted that in this study lithium- 
modified episodes or milder mood swings were not included 
in evaluating response to lithium.
Waters et al (1982) , in the only double-blind pro­
spective investigation, studied the relapse rates of 
bipolar patients who were randomly assigned to low levels 
(0.3-0.8mmol/l) and high levels (0.8-1.4mmol/l) of lithium. 
Patients in each group were followed up for six months 
before being switched over to the other group (cross-over 
design) for another six months. They found that signifi­
cantly more of the relapses (83%) occurred during the low 
level phase (mean 0.51, SD 0,12mmol/l) with 17% of the 
relapses occurring during the high level phase (mean 0.99,
SD 0.2‘lmmol/l) of the trial.
1.4 DISCUSSION OF THE REVIEW; THE PROBLEM
This review of the literature pertaining to prediction 
of response to antidepressive therapies has focused on res­
ponse to prophylactic lithium, a strikingly neglected area 
of investigation, yet is undoubtedly of paramount import­
ance in view of the strong natural tendency of affective 
disorders to recurrence and in some cases to chronicity.
It is crucial to determine predictive factors and to deline­
ate clinically meaningful subgroups of affectively ill 
patients that are good or poor responders to prophylactic 
treatment. This would help rationalise the long-term 
management of affective disorders and improve on the 
largely empirical approach that prevails in clinical prac­
tice. It would also spare those patients with illnesses 
that are poorly responsive to prophylactic treatment a 
long-term exposure to treatments that are not without 
hazards and side effects.
The review has indicated neglected areas of research
187
into prediction of response to prophylactic lithium and 
thus highlighted potential areas for investigation, 
including clinical, psychological, biological and psycho- 
pharmacological .
2. AIMS AND HYPOTHESES
This series of studies aimed at the investigation of 
clinical, psychological and biological correlates of 
therapeutic antidepressant responses, particularly long­
term response to lithium therapy, as follows.
2.1 Response to ECT and antidepressants
Acute antidepressive response to ECT and antidepress­
ants was investigated in relation to endogenicity of 
depression: the hypothesis was that patients with more 
endogenous illness had better responses than those with 
non-endogenous illness.
2.2 Response to prophylactic lithium
2.2.1 Clinical correlates
Response to prophylactic lithium was investigated in 
relation to major clinical and genetic distinctions in 
unipolar and bipolar illness: the hypothesis was that 
patients with unipolar and bipolar illness are equally 
responsive and that in these groups, patients with a 
family history of affective illness were more favourable 
responders than those without a family history of affective 
illness.
2.2.2 Psychological correlates
Response to prophylactic lithium was investigated in 
relation to patients’ psychological characteristics: the 
hypothesis was that patients who responded less well have 
more abnormal personality profiles than those who res­
ponded well.
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2.2.3 Dexamethasone Suppression Test (DST)
Response to prophylactic lithium was studied in 
relation to patients' responses to the DST: the hypothesis 
was that patients with abnormal responses to DST showed 
greater affective morbidity both at the time of investigation 
and over time than those with normal responses to DST.
2.2.4 Subjective side effects
Subjective 'side effects' reported by drug-free ill 
depressive patients and by patients receiving prophylactic 
lithium were studied in relation to their affective 
morbidity and personality characteristics: the hypothesis 
was that patients who reported more side effects had 
greater affective morbidity and were more abnormal in their 
personality characteristics than those who reported fewer 
side effects.
2.2.5 Plasma lithium concentrations
Response to prophylactic lithium was investigated in 
relation to variable lithium dosage, plasma concentration 
in the context of a prospective double-blind study: the
hypothesis was that patients maintained on plasma lithium 
concentrations below 0 .6mmol/l suffered significantly 
greater affective morbidity than those maintained on plasma 
lithium concentrations above 0 .6mmol/l.
2.2.6 Initial response as a predictor of long-term response 
to lithium
Initial response over the first six months and first 
year was studied in relation to long-term response : the 
hypothesis was that initial response is strongly predictive 
of long-term response to lithium.
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3. PATIENTS AND METHODS
3.1 Response to ECT and antidepressants
Patients were consecutive admissions to the MRC Neuro­
psychiatrie Ward referred by their general practitioners 
or other hospital consultants. For entry into the study, 
patients had to satisfy criteria for primary depressive 
illness (Medical Research Council Clinical Psychiatry Com­
mittee, 1965) and a criterion of severity; a score of 16 
or more on the first 16 items of the Hamilton Rating Scale 
(HRS) for depression. Patients were also classified on 
the Newcastle Scale during their first week of admission.
Allocation of patients to receive antidepressant 
medication or ECT was done on an alternate basis, i.e.
ECT was given to every other patient unless the patient 
was judged to be clinically too deteriorated or to have 
marked suicidal inclination, in which case ECT was administered
One hundred and forty four female and 56 male patients 
were studied. Their mean age was 51.6 ± 2.1 years.
Seventy eight of the patients were treated by ECT and 
122 patients received antidepressant medication. Patient 
progress was assessed by the HRS at two and four weeks. 
Clinicians who rated these patients were not blind to 
their Newcastle scores. During treatment only night sed­
ation in the form of nitrazepam (5-lOmg) was allowed. 
Response to treatment was evaluated in terms of percentage 
improvement. This was calculated by subtracting the out­
come HRS score at four weeks from the baseline score, and 
dividing by the baseline score.
Eighty seven female and 35 male patients were treated 
by antidepressant medication in the context of clinical 
trials of amitriptyline, zimelidine and clomipramine.
They all received placebo tablets for 7-10 days before
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active treatment. Fifty eight patients received amitrip­
tyline 150mg at night and 54 patients received zimelidine 
200mg or clomipramine lOOmg at night.
3.2 Response to prophylactic lithium
Unipolar and bipolar patients attending the Lithium 
Clinic for periods varying between one to 14.5 years (mean 
5.9 years) were studied. All patients had received lithium 
carbonate in the form of sustained-release tablets (Priadel) 
Lithium was given once daily, at night, to achieve plasma 
lithium levels of 0.8-1.2mmol/l 12 hours later. Lithium 
prophylactic response was determined over a period of two 
years excluding their first year on lithium, which was 
also determined. Response to lithium was measured in two 
ways; the first using the Affective Morbidity Index (AMI) 
(see p. 64 ) and the second by the presence or absence of 
a relapse during their two years follow-up. Patients who 
suffered no relapse were classified as excellent responders 
while patients who had a relapse or relapses were classi­
fied as fair to poor responders, A relapse was defined as 
a depressive or manic episode of no less than four weeks 
duration and of a severity that required the patient to 
be admitted into hospital or prescribed antidepressant 
or neuroleptic medication. The prescription of minor 
tranquillisers (benzodiazepines) as hypnotics was allowed 
and was not considered in the classification of response 
to lithium.
3.2.1 Clinical correlates
Phenomenological and genetic clinical classifications 
were studied in relation to lithium response as measured 
by AMI.
3.2.1.1 Bipolar illness
Bipolar patients were classified in terms of the 
presence or absence of family history of depression or
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mania. This information was obtained from the patients 
themselves and from their first degree relatives whenever 
possible. Patients were also classified according to 
Angst typology; major mania and major depression; major 
mania and minor depression; major depression and minor 
mania (hypomania).
3.2.1.2 Unipolar illness
Unipolar patients were classified on the Newcastle 
Scale and their AMI was measured for their first year on 
lithium (95 patients) and for the first two years follow- 
up excluding their first year on lithium (39 patients). 
Newcastle Scale classification for the latter group was 
based on information available in their case notes, i.e. 
in retrospect, and this group is included in the larger 
group (95 patients). The remainder (46) were patients 
newly started on lithium prophylaxis who were classified 
on the basis of clinical interview. Patients were also 
classified according to Winokur's genetic subtypes (see 
Introduction, p . 26 ). Information for this classification 
was obtained from the patients themselves and their first 
degree relatives whenever possible.
3.2.2 Psychological correlates
Unipolar and bipolar patients completed the following 
personality questionnaires when they showed no conspicuous 
morbidity (see section on rating scales, p. 69 ):
1. The Eysenck Personality Questionnaire (EPQ).
2. Foulds' Personality Deviance Scale (PDS).
3. The Marke-Nyman Temperament Scale (MNTS).
4. The Crown-Crisp Experiential Index (CCEI),
Comparisons were made between excellent and fair to 
poor responders in terms of all these questionnaires' 
measures.
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3.2.3 Dexamethasone Suppression Test (DST)
Ninety eight unipolar and bipolar patients receiving 
prophylactic lithium had the DST (vide infra). Their 
affective morbidity was subjectively assessed by the Beck 
Depression Inventory (BDI) and objectively by the global 
affective scale on the day the DST was carried out.
AMI in the preceding two years was also calculated for all 
these patients. The DST was repeated approximately one 
year later in 65 of these patients.
3.2.3.1 Control subjects
Twenty seven male and 52 female volunteers (local 
office workers and hospital staff), who had no history 
of psychiatric illness or current physical illness and 
whose ages ranged from 21-71 years, also had the DST 
for comparison with the patient group.
3.2.3.2 Dexamethasone Suppression Test procedure
One mg of dexamethasone (Oradexon: Organon Laboratories, 
Cambridge, U.K.) was administered orally to the subject 
at 20.0Oh. Blood samples were collected into calcium 
heparin tubes from the subject between 15.00 and 16.00h 
the following day for the estimation of cortisol; the plasma 
was obtained by centrifugation and stored at -20°C until 
required for the estimation of cortisol.
Cortisol was estimated using a radioimmunoassay 
technique (CIS International). This technique has a 
sensitivity of 2.5±0.7ng/ml and a coefficient of vari­
ation of 7.9% (within assay). A post-dexamethasone 
cortisol level of <50ng/ml was taken as a normal response; 
an abnormal response was taken as >50ng/ml of cortisol.
The scientific officer who estimated these cortisol levels 
was kept unaware of the clinical details of the patients.
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3.2.4 Subjective side effects
The prevalence of side effects, i.e. percentage of 
patients reporting specific side effects, and the total 
side effects score on the side effects checklist (Ghose, 
1977) were studied in drug-free depressed patients, in 
patients on long-term lithium therapy, and in the general 
population. The relationship of these symptoms to age, 
sex and affective morbidity was also investigated.
The prevalence and total side effects scores were 
compared between three groups. In lithium-treated patients, 
total side effects scores (mean over two years) were related 
to their AMI over two years and to their psychological 
characteristics (personality questionnaires administered, 
vide supra).
3.2.4.1 Side effects checklist
Subjective side effects were measured by a side effects 
checklist (Ghose, 1977), a self-rated list of symptoms 
that are commonly reported by patients receiving psycho­
tropic medication; each item is rated on a 4-point scale 
from no symptoms = 0 to severe symptoms = 3.
3.2.4.2 Control subjects
One hundred and fifty three male and 105 female control 
subjects completed the side effects checklist. These con­
trols were drawn from employees of local factories and 
members of staff at West Park Hospital.
3.2.4.3 Drug-free depressed patients
Forty eight female and 17 male patients suffering 
from primary depressive illness (Medical Research Council, 
1965) were studied. All patients scored 16 or more on 
the first 16 items of the HRS and completed the side 
effects checklist 7-10 days after admission; during this 
time they received no antidepressant treatment but were 
prescribed nitrazepam for night sedation when needed.
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3.2,4.4 Lithium-treated patients
Seventy-two unipolar and 22 bipolar patients on long­
term lithium therapy were studied over two years. At 
each attendance, each patient completed the side effects 
checklist and the mean score of this period was calculated. 
Their AMI was also measured for this period. Fifty eight 
unipolar and 18 bipolar patients who showed no conspicuous 
affective morbidity completed four personality questionn­
aires (vide supra).
3.2.5 Plasma lithium concentration
Changes in affective morbidity and side effects were 
studied in patients who were previously maintained on 
lithium dosages to give a 1 2 -hour plasma lithium concen­
tration of 0 .8 -1 .2mmol/l and who had their lithium dosage 
reduced by 25% or 50%. The study was a double-blind pro­
spective trial over one year.
3.2.5.1 Design of the trial
Eighty eight patients attending the Lithium Clinic 
agreed to take part in the trial after the aims and nature 
of the trial had been explained to them. These patients 
were then randomly allocated either to remain on their 
previous dosage or to receive a 25% or 50% reduction in 
lithium. Different amounts of lithium carbonate (sustained- 
release preparation: Priadel; Delandale Laboratories, 
Canterbury) were packed into identical looking capsules to 
maintain the double-blind nature of the trial. A research 
coordinator (who was not involved in the clinical assess­
ment of patients) monitored the plasma levels of lithium 
and he ensured that no patient had a 1 2 -hour plasma lithium 
concentration of less than 0.45mmol/l.
During the trial period of at least one year, most 
patients were assessed at 6 - 8 weekly intervals and their 
affective morbidity and side effects were compared with a 
similar period immediately preceding the trial. If the 
patients were affectively ill they were assessed at weekly
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intervals. The patients' affective morbidity over the 
trial period was assessed using the AMI. The number and 
severity of side effects were assessed using the checklist 
that was completed by the patient at each visit to the 
clinic. The mean side effects score was calculated for 
each patient during the present investigation both during 
the trial and for the same period preceding the trial.
3.2.5.2 Patients
These were unipolar and bipolar patients who had 
suffered three or more episodes of major affective illness. 
Unipolar patients were classified on the Newcastle Scale 
where the necessary information was available in their case 
notes. After the initial lithium level adjustment period, 
the patients were classified into four groups according to 
their plasma lithium concentrations over the trial period:
1. 0.45-0.59mmol/l
2. 0 .6-0.79mmol/l
3. 1 and 2 combined, i.e. <0.79mmol/l
4. >0.80mmol/l.
3.2.6 Initial response and long-term response to lithium
To determine the value of initial response to lithium 
as an empirical predictor of prophylactic response, 76 
unipolar and 31 bipolar patients were classified into 
good and fair to poor responders on the basis of the 
presence or absence of relapses during two years follow- 
up (vide supra). AMI was calculated for the first six 
months, for the first year and for the two years follow- 
up for all patients. These groups were also compared in 
terms of their previous morbidity, i.e. number of episodes 
prior to starting lithium.
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4. RESULTS
4.1 Response to ECT and antidepressants
Tables 5.1 and 5.2 show baseline HRS scores and per­
centage improvement after four weeks treatment with ECT and 
antidepressant medication respectively. Patients with New­
castle scores between 4 and 8 showed significantly higher 
percentage improvement than those with high (9-12) scores 
on ECT and those with low (0-3) scores on antidepressant 
medication. It was noted, however, that among patients who 
received antidepressants and had high (9-12) Newcastle scores, 
some had significantly higher mean HRS scores than those 
with lower Newcastle scores.
4.2 Response to prophylactic lithium
4.2.1 Clinical correlates
Table 5.3 shows that among bipolar patients, those who 
had a family history of depression had significantly lower 
AMI than those with no family history of affective disorder 
during their first year on lithium and significantly lower 
AMI than those with a family history of mania during their 
two years follow-up. The combined group of bipolar patients 
with a family history of mania or depression had signifi­
cantly lower AMI than those with no family history of 
affective disorders but only during their first year on 
lithium. During two years follow-up only the group with 
a family history of mania had a significantly higher AMI 
than during their first year on lithium.
Angst's typology of bipolar illness showed no associ­
ation with AMI (Table 5.4). Among unipolar patients, those 
with the highest Newcastle scores (9-12) had significantly 
lower AMI than those with lower Newcastle scores both 
during their first year (Table 5.5) and their two years 
follow-up (Table 5.6) on lithium. It is worthy of note 
that this group, with the highest Newcastle scores, had 
even lower AMI than the group of bipolar patients during
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TABLE 5 .1
The Newcastle Scale: response to ECT; baseline HRS and percentage improvement at 4 weeks
NewcastleScalescore n HRS Percentageimprovementt
0-3 5 17.6 ±2.0 47.7 ± 13.2
4—8 51 23.4 ±0.9 57.4 ± 3.0*
9-12 22 21.3±1.3 44.3 ±7.0
Results are expressed as mean ± sem
*Significantly higher than (9-12) and (0-3) + (9-12) combined, p < 0.05.
tAfter angular transformation.
TABLE 5.2
The Newcastle Scale: response to anti­depressant medication; baseline HRS and percentage improvement at 4 weeks
Newcastle Scale • score n HRS Percentageimprovementt
0-3 22 21.4 ±0.7 34.9 ±3.8
4-8 80 21.4 ±0.5 41.2±2.0*
9-12 20 26.3 ± 1.1** 28.8 ±6.4
Results are expressed as mean ± sem
*Significantly higher than (0-3) and (0-3) + (9-12) combined, p < 0.05.
**Significantly higher than (0-3) and (4-8), p < 0.01 
tAfter angular transformation.
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TABLE 5.4
Angst bipolar subtypes and response to lithium over 2 years
Group nM F AMI over 2 years
Major manic/major depressive 
Major manic/minor depressive 
Major depressive/minor manic
6 5
3 7
4 0
0,13 ± 0.06 
0.19 ± 0.07 
0.19 ± 0.11
Results are expressed as mean ± sem,
TABLE 5.5
Newcastle Scale: affective morbidity index during first year of lithium therapy
Newcastle score n Affective morbidity score
0-3 12 0.31± 0.07
4-8 69 0.20 ± 0.03
9-12 14 0.06 ± 0.04*
Bipolars 33 0.09 ± 0.02**
Results are expressed as mean ± sem.
*Significantly lower than (0-3) group, p < 0.01 and (4-8) group, p < 0.05.
**Significantly lower than (0-3) group, p < 0.01 and (4-8) group, p < 0.05.
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TABLE 5 .6
Newcastle Diagnostic Scale and responseto lithium over 2 years
Newcastlescore n AMI over 2 years
0-3 9 0.28 ± 0.06
4—8 20 0.23 ± 0.05
9-12 1 0 0.08± 0.04*
Bipolars 27 0.15 ± 0.04
Results expressed as mean ± sem,
*Significantly lower that (0-3) group, p < 0.02 and (0-3) + (4-8) groups combined, p < 0.03.
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both their first year and their two years follow-up on 
lithium. Bipolar patients had significantly lower AMI than 
unipolar patients with lower Newcastle scores during their 
first year but not during their two years follow-up on 
lithium (Tables 5.5 and 5.6).
On Winokur's typology (Table 5.7 and 5.8), patients 
with PFDD had significantly lower AMI than patients with 
SDD and DSD during their two years follow-up but not 
during their first year on lithium and similar AMI to bi­
polar patients. Bipolar patients, however, had signifi­
cantly lower AMI than patients with SDD and DSD during 
their first year and significantly lower AMI than DSD 
during their two years follow-up on lithium.
To explore the relationship between previous morbidity, 
i.e. number of episodes of illness before starting lithium 
and morbidity during lithium therapy, i.e. AMI, these 
variables were correlated (product-moment): there was no 
significant correlation between these variables for the 
whole group of unipolar and bipolar patients or for the 
group of unipolar patients, but there was a significant 
positive correlation for the group of bipolar patients 
(r = 0.49, p<  0.001). Other variables studied, such as 
age at onset and onset following childbirth, showed no 
association with morbidity during lithium therapy.
4.2.2 Psychological correlates
Comparisons between good and fair to poor responders 
in the whole group, i.e. combined group of unipolar and 
bipolar patients, showed several significant differences 
in psychological characteristics, with the group of fair 
to poor responders showing more abnormality than good 
responders on Eysenck's extraversion, neuroticism and lie 
scale, Foulds' intropunitiveness, MNTS validity and CCEI 
free floating anxiety, depression, hysteria and total score
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TABLE 5 .7
Winokur's genetic subtypes and affective morbidity during first year on lithium compared with bipolar depressives
Group
n
M F No. of episodes pre-lithiura AMI
PFDD 15 36 3.7 ± 0.3 0.16± 0.03
SDD 13 36 4.3±0.4 0.22±0.04
DSD 4 6 5.1± 1.1 0.22 ± 0.05
Bipolars 14 19 5.5±0.7 0.09 ± 0.02*
Results are expressed as mean ± sem.
*Significantly lower than SDD, p < 0.03, and DSD,p < 0 .0 2 .
TABLE 5 .8
Winokur's genetic subtypes and affective morbidity during 2 -year follow-up compared with bipolar depressives
Group
n
M F No. of episodes pre-lithium AMI
PFDD 9 19 4.0±0.4 0.13 ± 0.03*
SDD 10 18 4.6 ± 0.6 0.27 ± 0.05
DSD 4 6 5 .1± 1.1 0.31±0.06
Bipolars 13 14 5.6±0.7 0.15 ± 0.04**
Results are expressed as mean ± sera.
*Significantly lower than SDD, p < 0.05, and DSD, p < 0 .0 1 .
**Significantly lower than DSD, p < 0.05.
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(Tables 5.9-5.12 respectively). There were no significant 
differences in the sex ratios of good and fair to poor 
responders. Good and fair to poor responders in the bipolar 
and unipolar groups were separately compared in terms of 
all psychological variables; differences held for neuroticism 
and CCEI free floating anxiety and total scores in bipolars 
and significant differences held for intropunitiveness, lie 
scale and validity in unipolar patients.
4.2.3 Dexamethasone Suppression Test
Table 5.13 shows the percentage of patients with 
abnormal DST responses on both occasions in comparison 
with the DST results in control subjects: patients had a 
significantly higher percentage of abnormal DST responses 
on both occasions, 34% and 3 5% respectively, than the 
control subjects (11.4%). Patients with normal and 
abnormal DST responses had similar 'spot' morbidity 
(morbidity at the time of DST) and morbidity during the 
preceding two years (Table 5.14). Six patients who had an 
abnormal DST on the first occasion had a normal DST on 
the second, and seven patients who had a normal DST on 
the first occasion had an abnormal DST on the second.
This change in DST status was not associated with a change 
in morbidity on global morbidity scale or BDI,. change in 
weight or percentage change in weight (change in weight 
at time of DST from weight on previous attendance) (Table 
5.15) .
4.2.4 Subjective side effects
Females and males had significantly lower side effect 
scores than female and male drug-free depressed patients 
(Table 5.16). Female control subjects had significantly 
high side effect scores than males. Females had a sig­
nificantly lower age than males; there was also a signifi­
cant positive correlation between age and side effect
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TABLE 5.13
DST status in control subjects and lithium-treated patients
Group
DST status
Abnormal Normal
Control subjects
Lithium-treated patients : 
1 st test 
2nd test
9 (11.4%)
33 (34%)* 
23 (35%)*
70 (8 8 .6 %)
65 (6 6 %)
52 (65%)
Results expressed as number and percentage with abnormal DST responses.
*Significantly higher than control subjects, p <  0.001.
TABLE 5.14
DST status in relation to spot morbidity and AMI over the preceding 2 years
Spot
Affective AMI overDST status n morbidity BDI 2 years
Normal 65 0.07 ± 0.02 5.7 ± 0.8 0 .2 1 ± 0 . 0 2
Abnormal 33 0.18± 0.07 6 .2 ± 1 . 2 0.19 ± 0.03
Results are expressed as mean ± sem
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TABLE 5 .15
Change in DST status in relation to spot morbidity, weight and weight change in 13 patients
DST status Affectivemorbidity BDI Weight(kg)
Percentage change in weight
Normal 0.06 ± 0 . 0 2 2.7 ± 0.9 61.8 ± 3.1 -2.7± 1.5
Abnormal 0.13 ± 0.07 2.6 ±0.9 62.2 ± 2.8 —1.3 ± 1.0
Results are expressed as mean± sem,
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scores. The most commonly reported symptoms on the side 
effects checklist are shown in Table 5.17. Control subjects 
complained mainly of headache, aches and pains, and in­
digestion .
4.2.4.2 Drug-free depressives
Female and male drug-free depressives had significantly 
higher side effect scores than corresponding controls and 
lithium-treated patients (Table 5.16). Female depressives 
had higher side effect scores than males, but this differ­
ence was not significant. There was a significant positive- 
correlation between HRS scores and side effect scores in 
these patients (r = 0.47, p<0.02). Depressed patients 
reported more side effects than controls on all the items 
on the checklist. Table 5.17 shows the percentage of 
patients who complained of the five most commonly reported 
side effects. Differences from control subjects were only 
significant for poor memory, poor appetite, dry mouth and 
drowsiness in both males and females. Female depressives 
reported more side effects than males on all items; these 
differences, however, were not significant.
4.2.4.3 Lithium-treated patients
Female and male lithium-treated patients had similar 
mean side effect scores to control subjects (Table 5,16) . 
Female patients also had similar mean side effect scores 
to males. There was no significant correlation between 
age and side effect scores in these patients.
Table 5.18 shows the incidence of the five most 
commonly reported symptoms in each group. Female sub­
jects complained more often than males in both the patient 
and control groups. Lithium-treated patients compared to 
control subjects complained significantly more of poor 
memory, trembling hands, excessive thirst, dry mouth and 
drowsiness, but significantly less often of headache.
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Lithium-treated patients were divided into groups in 
terms of their affective morbidity index. Patients who 
had no affective morbidity during two years follow-up had 
significantly lower side effect scores than those who had 
mild and moderate or severe affective morbidity (Table 5.19) . 
There was a highly significant correlation between mean 
side effect scores over two years and affective mor­
bidity (r = 0.50, p <  0.001).
Patients who were maintained solely on lithium had 
significantly lower affective morbidity than those who 
had tricyclics (mean duration of treatment = 43 weeks) 
added to their lithium (p < 0.001) . Patients who had benzo­
diazepines in addition to lithium showed only a slight 
increase in their affective morbidity (Table 5.20). Only 
in the subgroup of patients who were given tricyclics in 
addition to lithium was there a significantly higher mean 
side effect score.
Lithium patients were also divided into groups in 
terms of their mean side effect scores over two years.
The group which had higher mean side effect scores had 
significantly higher neuroticism, significantly higher 
intropunitiveness, significantly lower dominance and sig­
nificantly lower validity than the group with lower mean 
side effect scores (Table 5.21). The two groups showed 
no differences in terms of their extraversion, psychoticism, 
lie scale, extrapunitiveness, solidity, stability, and 
CCEI subscales mean scores. There was a significant cor­
relation between patients' side effect scores and neuroticism 
(r = 0,44, p <  0.001), dominance (r = -0.4, p<0.02), 
validity (r = -0.4, p < 0.01) and intropunitiveness (r =
0.66, p< 0.001). In view of the significant correlations 
between these personality variables and AMI (vide supra), 
partial correlations between side effect scores and these 
variables, excluding the influence of AMI, were calculated. 
Correlations between side effect scores and these variables
TABLE 5 .1 9
Lithium-treated patients; side effects and affective morbidity
Affective morbidity^ over 2 years n Side effects
Nil 28 4.7 ± 0.8
Slight (< 0 .2 ) 27 5.8 ± 0.8
Mild (0.2 - 0.4) 27 8 . 6 ± 1 .6 *
Moderate and severe (> 0.4) 12 14.6± 1.6**
Results are expressed as mean ± sem.
'Based on affective morbidity index.
*Significantly higher than the nil morbidity group, p < 0.03.
**Significantly higher than the nil morbidity group, p < 0 .0 0 1 .
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TABLE 5 .20
Side effects and affective morbidity according to medication received
Group n Affectivemorbidity Side effects
Lithiumonly 25 0.03 ± 0.01 5.4 ± 0.9
Lithium + tricyclics 30 0.37 ± 0.04* 9 .6 ± 1 .1 **
Lithium + MAO I 7 0.22 ± 0.05* 5.7 ± 1 . 6
Lithium + neuroleptics 8 0.29 ± 0.05* 5.3 ± 1 . 2
Lithium+ benzodiazepines 24 0.08 ± 0 . 0 2 8 . 0 ± 1 . 8
Results are expressed as mean ± Sem.
*Significantly higher than lithium only group, p < 0.001
**Significantly higher than lithium only group, p <0.02.
217
TABLE 5.21
Lithium-treated patients: side effects and personality variables
Personality dimension
Side-effects score
0-5 (n = 32) >5 (n = 42)
Neuroticism
Intropunitiveness
Dominance
Validity
8.4 ±0.8 
24.4 ± 1.1 
29.3 ±0.9 
1 1 . 2 ± 0.8
13.8± 0.7* 
27.6 ± 0.8* 
26.3± 0.7** 
6 .4 ± 0.6**
Results are expressed as mean ± sem.
*Significantly higher than the low side effect score group; neuroticism, p < 0 .0 0 1 , intropunitive­ness , p < 0.05.
**Significantly lower than the low side effect score group; dominance, p<0,05, validity, p<  0.001
Assessments were carried out in 74 patients only.
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remained statistically significant for neuroticism (r =
0.28, p<0.03), validity (r = -0.31, p<0.02), dominance 
(r = -0.47, p <  0.001) and intropunitiveness (r = 0.64;
p < 0 .0 0 1 ) .
4.2.5 Plasma lithium concentrations
Sixteen patients failed to complete the trial; seven 
patients were discontinued because of deterioration in 
their clinical state. Of these, three had plasma lithium 
levels between 0.45 and 0.59mmol/l, one between 0.60 and 
0.70mmol/l, and three had levels > 0 .80mmol/l. The other 
patients discontinued for a variety of reasons, for example 
moving away from the area, asking to be withdrawn because 
they disliked taking capsules, poor compliance with the new 
regime.
Table 5.22 shows the general details of patients 
classified into four groups corresponding to the four plasma 
concentrations of lithium. The affective morbidity of the 
unipolar and bipolar patients before and during the trial 
is shown in Table 5.23. The patients with plasma lithium 
concentrations< 0.79mmol/I had a significant decrease (34%) 
in their affective morbidity during the trial period.
The patients with plasma concentrations of 0.45-0.59mmol/l 
also had a mean decrease of 34%. Patients with plasma 
concentrations >0.80mmol/l showed little change.
The results of changes in morbidity for the unipolar 
patients are shown in Table 5.24. Patients maintained 
with plasma levels of^0.79mmol/l showed a significant 
decrease in morbidity of 34%. Patients with a plasma 
level of 0.45-0.59mmol/l had a mean decrease of similar 
magnitude. Those unipolar patients with a level of > 
0.80mmol/l had an increase in morbidity of 17%.
The results of dosage reduction in unipolar patients 
classified according to the Newcastle scale are shown in
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Table 5.25. In those patients with a plasma lithium con­
centration o f < 0.79mmol/l and a low Newcastle score (0-5), 
the decrease in morbidity during the trial was considerable 
(-58%) and significant (p<0.05). Patients in the lower 
lithium group (< 0.79mmol/l) who had a Newcastle score of 
C 5 had a.mean change in side effects of -0.29 ± 0.73; 
patients with a Newcastle score > 6 had a mean change in 
side effects of -0.52± 0.53. Table 5.26 ahows the changes 
in morbidity for the bipolar patients. No statistically 
significant change was noted in morbidity during the trial.
The mean total side effect scores for both unipolar 
and bipolar patients before and during the trial period 
are shown in Table 5.27. Those patients with a plasma 
lithium concentration o f 0.79mmol/l showed a small but 
significant reduction in side effects. Items listed on 
the side effects checklist that are particularly related to 
lithium treatment were examined, and the tremor scores 
are shown in Table 5.28. Patients in the three lower 
lithium concentration groups showed a decrease of more than 
20% in tremor. Those patients with a lithium level of ^ 
0.80mmol/l showed a significant increase (37%) in this 
troublesome side effect.
In order to assess whether the beneficial effects of 
a reduced lithium plasma level were due to patients re­
ceiving additional psychotropic medication, an analysis 
was made of the neuroleptic and antidepressant drugs 
prescribed during the last three months of the trial and 
compared with those prescribed in the three-month period 
preceding the trial (Table 5.29). In the patients with 
a plasma lithium concentration of < 0.79mmol/l, four 
patients (7.5%) receiving a neuroleptic before the trial 
were still taking the drug in the last three months of 
the trial. Eight patients (15%) received an antidepress­
ant before the trial and seven patients (13%) received 
the drug during the last three months of the trial.
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In the group of patients with a plasma lithium con­
centration of > 0.80mmol/l, three patients (16%) received 
a neuroleptic before and two patients (1 1 %) received a 
neuroleptic during the last three months of the trial period. 
Four patients (21%) received an antidepressant before the 
trial and seven patients (13%) received the drug during 
the last three months of the trial.
4.2,6 Initial response and long-term response to lithium
Table 5.30 shows the relationship of AMI during the 
first six months, first year to long-term response. Uni­
polar patients who were fair to poor responders had sig­
nificantly higher AMI during their first six months and 
first year on lithium than good responders. For bipolar 
patients, the difference was statistically significant for 
their first year on lithium. AMI was calculated for the 
two years follow-up: the results validated the classification 
of patients into good and fair to poor responders, with the 
latter group having a significantly higher AMI than the 
former group. It was noted that the bipolar patients who 
were fair to poor responders had a significantly higher 
number of episodes prior to starting lithium than good 
responders.
5. DISCUSSION
5.1 Response to E.CT and antidepressants
The results show a curvilinear relationship between 
scores on the Newcastle diagnostic scale and response to 
ECT and antidepressant medication. Previous studies from 
this laboratory have shown that the group with middle 
of the range scores had the most favourable response to 
amitriptyline (Rao and Coppen, 1979; Milln and Coppen, 
1980). The latter study showed that this tendency was 
more marked in those with a positive family history of 
depression. The differential response and more favourable
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responses of the middle Newcastle group to ECT and anti­
depressants is intriguing and warrants exploration. The 
less favourable response of the most endogenous dépress­
ives to antidepressant medication is not a surprising 
finding. Delusional depressions were found to be less 
responsive to tricyclic antidepressants than non-delusional 
depressives (Friedman, 1961; Angst, 1961; Hordern, 1965; 
Classman et al, 1975). Severely ill depressives were found 
to have less favourable responses to ECT and imipramine 
than moderately ill depressives (Medical Research Council 
Clinical Trial, 1965).
The relatively poor response to antidepressants of 
patients with very low Newcastle scores would suggest that 
these patients may be suffering from a neurotic rather 
than an affective disorder: they may be better helped by 
psychological treatments.
5.2 Response to prophylactic lithium
Response to prophylactic lithium was measured in two 
ways: the presence or absence of relapse(s) - a discon­
tinuous measure, and by the AMI - a continuous measure.
These two measures allowed variable analysis to be carried 
out on the data and the continuous measure (AMI), a more 
sensitive outcome measure of morbidity over time, indeed 
cross-validated the discontinuous measure and vice versa. 
Table 5.30 shows a highly significant difference in AMI be­
tween the two categories of response (p < 0.001) in both bi­
polar and unipolar patients. Furthermore, affective morbid­
ity measured on the global scale showed a significantly 
positive correlation with self-rated morbidity on the BDI. 
Similarly, AMI and mean BDI over two years were significantly 
correlated.
5.2.1 Clinical correlates
Among bipolar patients, those with a family history
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of depression had the most favourable response to lithium 
both during the first year and two years follow-up.
Patients with a family history of mania had a relatively 
good response during their first year on lithium but not 
during two years follow-up, when they showed a significant 
increase in morbidity as compared with'their first year 
on lithium. This might be related to the notion that the 
bipolar patients with a family history of mania were a 
relatively high risk group as suggested by their increased 
number of episodes prior to starting lithium. It was shown 
that in bipolar illness greater previous morbidity is 
associated with greater morbidity during lithium therapy.
The findings of previous studies have been inconclusive 
(see Introduction, p..179). It must be noted, however, that 
the present series of patients was a small one in comparison 
with series investigated in previous studies.
Angst's typology of bipolar illness showed no associ­
ation with response to prophylactic lithium. In unipolar 
illness, greater 'endogenicity' on the Newcastle Scale was 
associated with a more favourable response to lithium than 
less endogenous illness, and the relationship between the 
two indices (Newcastle Scale and AMI) was a linear one, 
particularly during the first year on lithium. Furthermore, 
it was noted that patients with very endogenous illness had 
very similar responses to bipolar patients, indicating a 
possible biological similarity between these illnesses.
On Winokur's genetic typology, the results show a distinction 
between patients with PPDD from patients with SDD and DSD 
and also a similarity between PFDD and bipolar illness as 
validated by response to prophylactic lithium. Studies by 
Winokur (1978) failed to show a differential response of 
patients with PFDD and DSD to ECT or to antidepressant medic­
ation. A study by Andreasen and Winokur (1979) found that 
patients with PFDD and SDD had better response to antidep­
ressants than those with DSD, while more DSD patients
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responded to major tranquillisers. It was noted, however, 
that the number of patients was small and treatment assign­
ment was non-random. Milln and Coppen(1980) found that 
patients with PFDD and with Newcastle scores in the middle 
range (4-8) had the best response to amitriptyline therapy 
compared with those with SDD with a similar range of New­
castle scores.
5.2.2 Psychological correlates
Fair to poor responders showed significantly greater 
personality pathology than good responders on most measures: 
EPQ neuroticism, extraversion; PDS intropunitiveness; MNTS 
validity, and CCEI anxiety, depression, hysteria and total 
scores. For bipolar patients significant differences were 
found only in neuroticism and validity.
These findings confirm the results of previous investi­
gations of response to prophylactic lithium for neuroticism 
(Coppen et al, 197 9a; Abou-Saleh, 1980; Maj et al, 1984) 
and validity (Bech et al, 1976), but are contrary to the 
findings of significant associations between good response 
and greater obsessionality on CCEI (Maj et al, 1984) and
lower MNTS stability (Bech et al, 1976).
In studies of long-term outcome of depressive illness, 
high neuroticism (Weissman et al, 1978) and low validity
(NyStrom and Lindegard, 1975) proved to be powerful pre­
dictors of outcome. This association between poor response 
to lithium and greater personality disturbance might be 
mediated by other factors such as low 'endogenicity' on 
the Newcastle Scale and/or the presence of residual affect­
ive morbidity in poor responders. The first notion could 
be disputed by the findings of similar associations in 
bipolar patients, a strictly endogenous group, and the 
second by the ascertainment that personality measurement 
was carried out during an euthymie phase of illness. The 
patients, however, were not instructed to respond to these
233
questionnaires in terms of their premorbid psychological 
characteristics and any concurrent or previous morbidity 
may have influenced their response set. As regard the 
effects of lithium on personality characteristics, these 
are essentially in the direction of less pathology 
(Bonetti, 1977). Another possible mediating factor is 
poor compliance: patients who had greater personality 
disturbance complained of more side effects a
situation that may be conducive to poor compliance with 
lithium. 'In the present investigation compliance was 
ensured by regular monitoring of plasma lithium concen­
trations during follow-up, and the population investigated 
had received lithium for years in a clinic that has a 
very low drop-out rate of only 5% per annum. Moreover, 
an extensive study of the relationship of compliance with 
lithium and personality found no significant associations 
(Jamison and Goodwin, 1983). Perosnality disturbance per 
se might contribute to response to lithium by impairing 
or retarding social recovery (Weissman and Paykel, 1974) 
and/or by rendering the individual more vulnerable to un­
desirable life events and changes that might well also be 
provoked by this personality disturbance.
5.2.3 Dexamethasone Suppression Test
The DST status showed no association with 'spot' 
morbidity or morbidity during the preceding two years. 
Furthermore, for the 13 patients who had a change in status 
on repeating the test one year later, no change in morbidity 
or weight was observed. These findings suggest that the 
DST has no prognostic value when carried out in patients on 
maintenance therapy and in a state of remission. Coppen 
et al (1983) observed that the DST in 53% of patients with 
an abnormal DST on admission reverted to normal just before 
discharge from hospital. For the remainder of the patients 
(47%) the DST remained abnormal just before discharge when 
they had a remarkably similar HRS score to those whose DST
234
became normal. All the patients were receiving continu­
ation treatment with antidepressants at the time their 
pre-discharge DST was carried out.
These findings suggest that DST status is not a 
state-dependent variable and indicate a state of dissoci­
ation between the clinical and biological disturbance.
This could be related to the effects of continuation treat­
ment with antidepressants or lithium which suppress the 
clinical manifestation of depression but do not influence 
the DST. This would imply that patients with abnormal DST 
are at a particular risk for a recurrence of illness if 
medication was discontinued, and DST may still prove to be 
a valuable management aid in determining when to discon­
tinue maintenance or prophylactic treatment.
5.2,4 Subjective side effects of lithium
5.2.4.1 Side effects in controls and drug-free depressives
The finding that side effects are reported by drug- 
free depressives and control subjects invites speculation 
as to its cause and associations. Firstly, it is con­
ceivable that 'side effects' such as poor appetite, dry 
mouth, poor memory, excessive thirst and trembling hands, 
which are reported significantly more often by drug-free 
depressives than controls, are in fact somatic symptoms 
of anxiety-depression. Secondly, it has been suggested that 
the side effects of antidepressant medication are also 
symptoms of depression (Schulterbrandt et al, 1974) .
These findings could also be related to the phenomena 
of side effects following the ingestion of placebo (Dhume 
et al, 1975). Pogge (1963) tabulated the findings of 67 
studies and found that 23% of the patients had reported 
such effects following placebo administration. Reidenberg 
and Lowenthal (1968) found that 81% of healthy subjects 
not taking medication experienced at least one of the 25
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symptoms enquired about in the last two days. Shapiro 
et al (1974) reported that the number of side effects was 
similar in subjects taking placebo and control subjects 
not given placebo, and subjects on placebo tended to 
report cognitive and affective 'side effects'. The high 
prevalence of drowsiness reported by depressives who are 
receiving no antidepressant medication could not simply 
be accounted for by the fact that they were receiving 
benzodiazepine hypnotics. Drowsiness is often reported 
by patients during tranquilliser placebo ingestion (Pogge, 
1963). Furthermore, patients receiving amitriptyline 
and hypnotics complained of less drowsiness after two 
weeks on these medications than before starting them 
(Coppen and Ghose, 1976) .
The correlation between HRS and side effects in these 
patients in the present investigation is not surprising 
since the HRS contains many items that refer to somatic 
symptoms.
5.2.4.2 Lithium-treated patients
Subjective side effects reported^by patients receiving 
lithium prophylaxis are only partially related to lithium. 
Rates reported by drug-free depressed patients for diarrhoea 
(23%), metallic taste (31%), trembling hands (51%) and 
poor memory (80%) are all side effects ascribed to lithium 
(Ghose, 1977? Brown, 1980) and were higher than rates 
reported by lithium-treated patients. Lithium-treated 
patients, compared with control subjects, complained of 
less headache. The latter finding is in agreement with 
reports that lithium could be useful in the treatment of 
migraine and particularly cluster headaches (Mathew, 1977).
Compared with drug-free depressives and control sub­
jects, lithium-treated patients reported more side effects 
such as excessive thirst, weight gain and frequency of
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micturition, side effects that have been associated with 
lithium prophylaxis (Schou et al, 1970). Patients on 
lithium prophylaxis and control subjects both had sig­
nificantly fewer side effects than drug-free depressives.
The frequency with which patients complained of tremor, 
dryness of mouth, poor memory and excessive thirst was 
similar to that reported by Bech et al (1976) and Ghose 
(1977). Vestergaard et al (1980) also found similar fre­
quency for tremor and excessive thirst, but very few of 
their patients complained of poor memory. Reports of poor 
memory in lithium-treated patients are more likely to be 
due to their residual affective morbidity than to lithium. 
Coppen et al (1977) found no difference in complaints of 
impaired memory between patients on long-term lithium and 
patients on tricyclic medication, and both groups complained 
significantly more of poor memory than did the control sub­
jects. There was also no association between the memory 
impairment and the duration of lithium therapy.
Patients who had tricyclic medication in addition to 
their lithium had significantly more side effects than those 
maintained solely on lithium. This observed difference 
could simply be due to the former's significantly higher 
affective morbidity. Patients who had benzodiazepines, 
neuroleptics and MAO inhibitors did not report more side 
effects and had less morbidity than those who had tricyclic 
antidepressants. Bech et al (1976) found that patients 
who were prescribed other drugs in addition to lithium had 
a higher frequency for almost all the side effects they 
investigated when compared with patients prescribed lithium 
alone. The former group, however, was found to have a 
significantly higher Beck depression -score which suggests 
that the increase in these complaints was related to 
depression. Similar findings were reported by Bone et al 
(1980) and by Lynkowski et al (1982) in their cross-sectional 
survey of side effects in a lithium clinic. Longitudinal 
surveys of subjective side effects of lithium found no
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association between greater affective morbidity and greater 
side effects (Lynkowski et al, 1982; Duncarage et al, 1983) .
In the present investigation, side effects and morbidity 
were measured over two years and their strong association 
was not apparently mediated by the effects of extramedication, 
a notion that was supported by the observed similar associ­
ation in drug-free depressives. , However, Coppen et al 
(1979a) observed that discontinuing tricyclic medication 
in patients on lithium prophylaxis had little effect on 
morbidity. This would suggest that very little variation 
in side effects is due to this extra medication and it 
was shown in the present investigation that side effects 
correlated very highly with the affective morbidity index. -
Of the personality characteristics investigated, 
neuroticism, intropunitiveness, dominance and validity 
were significantly associated with side effects. These 
personality characteristics were also associated with 
response to lithium (vide supra). Higher neuroticism 
scores in patients with unipolar (Coppen et al, 1979a) 
and bipolar .(Abou-Saleh, 1983) illness were associated 
with a poor response to lithium prophylaxis. The latter 
study also found thst lower dominance and higher lie scale 
scores were also associated with a poor response to lithium. 
In the present investigation, the lie scale (a measure of 
dissimilation or denial) did not show an association with 
side effects. Partial correlations between these psycho­
logical variables and side effect scores, after the 
influence of morbidity was excluded, indicated that these 
variables independently contributed to side effects. 
Neuroticism (Coppen and Metcalfe, 1965? Kendell and 
DiScipio, 1968) and validity (Bech et al, 1976) are mood- 
related characteristics and it could be argued that the 
presence of residual affective morbidity at the time of 
personality measurement may have contributed to the 
psychological differences between the groups with low and 
high mean side effect scores.
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5.2.5 Plasma lithium concentrations
Contrary to the hypothesis forwarded, a reduction of 
5 0% in lithium dosage and patients with plasma lithium 
levels below 0.6mmol/l had a considerable reduction in 
morbidity which was particularly marked in patients with 
non-endogenous depressive illness. These patients were 
shown earlier (Tables 5.5 and 5.6) to respond less well to 
prophylactic lithium than patients with more endogenous 
depressive illness. This greater beneficial response in 
patients with low Newcastle scores could not be accounted 
for by a greater reduction in the occurrence of side effects. 
Previous studies (Sarantidis and Waters, 1981; Decina and 
Fieve, 1981; Sashidharan et a l , 1982) found an association 
between higher plasma lithium levels and poor response to 
prophylactic lithium, a spurious association that is related 
to increasing the daily dosage of lithium in those who had 
relapsed on lithium. These results suggest that greater 
benefit to the patients may be obtained by actually re­
ducing their daily dosage of lithium.
The findings of the present investigation support 
the findings of previous retrospective (Marchetti and 
Cabras, 1980; Preslow et al, 1982) and prospective (Jerram 
and McDonald, 1978) studies, that indicated that plasma 
lithium levels as low as 0.4mmol/l are adequate for effect­
ive prophylaxis. Two studies, however, argued against 
maintenance at such low levels. Prien and Caffey (1976), 
in a retrospective study, suggested that levels below 0.7 
mmol/1 were ineffective in their patients which were des­
cribed as a high risk group and thus may not be representative 
of the average population of patients attending lithium 
clinics. In the retrospective study by Waters et al (1982), 
only bipolar patients were investigated. Patients were assigned 
to low (0.3-0.8mmol/l) and high (0.8-1.4mmol/l) lithium 
levels in the context of a double-blind crossover study 
over one year. They found that 83% of relapses occurred 
during the low level phase. It was shown elsewhere that
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levels below 0.4mmol/l (Hullin, 1980) were ineffective. 
Moreover, bipolar patients may need optimum levels higher 
than 0.4mmol/l. The present results, however, argue 
against such a notion at levels of 0.45mmol/l and above.
Reduced plasma concentrations of lithium were associ­
ated with a decrease in side effects. The mean total side 
effect score of the lithium-treated patients was similar 
to that of the general population (Table 5.16). With 
lower doses of lithium (and hence lower plasma concen­
trations) , the troublesome unwanted side effect of tremor 
was significantly reduced.
It has been reported (Plenge et al, 1982) that once- 
a-day regimes require approximately 15% less lithium to 
be administered than twice-a-day regimes to maintain 
similar plasma levels. Apart from encouraging compliance, 
a once- rather than twice-a-day regime significantly re­
duces the 24-hour urinary output (Perry et al, 1981) and 
reduces the risk of renal damage (Plenge et al, 1981) .
A reduction of the once-a-day regime may therefore be of 
more benefit than the twice-a-day system.
These results suggest that the reduction of lithium 
dosage should be investigated further, since the lowest 
plasma concentration of lithium studied (not lower than
0.45mmol/l) in the present investigation was generally 
associated with a low affective morbidity and a low side 
effect score. The effectiveness of a plasma lithium con­
centration within the range 0.35-0.45mmol/l is worthy of 
further investigation in a prospective, double-blind design
5.2.6 Initial response and long-term response to lithium
Initial response over 6-12 months appears to be a 
powerful predictor of long-term response, Prien et al 
(1974) found that the occurrence of a relapse within one
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year of starting lithium predicted future relapses. Dunner 
et al (1976) , in their investigation of predictors of 
lithium prophylaxis failure in bipolar illness, found that 
a quarter of their lithium-failure patients had relapsed 
within three months of starting treatment and this tended 
to predict earlier relapses during their continued treat­
ment. Furthermore, they observed that patients who 
received lithium had a similar failure rate to those who 
received placebo during the first six months of treatment.
From the present investigation a six-month trial of 
lithium appears to be a satisfactory period to determine 
long-term response in unipolar but not in bipolar illness.
In a recent study from this laboratory, the value of lithium 
continuation therapy was evaluated in a double-blind 
placebo-controlled trial over one year in depressive 
patients who recovered by ECT. There was a significant 
difference in morbidity during the second six months but 
not in the first six months of the trial. These findings 
would argue against a six-month trial of lithium in non- 
bipolar illness and a year's trial could therefore be 
suggested as a minimum period to determine long-term 
response to lithium.
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CHAPTER 6
CONCLUSIONS, FINAL DISCUSSION AND 
IMPLICATIONS FOR FUTURE RESEARCH
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The present series of studies have explored the 
construct of depressive illness from a number of 
defining aspects or dimensions; clinical, psychological, 
biological and therapeutic. The findings indicate a 
great heterogeneity and variation in the phenomena of 
depressive illness along these dimensions and highlight 
the complexity of interaction between elements of noso­
logy, personality, biology and response to treatment.
The literature pertaining to these results has 
been reviewed and particular reference was made to the 
results of the NIMH project on the psychobiology of 
depression (see General Introduction), a project that 
addressed questions similar to those in the present 
studies. The central question is one of nosology; the 
definition of discrete clinical entities validated by 
a variety of criteria including clinical, psychological, 
biological and therapeutic with the aim of refining 
these definitions and determining their ultimate or 
construct validity.
The findings of independent studies have already 
been discussed in the previous chapters. The present 
chapter will provide a summary of these findings, con­
clusions and further discussion with the aim of deter­
mining areas that warrant further investigation.
1. NOSOLOGY
The two clinical distinctions examined, the bipolar- 
unipolar and endogenous-nonendogenous, showed differences 
in clinical and psychological characteristics, biological 
aspects and treatment response in acute and prophylactic 
studies.
Bipolar illness appears to be a more homogeneous 
clinical entity than unipolar illness, with the latter 
showing greater heterogeneity along dimensions of
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endogenicity, genetic disposition, biological variables 
and response to treatment. In this study, bipolar ill­
ness has an earlier age of onset, shows greater morbidity 
over time, occurs in individuals with less personality 
disturbance and is more favourably responsive to pro­
phylactic lithium than non-bipolar illness.
Endogenous unipolar illness including psychotic 
and nonpsychotic illness has a later age of onset than 
both bipolar and nonendogenous illnesses, occurs in 
individuals with less personality disturbance than non­
endogenous depressive illness, shows biological differ­
ences from the nonendogenous illness including greater 
likelihood of folate deficiency and 5-HT receptor 
functional overactivity. More endogenous unipolar 
illness including psychotic depression is less favour­
ably responsive to ECT and antidepressants but more 
favourably responsive to prophylactic lithium than 
moderate endogenous illness. The least endogenous 
illness is poorly responsive to both acute and prophy­
lactic treatment and occurs in individuals with greater 
personality disturbance than both bipolar and endogenous 
unipolar illnesses.
Nonendogenous illness is probably more hetero­
genous than endogenous illness (Paykel, 1971) and in­
cludes neurotic illness, an outgrowth of the disturbed per­
sonality, and illness with incomplete clinical pene­
trance of the biological type or an early form of the 
full-blown endogenous type that might fully manifest at 
a later age. Patients with less endogenous illness 
showed significantly greater reduction in morbidity on 
reduction of their lithium dosage than those with endo­
genous illness.
Other clinical distinctions were only studied in 
relation to response to prophylactic lithium. It was
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found that unipolar patients with pure familial depress­
ive disease had a similar response to bipolar patients 
and both groups were more favourably responsive than 
patients with sporadic and depression spectrum diseases. 
Bipolar patients with a family history of depression 
responded better than those with a family history 
of mania and those with no family history of affective 
disorder. Other subdivisions of bipolar illness, 
including Angst's typology and postpartum onset, showed 
no differences in response to prophylactic lithium.
In brief, patients with bipolar and endogenous uni­
polar illnesses showed similarities in personality and 
response to prophylactic lithium in comparison with 
those with nonendogenous illness. Patients with endo­
genous illness showed evidence of greater biological 
disturbance than those with nonendogenous illness.
These differences further refine the boundaries between 
these clinical entities and confirm findings of previous 
studies that showed similar clinical and personality 
differences between these entities. The findings of 
biological and therapeutic differences provide advances 
and further dimensions of the construct of depression 
and add to the inevitable complexity imposed on these 
clinical phenomena pending final classification.
It is surprising that the NIMH project found few 
differences between the accepted clinical entities of 
depression, despite the introduction and use of highly 
reliable definitions such as the RDC and DSM-III. The 
present series of studies has not investigated the 
entity of psychotic depression or the importance of 
situational factors. The NIMH project found that 
psychotic depression showed a strong relationship to 
bipolar illness and that situational and nonsituational 
depressions had similar clinical, psychological, bio­
logical and therapeutic features.
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Further advances in the nosology of depression 
will depend upon the discovery of other biological 
dimensions, particularly those related to genetic dis­
position, and on the determination of the interactions 
of these variables with clinical dimensions to provide 
points of intersection that are clinically meaningful 
and distinguishable.
2. AGING
As shown and discussed, bipolar and endogenous uni­
polar depressive illnesses show similarities in clinical 
and psychological characteristics when compared with 
nonendogenous depression except for age of onset, which 
is significantly lower in bipolar than in endogenous- 
psychotic depression. This notion must be tempered by 
the findings that bipolar illness shows a second and 
smaller peak of age of onset that is similar to that of 
endogenous-psychotic depression, and that the latter 
illness may also have an earlier age of onset. This 
question could be resolved by the suggestion that 
aging provides a compounding vulnerability factor in 
addition to genetic liability. Endogenous-psychotic 
depression occupies a lower rank in the hierarchy of 
genetic liability to bipolar illness than does bipolar 
illness (Gershon et al, 1982). Aging becomes one essen­
tial vulnerability factor for the occurrence of endogenous- 
psychotic illness and the greater recurrence of bipolar 
illness, probably by lowering the precipitation threshold. 
Aging may also aggravate affective illness and contribute 
to its chronicity and relative refractoriness to anti- 
depressive therapies.
The effects of aging could be mediated by both 
psychological and biological mechanisms. Psychological 
mechanisms might be related to the increased personal 
vulnerability with increased introversion, dependency, 
rigidity (disengagement) and to the occurrence of psycho-
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social strain (life events). In a prospective study of 
elderly depressed patients, Murphy (1983) found that only 
one-third had a good outcome and that poor outcome was 
associated with greater severity of illness, with psychotic 
features and severe life events. The contribution of 
antidepressive therapies was not controlled for in this 
study. Prophylactic lithium was shown to be equally 
effective in depression of adulthood and old age (Abou-- 
Saleh and Coppen, 1983). Biological mechanisms that may 
mediate the effects of aging involve neurochemical and 
neuroendocrine processes. With aging, brain concentrations 
of monoamine show progressive decline (Carlsson, 1980) 
and monoamine oxidase activity is increased (Robinson 
et al, 1971), factors which may predispose to depression. 
Neuroendocrine studies of the HPA system found an associ­
ation between greater DST, non-suppression (a highly 
sensitive index of endogenous-psychotic depression) and 
increased age in depressive patients (Asnis et al, 1981), 
in demented patients (Spar and Gerner, 1981), and in 
normal controls (Oxenkrug et al, 1983). Dilman (1971) 
postulated an elevation of hypothalamic threshold to 
feedback control with aging, a homeostatic function that 
provides stability for the internal environment by an 
increase in the activity of hypothalamic centres and a 
compensatory increase in the activity of peripheral 
endocrine glands. He argued that these alterations 
gradually result in permanent deviations from the law of 
constancy of the internal environment, ultimately pro­
ducing the specific lesions of aging 'diseases of compen­
sation', e.g. metabolic obesity, prediabetes, arterio­
sclerosis and some forms of cancer. Two important 
peculiarities of these diseases are the absence of 
strict aetiological specificity and a striking dependence 
on environmental factors.
It could be proposed that endogenous-psychotic 
depressive illnesses are also 'diseases of compensation'
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and might be related to an increase in the threshold of 
the HPA system to feedback control, a disposition to 
elevation that could have been set by exposure to early 
life stress, e.g. early object loss. This disposition 
could be. unmasked or brought forward in time by the 
presence of life events (Brown et al, 1977; Paykel, 1978). 
Brown et al (1977) also showed that in childhood loss of 
mother by death disposes the individual to develop psychotic 
depressive illness which was shown to be associated with 
very marked HPA activation (Sachar et al, 1973) and very 
high rates of DST non-suppression (Carroll, 1982).
Moreover, animal studies of the impact of early stressful 
stimulation on the HPA response to stress in later life 
support such effects; greater adrenocortical responses 
were observed in rats which were exposed to stress in 
early life (Ader, 1970) and in monkeys at high risk for 
depressive separation reactions (Soumi, 1983).
The aforementioned would indicate that the importance 
of aging has been largely ignored as a factor in the 
investigation of depression: this is tantamount to the 
exclusion of the time dimension of the construct. The 
entity of 'involutional melancholia', discarded from 
clinical classifications and the ICD on the grounds that 
it is clinically indistinguishable from psychotic dep­
ression (Kendell, 1968), may still have a heuristic 
value and affords further investigation in relation to 
the emergent biological variations specific to depression. 
Moreover, the emerging evidence that severe and psychotic 
depressions are associated with structural brain abnormal­
ities in the elderly (Jacoby and Levy, 1980) lends 
further support to the importance of the aging factor.
3. PERSONALITY
In this series of studies personality was examined 
in relation to nosology, response to prophylactic lithium.
and subjective side effects. In relation to nosology, 
bipolar and endogenous unipolars were both less deviant 
from the norm on MNTS validity and CCEI scales than non- 
endogenous depressives. Bipolars showed differences from 
endogenous unipolars on EPQ extraversion, MNTS solidity and 
PDS extrapunitiveness, with bipolars showing less person­
ality pathology than both endogenous and nonendogenous 
unipolar depressives. Greater personality pathology 
was associated with poor response to lithium in the com­
bined group of unipolars and bipolars on neuroticism, 
extraversion, intropunitiveness, validity and CCEI 
anxiety, depression and hysteria scales, and in bipolars 
on neuroticism and validity. Greater subjective side 
effect scores were associated with greater disturbance on 
neuroticism, validity, intropunitiveness and dominance.
Interestingly, the gradient of increasing personality 
disturbance from bipolars to endogenous to nonendogenous 
depressives is associated with an inverse trend in their 
pre-lithium morbidity (number of previous episodes) but 
with a similar gradient in their post-lithium morbidity.
It is difficult to interpret these associations in terms 
of models of interaction between personality and affect­
ive disorders (see General Introduction, p. 30) . It is 
conceivable, however, that these associations indicate 
that depressive illnesses with more biological disturbances 
(bipolar and endogenous unipolar) are more reliably 
recognised in individuals with less premorbid personality 
disturbance and that these illnesses are more favourably 
responsive to prophylactic lithium in comparison with 
those biological depressions that occur in the context 
of persobality disturbance. As discussed earlier (see 
p. 232) the results suggest that personality disturbance 
per se may contribute to poor response to prophylactic 
lithium by impairing or retarding social recovery and/or 
by rendering the individual more vulnerable to undesirable 
life events and changes that might well also be provoked
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by this personality disturbance.
The interaction between personality and affective 
disorders has been extensively investigated but little 
attention has been given to the interaction between 
personality and response to pharmacotherapy. This should 
be studied in the wider context of the impact of psycho­
social factors on the initiation and promotion of these 
disorders.
These notions have implications for management and 
suggest combined psychosocial-pharmacological approaches. 
Combined dynamic psychotherapy and prophylactic lithium 
have been evaluated and the results? were encouraging 
(Jamison and Goodwin, 1983). No studies have explored 
the usefulness of these combined approaches in selected 
patients who had poorly responded to prophylactic lithium. 
Moreover, the value of cognitive therapy, a specific 
psychological treatment for depression, has not beam 
explored in this context.
4. RESPONSE TO TREATMENT
Response to acute antidepressive therapies was 
associated with 'endogenicity' of depression; response to 
ECT and antidepressants was best in those with a moderately 
endogenous illness, whilst those with the very endogenous 
illnesses, including psychotic, and the least endogenous 
illnesses, including reactive and neurotic, have less 
favourable responses. A further evaluation of response 
at six weeks, however, sustained this notion for anti­
depressants but not for ECT (Abou-Saleh and Coppen, 
unpublished observations), thus confirming the results 
of previous studies for antidepressants (Rao and Coppen, 
1979) and for ECT (Crow et al, 1984).
Response to prophylactic lithium, however, showed 
a linear relationship to endogenicity which highlights
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the differences between acute and prophylactic treat­
ments. It is conceivable that full therapeutic effect 
in very endogenous and psychotic depressions requires 
long-term exposure. Indeed the efficacy of lithium con­
tinuation therapy in comparison with placebo was more 
evident in the second six months of treatment in patients 
who had recovered by ECT (Coppen et al, 1981). Moreover, 
a trial of lithium over six months and one year proved 
a powerful predictor of long-term response. Response to 
prophylactic lithium is related to nosology, personality, 
biological, pharmacokinetic and pharmacodynamic factors.
Nosological and personality factors have already been 
discussed (vide supra) and pharmacodynamic factors have 
not been investigated in the present study, hut two 
biological factors were investigated: DST status and 
plasma folate concentrations and pharmacokinetics were ^
studied in the context of a double-blind lithium reduction j
study. I
DST status was not associated with response to lithium .
and its abnormality in one-third of the patients in two i
separate investigations was dissociated from clinical |
status. Moreover, in the subgroup that changed status |
from normal to abnormal DST and vice versa, this was not 
associated with a change in morbidity. This dissociation 
between clinical and biological disturbance could be 
attributed to lithium suppressing the clinical manifest­
ations of depression that continues its periodicity under 
the cover of lithium. This would imply that patients with 
abnormal DST are at a particular risk for a recurrence 
of illness if lithium was discontinued. This hypothesis 
is readily falsifiable by conducting a double-blind 
placebo-controlled lithium discontinuation trial following 
DST administration. The relatively high risk of relapse 
within two to six weeks of lithium discontinuation might 
be a reflection of this phenomenon (Sashidharan and 
McGuire, 1983) , The DST might still, therefore, be a
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valuable management aid in determining when to discontinue 
maintenance or prophylactic treatment.
In the context of a double-blind lithium reduction 
trial, patients who had a 25-50% reduction in their daily 
lithium dosage(as determined and monitored by 12-hour 
plasma lithium levels) had significant reduction in their 
affective morbidity and side effects over one year on 
the trial in comparison with their morbidity during the 
preceding year.. This reduction in morbidity, particularly 
observed in patients with nonendogenous recurrent depression, 
was not related to reduction in side effects and was not 
associated with prescription of extra medication during 
the year on the trial. This study suggests that 12-hour 
plasma lithium levels as low as 0.45mmol/l are thera­
peutically effective and are more effective than the widely 
accepted 12-hour therapeutic range of plasma lithium 
levels (*0.8-1 . 2ramol/l) . This finding confirms the results 
of an open prospective study by Hullin (1980) who found 
that patients maintained at lithium levels below 0.4mmol/l 
had a higher relapse rate (62%) than those who were main­
tained on levels higher than 0.4ramol/l (13-20%).
The question of the optimum or minimally effective 
12-hour plasma lithium concentration requires further in­
vestigation using the design of the prospective study to 
explore the therapeutic value of even lower plasma lithium 
levels, ideally by comparison with a placebo (double­
blind discontinuation).
It would also be valuable to carry out a prospective 
double-blind placebo-controlled study to explore the use­
fulness of variable lithium dosages and plasma levels in 
carefully selected patients with recurrent affective 
disorders diagnosed, classified and subclassified on the 
established diagnostic systems and scales such as DSM-III, 
RDC, the Newcastle Scales, Winokur's genetic types; self­
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rated on a variety of personality questionnaires, and 
biologically investigated using established markers 
such as the DST, 5-HT uptake, imipramine binding to 
platelets, CSF 5-HIAA and urinary MHPG, Such a study 
would allow the determination of the comparative efficacy 
of variable lithium dosage/plasma levels in groups and 
subgroups of patients defined in terms of clinical, 
psychological and biological variables, and rationalises 
the practice of lithium prophylaxis.
Last but not least, a powerful predictor of long-term 
response to lithium was an empirical one; response over 
the first six months in unipolar illness and over the 
first year in bipolar illness was strongly associated 
with long-term lithium response. This suggests that a 
lithium continuation-maintenance treatment predicts long­
term response and a trial of lithium for up to one year 
would be warranted in patients with recurrent affective 
illness that is not an established indication for prophy­
laxis, such as nonendogenous. depression. Moreover, poor 
response during the first year would indicate the need for 
extra or alternative medication such as antidepressants, 
neuroleptics and carbamazepine.
5. NUTRITION
Plasma and red blood cell folate concentrations were 
significantly reduced in drug-free depressive patients 
in comparison with normal controls. Lower plasma folate 
concentrations were associated with greater concurrent 
affective morbidity in alcoholic and lithium-treated 
patients and with greater morbidity during the preceding 
two years in the latter group. Plasma folate concentrations 
were not associated with weight loss in drug-free depress­
ives and lithium-treated patients; with extra medication 
in lithium-treated patients; with severity of alcohol 
dependence and liver function disturbance in the alcoholic
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patients. In a group of patients on prophylactic lithium 
who had low plasma folate concentrations, placebo- 
controlled folic acid treatment in physiological doses 
caused a significant increase in plasma folate concen­
trations but was not associated with a significant change 
in their morbidity over the six months of the trial in 
comparison with their morbidity during the six months 
preceding the trial.
These results were discussed in Chapter 4. The 
findings suggest that folate deficiency is a common 
occurrence in depression and that this could not be 
explained away as a secondary phenomenon caused by the 
anorexia and poor nutrition that are commonly observed 
in depression and other psychiatric illnesses (Post, 1956). 
It is conceivable that folate deficiency might have 
aggravating/promoting effects. It could cause further 
clinical deterioration, delay recovery or contribute to 
chronicity of depression and other psychiatric illness.
Such effects might be more specific in patients pre­
disposed to particular monoamine deficiency, e.g. 5-HT 
deficient depression, or in those who might need folate 
in excess. The aetiopathogenesis of this contribution 
involves metabolic processes of méthylation and hydroxy­
lation that could well be reconciled with- the amine hypo­
theses for depression, processes that also implicate a 
variety of nutritional factors such as monoamine precursors 
(tyrosine, tryptophan), methionine and vitamin B 1 2 .
Folate deficiency is also common in other psychiatric 
illnesses including schizophrenia and dementia, and 
folate supplements lead to improvement in organic psychoses 
(Carney, 1979) and in schizophrenia (Freeman et al, 1975; 
Carney, 1979) .
Folate deficiency and, for that matter, the afore­
mentioned deficiencies could also aggravate these illnesses 
and contribute to their chronicity and their refractoriness
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to treatment. Hare (1981), in his exploration of the 
natural history of mania, introduced the concept of muta­
bility of psychiatric disease: psychiatric diseases 
evolve and continuously undergo changes in their natural 
history. He plausibly argued that improved prognosis 
of the two insanities, schizophrenia and manic depression, 
deemed originally incurable, could be attributed to 
improvements in physical health and constitutional resist­
ance to disease in consequence of better nutrition. He 
referred to incidences of clinical deterioration in manic 
depressive patients characterised by neurasthenic symptoms 
well described by Kraepelin and to Lewis' descriptions of 
chronic forms of depression characterised by similar 
symptoms (Lewis, 1968), a syndrome that is akin to the 
schizophrenic defect state. Schizophrenic and manic 
depressive patients similar to folate-deficient patients 
(Botez et al, 1984) show evidence of cerebral atrophy and 
enlarged ventricles (Crow, 1980; Jacoby, 1982). In 
schizophrenic patients structural brain abnormalities 
have been specifically related to 5-HT deficiency 
(Wiseman et al, 1980) or to dopamine deficiency in type 
II schizophrenia (MacKay and Crow, 1980).
Surveys of nutritional state of psychiatric patients 
in hospitals and other institutions have indicated the 
widespread prevalence of nutritional abnormalities in 
these patients reflecting the nutritional effects of 
large-scale catering (Bender, 1984). These hypotheses 
have an heuristic value and the days of orthomolecular 
psychiatry may not yet be over.
6. BIOLOGY (5-HT)
The functional activity of peripheral 5-HT receptors 
on platelets was shown to be increased in patients with 
endogenous depression in comparison with affectively 
normal subjects and patients with nonendogenous depression
255
This relative supersensitivity was also found in euthymie 
patients on prophylactic lithium. These findings could 
be interpreted in two ways.
The first interpretation assumes that the abnormality 
in question is a predisposing biological factor (trait- 
dependent) that persists after clinical recovery and is 
not affected by pharmacotherapy. The second interpret­
ation assumes that the abnormality is illness-related 
(state-dependent) and is part of the organism's adaptive- 
restorative response that is maintained and/or enhanced 
by pharmacotherapy, i.e. 5-HT receptor overactivity is 
an adaptive-compensatory response to 5-HT functional 
deficiency that is maintained and/or enhanced by prophy­
lactic lithium. This controversy could be resolved by 
a placebo-controlled study of the effects of antidepress­
ants and prophylactic lithium on this biological dysfunction 
It would also allow the isolation of the effects of clinical 
recovery per se from the effects of pharmacotherapy.
It is important to study the relationship between 
this 5-HT functional activity (5-HT induced platelet 
aggregation) and the activity of other platelet 5-HT 
receptors studied by radioligand binding techniques (5-HT 
uptake and imipramine binding) in the clinical situation.
The 5-HT receptor that mediates platelet aggregation has 
been identified as the 5 -HT2 receptor on the basis of 
its strong inhibition by ketanserin (a specific 5-HT2 
inhibitor) (Peters and Grahame-Smith, 1980). In rat 
brain tissue, lithium causes region-specific decreases 
in 5 -HT2 binding sites and increased release of endogenous 
5-HT, effects that occurred in the hippocampus but not 
in the cortex, or in the hippocampus in the presence of 
lithium in vitro after lithium treatment (Treiser et al, 
1981). This underlines the heterogeneity in the changes 
that take place in 5-HT synapses in various brain regions.
Neuroendocrine techniques for the investigation of
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5-HT activity have recently been developed, including 
plasma prolactin response to fenfluramine or tryptophan 
administration, and studies using these techniques have 
reported decreased responsivity of the 5-HT system in 
depression (Siever et al, 1984). It should be feasible 
to characterise these 5-HT receptors by studying respons­
ivity before and after administration of ketanserin.
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Appendix 1 SUBJECTIVE SIDE EFFECTS CHECKLIST
H O S P IT A L  
N A M E  ____
D A T E .  
M  F A G E
Please lick in the appropriate bpx if you are suffering from any of the following conditions:—
Nil Mild ' Moderate Severe
Sickness
Vomiting
Diarrhoea
Constipation
Poor appetite
Dry mouth
Indigestion
Metallic taste
Excessive thirst
Headache
Drowsiness
Dizziness or giddiness
Fainting attacks or lightheadedness
Stiffness of arms and legs
Spontaneous twitching (contraction) of muscles
Trembling hands
Blurred vision
Double vision
Abnormal noise in ears
Difficulty in speech
Feeling of unreality
Poor m e m o r y
Flushing attacks
Increased sweating
Stuffy nose
Trouble starting urination
Passing urine too often
Passing more than usual quantity of urine
Palpitation
Ankle swelling
Weight gain
Goitre
Skin rash
Aches and pains over the muscles and joints
Weakness of legs and arms
Unsteady walk
Other remarks
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Appendix 2 
Name
NEWCASTLE SCALE
Age Sex Date of assessment
Check lists for diagnostic and EOT prediction indices.
Feature Present Diagnostic ECT Index.
Index M
1. Adequate personality + 1 »ttw
2 . No adequate psycho­
genesis t 2
3, Distinct quality t 1 ip.4 . Weight loss + 2 + 3
5. Pyknic + 3 Lp-.
6. Previous episode + 1 1
7. Early v/akening + 2
Ù. Depressive psychomotor + 2
S. Anxiety - 1 - 2 r,"
10. Nihilistic delusions + 2 WWI
11. Somatic delusions + 2
12. Paranoid delusions • •h 1
13. Worse p.m. - 3
14. Bl.ame others — 1
15. Self-pity - 1
15. Hypochondriacal ^ 3
17. -Hysterical - 3 fiv
1C, Guilt- •' - 1
Total 1
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Appendix 3
NAME _ 
F M 
DATE
THE HAMILTON RATING SCALE FOR DEPRESSION
Item
No.
Score
Range
Symptom , Score
1 0-4 Decreased Mood
2 0-4 Guilt
3 0-4 Suicide
4 0-2 Insomnia, initial
5 0-2 Insomnia, middle
6 0-2 Insomnia, delayed
7 0-4 Work and Interests
8 0-4 Retardation
9 0-4 Agitation
10 0-4 Anxiety, psychic.
11 0-4 Anxiety, somat ic
12 0-9 Somatic symptoms, gastrointestinal
13 0-2 Somatic symptoms, general
IM­ 0-2 Loss of libido
IS 0-4 Hypochondrias is
16 0-2 Loss of insight
17 0-2 Loss of weight
18 0-2 Diurnal variation
19 0-4 Depersonalization and derealization
20 0-4 Paranoid symptoms
21 0-2 Obsessional symptoms
RATER TOTAL SCORE
